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Background and Aims of the Study 
Steroid hormones and their receptors play crucial roles in the normal 
development of prostate gland as well as its neoplastic growth. Among these 
hormones, estrogens have been implicated to affect the normal and abnormal growth 
of the prostate and the estrogenic effects are mediated through the estrogen receptors, 
ERa and ERp. However, deficiencies of ERs do not prevent the normal prostate 
development as demonstrated in the ER knock-out mouse models. Therefore, it is 
speculated that in addition to ER-dependent pathway, alternative estrogen-signaling 
pathways mediated by other nuclear receptor may be present in the prostate cells 
regulating cellular processes involved in the prostate growth, development and 
carcinogenesis. Estrogen receptor-related receptors (ERRs) belong to the orphan 
receptor member of the nuclear hormone receptor superfamily and consist of three 
closely related isoforms: ERRa, ERRp and ERRy. They are highly homologous to 
ERs in their protein structures but they do not bind estrogens or any other known 
physiological ligands. Thus, they are classified as "orphan nuclear receptors". 
Expression studies demonstrate that ERRs are widely expressed in the human and 
murine tissues, suggesting that ERRs might be involved in many physiological 
processes. ERRs can transactivate and modulate the expression of a number of genes 
through their binding to the consensus estrogen responsive elements (ERE) as well as 
ERE-driven ERR responsive elements (EREJE or SF-1). Additionally, in vitro studies 
show that ERRs can interact with a number of steroid hormone receptor coactivators. 
It is hypothesized that these orphan receptors might share some similar regulatory 
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pathways as ERs in the normal and neoplastic prostate. Therefore, the present study 
was aimed to investigate the expression of ERRs in a board panel of human prostatic 
cells lines, tumor xenografts and tissues. In addition, the potential functional roles of 
ERRs in the prostatic growth was also investigated. 
Methodologies used 
In the first part of the study, the expression profiles of the human ERRa, 
ERRp and ERRy mRNA transcripts were investigated in several immortalized 
prostatic epithelial cell lines, cancer cell lines and primary prostate carcinoma 
xenografts by a semi-quantitative RT-PCR analysis. Their expression patterns were 
also compared to the expression of other steroid hormone receptors in order to reveal 
a possible correlation. The expression patterns of ERRs were also studied and 
confirmed in the hyperplasic and neoplastic prostatic tissues. Besides, polyclonal 
antibodies against ERRs were developed in order to study their protein expressions 
in the cell lines and human prostates by Western blot analysis and 
Immunohistochemistry. In the second part of the study, the interrelationship between 
ERR and ER expressions were investigated in the ERRa, ERRy and ERa transient 
transfected PC-3 cells by a semi-quantitative RT-PCR analysis. In the third part of 
study, the transcriptional activities of (green fluorescent protein) GFP-tagged ERRs 
towards the ERE and ERRE driven reporter genes and their subcellular localization 
in the transfected PC-3 cells were examined by luciferase assay and confocal 
microscopy respectively. In the last part of study, the role of ERRs in the growth 
regulation of prostatic cells were investigated in the ERRs-transient transfected PC-3 
cells and ERRy stable-transfected PNT2 and DU 145 cells, by examining several 
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growth parameters including cell proliferation rate, doubling time，cell cycle 
distribution, expression of cell cycle-related genes and anchorage independent 
growth. 
Principal Findings 
Results of RT-PCR and protein blottings showed that ERRa was 
ubiquitously expressed, whereas ERR(3 and ERRy showed variable expression 
patterns, in the selected human prostatic cell lines, xenografts as well as hyperplastic 
and neoplastic prostatic tissues. By immunohistochemtry, the immunoreactive 
proteins of ERRa and ERRp were mainly localized to the nuclei of both luminal and 
basal epithelial layers in the normal prostate whereas ERRy was localized in both the 
cytoplasm and nuclei of luminal epithelial cells. Positive immunosignals of ERRa 
and ERRP were also detected in dysplastic epithelail cells in the PIN lesions but 
variably expressed or down-regulated in carcinoma lesions. Besides, 
down-regulation of ERa and ERRy genes was induced in the ERRa-overexpressed 
PC-3 cells, providing evidence for the first time that a cross-talking between ERR 
and ER could be possible in the prostatic cells. Moreover, all three GFP-tagged ERR 
isoforms were localized to the nuclei and able to transactivate both the ERE and 
ERjRJE (SF-1) driven reporters in the transfected PC-3 prostatic cells in the presence 
or absence of serum. On the other hand, transient expression of ERRs in PC-3 cells 
could induce an inhibition of cell proliferation and disturbance of cell cycle. Similar 
effects were also confirmed in the ERRy stable transfected PNT2 and DU 145 cells. 
In addition, ectopic over-expression of ERRy in ERRy-stable transfectants could 





The results of present study show that the three ERR isoforms are 
constitutively active and nuclear localized in the prostatic cells, but exhibited 
differential expression patterns in different prostatic cell lines, tumor xenografts and 
prostatic tissues. The combined results from transient and stable transfection 
experiments demonstrates that the three ERR isoforms, particularly ERRy, exhibited 
a role in growth regulation in a negative manner and tumor suppressor function in the 
transformed and prostatic cancer cells. However, the exact mechanism of 





















































Abstract (English) II 
Abstract (Chinese) VI 
Contents VIII 
Chapter 1 Introduction 
1.1 Nuclear hormone receptor: a general review 1 
1.1.1 Classification of nuclear hormone receptors 1 
1.1.2 Mechanism of action 2 
1.1.3 Domains structure and functions 3 
1.1.4 Orphan nuclear receptors 4 
1.2 Prostate gland - a male accessory reproductive organ 6 
1.2.1 Anatomy, histology and physiology of the prostate gland 6 
1.2.2 Endocrinology of the prostate gland 8 
1.2.3 Pathogenesis of the prostate gland 8 
1.3 The role of estrogen receptors in the prostate gland and 9 
prostate cancer 
1.3.1 Estrogens in male 10 
1.3.2 Effects of estrogens in the prostate gland 11 
1.3.3 Estrogen receptors - two is of or ms 13 
1.3.4 Expression of ERs in the prostate gland 14 
1.3.5 Estrogen-modulated transgenic mice 一 functional studies of ERs 16 
VIII 
Contents 
in the prostate gland 
1.4 Estrogen receptor-related receptors: orphan receptors 18 
1.4.1 Estrogen receptor-related receptors: Three isoforms 18 
1.4.2 Expression of ERRs in different tissues 20 
1.4.3 Promoter binding and genes regulated by of ERRs 22 
1.4.4 Coregulators of ERRs 24 
1.4.5 Ligand of ERRs 25 
1.4.6 Functional roles of ERRs 29 
1.4.7 Cross talk between ERRs and ERs 31 
Table 1.1 33 
Figure 1.1 - 1.5 35 
Chapter 2 Aims of the Study 40 
Chapter 3 Methods and Materials 
3.1 Expression patterns of ERRs and steroid hormone receptors 41 
in the human prostate cell lines, tumor xenografts and 
prostatic tissues 
3.1.1 Human prostatic tissues 41 
3.1.2 Cell cultures 41 
3.1.3 Human prostate cancer xenografts 42 
3.1.4 Full length clones of ERR isoforms 42 
3.1.5 Reverse transcription-polymemse chain reactions (RT-PCR) 43 
IX 
Contents 
3.1.6 Semi-quantitative RT-PCR analysis 45 
3.1.7 Southern blot analysis 46 
3.1.8 Generation and characterization of polyclonal antibodies 49 
3.1.9 Western blot analysis 55 
3.1.10 Immunohistochemistry 56 
3.2 Relationship of ERR and ER expressions in the prostatic cells 57 
3.2.1 Expression vectors of ERRa, ERRy and ERa 57 
3.2.2 Transient transfection of ERRa, ERRy and ERa expression vectors 58 
in PCS cells 
3.2.3 Semi-quantitative RT-PCR analysis 59 
3.3 Intracellular trafficking and transcriptional activity of 59 
GFP-tagged ERRs in the prostatic cells 
3.3.1 Construction of GFP-tagged ERR fusion plasmids 59 
3.3.2 Examination of transcriptional activity of GFP-tagged ERRs by 61 
luciferase assay 
3.3.2 Subcellular localization of GFP-tagged ERRs in the living 63 
prostatic cells 
3.3.4 Immunofluorescent staining GFP-tagged ERRs 63 
3.4 The Role of ERRs in the growth of the prostatic cells 64 
3.4.1 Evaluation the transfection efficiencies of PCS and PNT2 cells 64 
3.4.2 Cells proliferation assays in ERRs transient transfectedprostatic 66 
cells 
3.4.2 Flow cytometry of ERRs transient transfected PC-3 cells 66 
X 
Contents 
3.4.4 RT-PCR of cell cycle-related genes in ERRs transient transfected 67 
PC-3 cells 
3.4.5 Generation of PNT2 and DU145 cells stably transfected with 68 
ERRy 
3.4.6 Cell proliferation assay of ERRy stable-transfected PNT2 and DU 72 
145 cells 
5.4.7 Anchorage independent growth assay of ERRy stahle-transfected 72 
PNT2 and DU 145 cells 
5.4.8 Flow cytometry of ERRy stable-transfected PNT2 and DU 145 74 
cells 
3.4.9 RT-PCR of cell cycle-related genes in ERRy stable-transfected 74 
PNT2 and DU 145 cells 
3.4.10 Western blot analysis of p21 in ERRy stahle-transfected PNT2 75 
cells 
3.5 Statistical analysis H 
Table 3.1 - 3.2，Figure 3.1 - 3.5 76 
Chapter 4 Results 
4.1 Expression patterns of ERRs and steroid hormone receptors 93 
in the human prostate cell lines, tumor xenografts and 
prostatic tissues 
4丄1 mRNA expression patterns of ERR isoforms in the prostatic cell 93 
lines, prostate cancer xenografts and human prostatic tissues 
XI 
Contents 
4.1.2 mRNA expression patterns of steroid hormone receptors and 95 
prostatic differentiation markers in the prostatic cell lines and 
xenografts 
4.1.3 Characterization of antisera against human ERRs by ERR 97 
recombinant proteins 
4.1.4 Protein expression of ERR isoforms in the human prostatic cell 98 
lines 
4.1.5 Immunolocalization of ERR isoforms in the normal, dysplastic 98 
and neoplastic prostates 
4.2 Interrelationship of ERR and ER expression in PC-3 prostate 100 
cancer cells 
4.2.1 Expressions of ERRy, ERa and ERp in the ERRa transient 100 
transfected PC-3 cells 
4.2.2 Expression of ERRa in the ERRy and ERa transient transfected 101 
PCS cells 
4.3 Intracellular trafficking and transcriptional activities of ERRs 102 
in the prostatic cells with fused green fluorescence protein 一 
ERRs 
4.3.1 Transactivation of ERE response element — driven reporter by 102 
ERR isoforms in the PC-3 cells in the presence or absence of 
serum 
4.3.2 Transactivation of SF-1 response element driven reporter by ERR 104 
isoforms in the PCS cells in the presence or absence of serum 
XII 
Contents 
4.3.3 Subcellular localizations of three ERR isoforms in the PC-3 cells 105 
in the presence or absence of serum 
4.4 The role of ERRs in the growth of prostatic cells 106 
4.4.1 The growth of ERRs transient transfected PC-3, PNT2 prostatic 107 
cells 
4.4.2 Cell cycle analysis of ERRs transient transfected PC-3 cells 108 
4.4.3 Expression of cyclin-dependent kinase (CDK) inhibitors andp53 108 
in the ERRs transient transfected PCS cells 
4.4.4 Establishment of ERRy stable-transfected PNT2 and DU 145 cells 109 
4.4.5 Transcriptional activation of ERE response element in ERRy 111 
stable-transfected PNT2 cells 
4.4.6 Effect of over-expression of ERRy on the growth of PNT2 and 112 
DU145 stable-transfected cells 
4.4.7 Efficiencies of colony formation of ERRy stable-transfected PNT2 113 
and DU 145 cells 
4.4.8 Cell cycle analysis of ERRy stable-transfected PNT2and DU 145 114 
cells 
4.4.9 Expression of cell cycle-related genes in the ERRy 116 
stable-transfectedPNT2andDU 145 cells 
Figure 4.1-4.38, Table 4 .1 -4 .3 119 
Chapter 5 Discussion 
5.1 Expression study in human prostatic cells, tumor xenografts 159 
XIII 
Contents 
and prostatic tissues 
5.1.1 Differential expression patterns of ERRs in prostatic cells, cancer 160 
xenografts and tissues 
5.1.2 Co-localization of ERRs and ER/3 in the human prostate 166 
5.1.3 Differential expression patterns of steroid hormone receptors and 168 
prostatic specific markers in prostatic cells and xenografts 
5.2 ERRa acts as a expression repressor of ERRy and ERa in 173 
PC-3 cells 
5.3 ERRs are nuclear localized and constitutively active in PC-3 176 
cells 
5.4 ERRs acts as the negative growth regulators in the prostatic 179 
cells 
5.4.1 Cell cycle control of mammalian cells 180 
5.4.2 The roles of AR and ERs in the cell cycle regulation 181 
5.4.3 Inhibition of cell proliferation in ERRs transient transfected PCS 184 
cells and ERRy stable-transfected PNT2 and DU145 cells 
5.4.4 Inhibition of anchorage independent growth in ERRy 188 
stable-transfected PNT2 and DU 145 cells 
Chapter 6 Conclusion 191 
Chapter 7 References 192 
XIV 
Contents 
Chapter 8 Publications 227 
XV 
Chapter 1. Introduction 
Chapter 1. Introduction 
1.1 Nuclear hormone receptors: a general review 
Small lipophilic molecules such as steroids (estrogens and androgen), 
thyroid hormones, active forms of vitamin A (retinoids) and vitamin D play an 
important role in the growth, differentiation, metabolism, reproduction, and 
morphogeneisis of mammals including humans. The actions of these molecules are 
mediated through binding to nuclear receptors that act as ligand-inducible 
transcription factors and regulate the genes expression. These nuclear receptors refer 
to “classic nuclear hormone receptor" because they have the well-defined ligands. 
However, the search for new proteins with similar structure to classic receptors 
during the last two decades, many new members were cloned but without any natural 
ligand. These receptors are called "orphan receptor". The identification and 
characterization of "orphan receptor" led to the discovery of novel concept "reverse 
endocrinology', in which the characterization of the receptor precedes the study of its 
physiological functions (Aranda and Pascual, 2001; Giguere, 1999). 
1.1.1 Classification of nuclear hormone receptor superfamily 
Nuclear receptors are grouped into a large superfamily and are 
evolutionarily derived from a common ancestor. Some classic and orphan hormone 
receptors and their ligands in mammal are shown in Table 1.1. Among the 
superfamily, Class III is formed by the steroid hormone receptors and the closely 
related orphan receptors, estrogen receptor-related receptors (ERRs). (Aranda and 
Pascual, 2001) The former includes androgen receptor (AR), estrogen receptors (ERs) 
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and progesterone receptor (PR) that are important to the growth, differentiation and 
normal function of male and female reproductive organs. 
1.1.2 Mechanism of action 
Binding of ligand to their receptor is the first step to initiate the 
transactivation function of classic nuclear hormone receptors. The active ligand or 
hormone is usually synthesized in the endocrine organ and enters the target cell 
through circulation. Some unliganded nuclear receptors, e.g. estrogen receptors 
(ERs), are predominantly nuclear localized (King and Greene, 1984). Some receptors, 
e.g. glucocorticoid receptors (GR) and mineralocorticoid receptors (MR), are 
cytoplasmic localized in the absence of ligand due to their association with the large 
multiprotein complex of chaperones, including Hsp90 and Hsp56 (Lombes et al, 
1990; Picard and Yamamoto, 1987). Ligand binding induces dissociation of receptor 
from chaperone complexes, translocates into nucleus as well as recruits the 
coregulators that are essential for the transactivation function. Once in the nucleus, 
the receptor regulates the transcription of targeted genes by binding as monomers, 
homodimers or heterodimers to hormone response elements (HREs) that usually 
locate in promoter or enhancer regions of targeted genes. Two consensus motifs have 
been identified: the sequence AGAAACA is preferentially recognized by class III 
steroid hormone receptors, whereas AGG/TTCA serves as recognition motif for the 
remaining receptors within this superfamily (Beato et al, 1995). Besides, nuclear 
receptors can regulate gene transcription via direct interaction with other 
transcription factors. For instance, GR has been shown to antagonize AP-1 and 
nuclear factor-KB activities through transcriptional interference (Karin, 1998). 
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1.1.3 Domains structure and functions 
Typical nuclear receptor consists of four well-defined regions with their 
own specific function including a variable NH2-terminal domain (A/B regions), a 
conserved DNA-binding domain (DBD) (C region), a linker hinge domain (D region) 
and a ligand binding domain (E region). Some receptors also consist of a 
COOH-terminal domain (F region) with unknown function. A typical structure of a 
nuclear hormone receptor is shown in Figure 1.1. 
A/B region is the most variable domain both in size and sequence among 
the nuclear hormone receptors. Multiple receptor isoforms can be generated from a 
single gene by alterative splicing in this region or using an alternative promoter. For 
example, the two isoforms of progesterone receptor PR-a and PR-p are identical 
except that PR-a lacks the N-terminal 164 amino acids of the A/B region (Kastner et 
al, 1990). Additionally, A/B region is the target of phosphorylation mediated by 
different signaling pathways and in turn affects the transcriptional activity. For 
instance, estrogen receptors (ERs) are phosphorylated at serine amino acid in this 
domain by the mitogen-actived protein kinase (MAPK) in vitro (Arnold et al, 1995). 
Many receptors also contain an autonomous transcriptional activation function, 
referred to as AF-1, in which contributes to constitutive ligand-independent 
activation by the receptor. DNA-binding domain (DBD) (C region) is the most 
conserved domain among the receptors in this superfamily. It consists of two 'zinc 
fingers' that span 60 — 70 amino acids and a COOH-terminal extension (CTE) that 
contains the T and A boxes. In each zinc finger, four cysteines organize 
tetrahedrically with one zinc ion and both zinc fingers fold together to form a 
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compact and interdependent structure. Finger 1 contains “P box" residues involved in 
the discrimination of the response element and finger 2 contains “D box" residues 
that are important to receptor dimerization. Following the zinc fingers, a 
COOH-terminal extension (CTE) is present possessing the T and A boxes that are 
critical for monomelic DNA binding. Hinge domain (D region) is not well conserved 
among the different receptors. This domain consists of nuclear localization signals as 
well as the residues that are important for interaction with nuclear receptor 
corepressors. Last but not least, ligand binding domain (LBD) (E region) is a 
multifunctional domain. It possesses high proportion of hydrophobic amino acids 
that form the "steroid-binding pocket" and the receptor undergoes a clear 
conformational change upon binding to ligand. Moreover, this domain contains the 
COOH-terminal AF-2 motif that is responsible for ligand-dependent transcriptional 
activation through agonist ligands binding (Schwartz and Brooks, 1997; Hoerer et al, 
2003). In addition, LBD is responsible for interacting with heat-shock proteins in 
unligand receptor and in turn repressing the receptor functional activity (Chambraud 
etal, 1990). 
1.1.4 Orphan nuclear receptors 
During the search for new members of the nuclear hormone receptor， 
multiple cDNAs were isolated. The encoding proteins consist of the structural 
features that can be found in classic receptor. However, the regulatory ligands for 
many of them have not yet been identified. Thus, they are called "orphan nuclear 
receptor". Estrogen receptor-related receptors a and (3 (ERRa and ERRP) are the first 
orphan receptors being identified and isolated during the search of another isoform of 
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estrogen receptor in 1988 (Giguere et al, 1988). Afterward, more than 60 "orphan 
receptors" have been cloned and described during the last two decades. 
Most of the orphan nuclear receptors possess all functional domains and 
they recognize specific hormone response elements (HREs) through their 
well-conserved DBD in a manner similar to classic nuclear receptors. Functional 
studies of orphan receptors have changed the previous concept on how nuclear 
receptors bind to DNA. For instance, the identification of Retinoid X receptor (RXR) 
led to the discovery of a large subset of classic and orphan receptors that binds DNA 
as heterodimers (Mangelsdorf and Evans, 1995). Besides, all vertebrate orphan 
receptors have a highly recognizable LBD. The presence of a conserved LBD may 
not be related to the ligand-binding function only since LBD mediates multiple 
functions, such as dimerization and coactivator interaction. More ligands have been 
found for several orphan receptors under the extensive researches recently. Some of 
these are the products of lipid metabolism, and it is now known that compounds such 
as fatty acids, leukotrienes, prostaglandin and cholesterol derivatives, bile acids, 
pregnanes, or even benzoate derivatives can regulate gene expression through their 
bindings to orphan receptors (Mohan and Heyman, 2003; Chiang, 2002). Therefore, 
as oppose to classic hormones, these ligands are presented intracellularly as 
metabolic products. Nevertheless, ligands of many orphan receptors are still 
unknown. They usually have alternative ligand-independent activation pathways. 
Some of them may be constitutively active, and the activity of others can be 
modulated by other means. For instance, phosphorylation mediated by hormones and 
growth factors that stimulates diverse signal transduction pathways (Aranda and 
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Pascual, 2001). 
Similar to the classic receptors, orphan receptors also play key roles in 
development, homeostasis and reproduction in mammals. Orphan receptors and their 
ligands have direct links with known diseases such as diabetes, atherosclerosis as 
well as cancer. These findings open much new therapeutic space for the management 
of these diseases. Together with the search for new agonist and antagonist ligands for 
classical receptors, they constitute important targets for drug discovery (Aranda and 
Pascual, 2001; Giguere, 1999). 
1.2 Prostate gland — a male accessory reproductive organ 
Prostate is the major reproductive accessory gland in the male. Its growth 
and development are totally dependent on endocrine control. Androgen, or more 
specifically dihydrotestosterone, is the major hormone that acts within the prostate. 
When this male hormone enters the prostate gland, it binds to the androgen receptor 
(AR) and initiates the transcription of AR-responsive genes. However, the abnormal 
changes of AR in the prostate are mainly responsible to progression of prostate 
cancer to the hormone-refractory status. 
1.2.1 Anatomy, histology, and physiology of the prostate gland 
Human prostate develops from the urogenital sinus during the embryonic 
period and it grows again at puberty under the influence of androgen. The 
reoccurrence of prostate growth in adult after 40 years old is believed to be affected 
by the hormonal changes. Prostate lies at the base of bladder where it surrounds the 
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urethra. The urethra separates the prostate into ventral and dorsal prostates. The latter 
can be further separated into four parts: the peripheral, central, transitional and 
periurethral zones. Benign prostatic hyperplasia (BPH) initially develops in the 
transitional and periurethral zone, whereas prostate cancer develops primarily in 
peripheral zone. Different from human, the prostates of rat and mouse divide into 
distinct lobes including ventral, dorsal, lateral and anterior lobes. Each lobe has its 
unique structure and specific protein synthesis (McNeal, 1983; McNeal, 1981). 
Prostate consists of many cell types that can be classified as either stromal or 
epithelial. The stroma consists of two main cell types: (1) smooth muscle and 
fibroblasts and (2) immune cells and neuromuscular cells. Stromal region is very 
important in the morphogenesis of prostate since it produces growth factors that 
work via autocrine and paracrine modes (Steiner, 1993). The epithelium also consists 
of two main cell types: (1) luminal and basal cells and (2) nemoendocrine cells. The 
epithelial basament membrane separates the epithelium from the stroma. Luminal 
cells are columnar and secretory but basal cells are flat and non-secretory. The latter 
are hypothesized to be the stem cells of the epithelium (Schalken and van Leenders, 
2003). 
Prostate is an exocrine gland and its epithelial secretions are transported 
into urethra and deposited into the seminal fluid in order to help sperm transport and 
possible regulation of fertility. The main secretions of human prostate include 
prostatic specific antigen (PSA), citrate and prostatic acid phosphatase (PAP) as well 
as prostatic binding protein (PBP) in the rat ventral prostate. PSA is a serine protease 
that functions in semem liquefaction (Lilja and Laurell, 1985). It is also a useful 
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clinical marker in human prostate cancer diagnostics since its level in blood is 
elevated in cancer patients. Moreover, prostate is a major source of zinc and 
selenium, but their roles in the physiology of prostate gland are not yet well known. 
1.2.2 Endocrinology of the prostate gland 
Testicular androgen or testosterone is the principal regulator of prostatic 
growth, differentiation and maintenance. Fetal testes start to synthesize testosterone 
after seventh week of gestation and it is converted by 5a-reductase to 
5a-dihydrotestosterone (DHT). DHT then binds to AR in the reproductive tract for 
the subsequent differentiation of the prostate (Cunha, 1992). The prostate is 
quiescent after birth until puberty, at which androgen triggers its renewed growth. 
Although the prostatic growth becomes quiescent again until later in adult life, it 
depends on androgen for normal maintenance and homeostasis, balancing the cell 
replication and cell death. In the prostate, AR is expressed at both stroma and 
epithelium (Leav et al, 2001, Leav et al, 1996). After androgen or its active form 
DHT binds to the AR, the activated AR complex initiates the transcription of 
AR-responsive genes. Androgen can also bind to AR in the stroma in order to 
produce growth factors that act on the epithelium, which is a paracrine mode of 
action (Culig et al, 1996). The production of androgen in testis is under the control of 
luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which are 
synthesized and secreted by the anterior pituitary under the control of 
gonadotropin-releasing hormone (GNRH). 
1.2.3 Pathogenesis of the prostate gland 
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The human prostate is a sex hormones targeted organ and both benign 
prostatic hyperplasia (BPH) and prostate carcinoma (Pea) are frequently developed 
in the prostate. About 50% of men from 51 to 60 years old and 90% over 80 year of 
age show histological evidence of BPH and suffer from various urinary symptoms 
(Berry et al, 1984). Besides, Pea is responsible for nearly 4% of all deaths in men 
over 55 years old and it is the second leading cause of male cancer deaths in the 
United States after lung cancer (Parker et al, 1997). Since the prostate is strictly 
androgen dependent, androgen ablation is the useful treatment for both BPH and 
prostate cancer. Reduction in androgen level is achieved by bilateral orchiectomy or 
by the administration of high dose of estrogens or GNRH agonists. The latter can 
block the axis between hypothalamus and pituitary, therefore inhibit the androgen 
production. However, most of the prostate cancer will progress to metastasis status 
and then be a hormone-refractory (androgen independent) carcinoma. The 
mechanism of progression from androgen dependent to androgen independent 
carcinoma usually involves abnormal changes of androgen receptor including 
mutation of AR coactivators, mutation of heat shock proteins (HSPs), AR 
amplification, AR mutation and the ligand-independent activation of AR by growth 
factors (Visakorpi et al, 1995; Marcelli et al, 2000; Culig et al, 1994). 
1.3 The role of estrogen receptors in prostate gland and prostate 
cancer 
Though androgen is the major hormone that controls the prostate growth 
and development, the roles of estrogens in prostate have been studied extensively 
over several decades. Accumulated evidences show that estrogens, which act through 
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the two isoforms of estrogen receptor (ERs), affect the normal growth and 
development, and also implicate in the pathogenesis of benign and malignant human 
prostatic tumors. 
1.3.1 Estrogens in male 
Estrogen is lipophilic hormone that regulates a wide variety of 
physiological processes, such as the reproductive cycle and bone homeostasis in 
female. Although both men and women synthesize both androgen and estrogens, 
relative ratios of two hormones in two sexes are quite different. The balance between 
systemic levels of these two hormones in male is changed significantly upon aging; 
plasma androgen level declines but estrogens level remain relatively constant. In 
male, estrogens synthesis occurs via aromatisation of androstenedione and 
testosterone by aromatase enzyme (cytochrome P450arom) in different tissues (Stone 
et al, 1986). This enzyme is a critical regulator of the balance between the androgen 
and estrogens. In male reproductive tract, aromatase is synthesized by germ cells 
within the testis (Carreau and Levallet, 1997). Both aromatase mRNA and protein 
have been detected in the stroma of prostate as well as epithelial tumour cells 
(Risbridger et al, 2003). Therefore, the effect of estrogens in the prostate can come 
from either exogenous or endogenous sources. In addition, Weihua et al (2002) 
demonstrate that the endogenous estrogen in the prostate is not 17(3-estradiol but 
5a-androstane-3(3, 17j3-diol (SpAdiol) which is a metabolite of 
5a-dihydrotestosterone. This steroid can directly interact with the estrogen receptors 
in the prostate. 
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1.3.2 Effects of estrogens in the prostate 
As estrogen is synthesized in male reproductive tract, it should have its 
own potential roles. In the experimental models, estrogens have both stimulating and 
inhibitory effects on the growth and differentiation of prostate gland through the two 
isoforms of estrogen receptor. The stimulatory effects of estrogens are revealed in the 
following studies. Estrogens can act synergistically with androgen in the rat prostate 
to increase prostatic growth and citric acid production. It has been hypothesized that 
this synergistic effect may be due to the induction of prolactin released by estrogens 
in the prostate gland. (39). Moreover, estrogens stimulate the growth of stroma and 
epithelium region in the castrated adult rodents (Thompson et al, 1979; Timms and 
Chandler, 1985). Santti et al (1994) discover that the neonatally estrogenized rats 
develop prostatic epithelial hyperplasia or even dysplasia if androgen is given 
together with estrogens. Besides, pharmacological doses of estrogens can induce 
squamous metaplasia which is a marked proliferative alteration of prostate 
epithelium in the normal or regressed prostate of castrated or hypophysectomized 
dogs (Leva et al, 1978). Furthermore, estrogens treatment of hypo gonadal (hpg) 
mouse model, a deficient in pituitary gonadotrophin and sex steroid production, 
results in squamous metaplasia of epithelial as well as expansion of stromal and 
luminal compartments of the mouse prostate lobes (Bianco et al, 2002). More 
important, studies in noble rats model of prostate cancer, in which premalignant 
lesions or cancer can be induced by long-term treatment with estrogens alone or with 
both androgen and estrogens, show that estrogens play some roles in the prostatic 
carcinogenesis (Li et al, 2001; Xie et al, 2000). Finally, the estrogen-dominant status 
in men after middle age implicates in the induction and progression of BPH as 
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patients have larger volumes of BPH tend to have high level of serum estrogens 
(Partin et al, 1991). 
On the other hand, several studies demonstrated that estrogens have the 
inhibiting effects in the prostate. Short-term treatments with high doses of estrogens 
to human and rodents cause atrophy of the prostate. This inhibiting effect on the 
prostate is indirect, and mainly mediated by suppressing the hypothalamus-pituitary 
axis and repressing the production of gonadotropins. This negative feedback effect of 
estrogens results in reducing the level of testicular androgen production and in turn 
regressing the prostatic epithelium since the prostate is absolutely androgen 
dependent. Thus, the inhibitory effect of chemical castration by estrogens have been 
applied to prostate cancer therapy for a long time. (46, 47). Estrogens action has also 
been tested in vitro organ cultured prostate. It has been found that the estrogens have 
a direct inhibitory role on the growth of the prostate epithelial cells (Jarred et al, 
2000). Moreover, estrogens supplementation causes growth inhibition of prostate 
cancer xenografts through the mechanisms that are independent of androgen action. 
(Corey et al, 2002) However, estrogens have both proliferative and anti-proliferative 
effects in different prostatic cell lines in vitro. For instance, estrogens treatment 
induces LNCaP cell proliferation but inhibits PC-3 cell proliferation. These 
differential responses may be due to the different of two isoforms of estrogen 
receptor transcripts levels in these two cell lines (Castagnetta et al, 1995; Carruba et 
al, 1994). Furthermore, two selective estrogen receptor modulators (SERM), 
raloxifene and 4-hydroxytamoxifen, induce apoptosis in androgen-independent 
human prostate cell. This apoptotic effects are probably mediated by estrogen 
12 
Chapter 1. Introduction 
receptors (El Etreby et al, 2000; Kim et al, 2002). 
1.3.3 Estrogen receptors - two isoforms 
The direct effects of estrogens on the prostate or their possible roles in 
BPH and Pea are believed to be mediated by estrogen receptors. Estrogen receptors 
(ERs) belong to class III nuclear receptor superfamily. There are two isoforms of ER, 
a and (3. ERa was cloned from MCF-7 human breast cancer cell line in 1985 (Greene 
et al, 1986; Walter et al, 1985) and ERp was later cloned from human testis and rat 
prostate (Kuiper et al, 1996; Mosselman et al, 1996). The structural comparison of 
ERa and ER(3 is shown in Figure 1.2. They share very high amino acid homology 
(96%) in the DBD, but only show 53% homology in the LBD and both of them 
consist of F domain with unknown functional role (Ogawa et al, 1998). This suggests 
that ERp would recognize and bind to similar response element as ERa, whereas 
each receptor may have a distinct spectrum of ligands. Both of them have their own 
mRNA isoforms either generated by alterative splicing or using different promoters 
with different potential functional significances and expression patterns in different 
tissues (Bollig and Miksicek, 2000; Lewandowski et al, 2002). ERa and ERp bind 
estrogens {particular the predominant natural form 17p-estradiol (Ei)}, 
4-hydroxytamoxifen (a selective estrogen receptor modulator) and ICI 164384 (an 
antagonist of ER) with similar affinities (Witkowska et al, 1997). Nonetheless, many 
other ligands show preferential binding to one of the ERs. For instance, some natural 
dietary components, coumestrol and genistein, show a preference to bind ERp 
(Kuiper et al, 1998) After binding to the ligands, ERs form the homodimer and 
activate transcription through binding same DNA target, an estrogen response 
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element (ERE). ERE is an inverted repeat of the core element AGGTCA which are 
separated by three nucleotides in the promoter regions of estrogen-regulated gene. 
However, ERs may act oppositely in regulating some target genes through other 
response elements other than ERE such as API site (Paech et al, 1997). In addition, 
ERa and ER(3 can form the heterodimer in vivo and in vitro and this indicates that 
they can cross-signaling each other (Paech et al, 1997). Nevertheless, the individual 
role of these two receptors has not been well characterized so far. 
1.3.4 Expression of estrogen receptors in the prostate 
Although ERa and ERp are similar in structures and transcriptional 
mechanisms, their expression patterns in different tissues are quite different. In rat, 
ERa is expressed moderately to highly in uterus, testis, pituitary, ovary, kidney, 
epididymis and adrenal while ER(3 is expressed mainly in prostate, ovary, lung, 
bladder, brain, uterus and testis (Kuiper et al, 1997). Two isoforms of estrogen 
receptor are found in human, rat as well as mouse prostate but they localize in 
different regions in the prostate. In human, several studies have consistently 
demonstrate that ERa is present in the stroma and at low level in basal cells (Shulze 
and Clans, 1990; Brolin et al, 1992; Hiramatsu et al, 1996), suggesting that 
estrogen-induced epithelial changes may be explained by a paracrine interaction 
between stromal and epithelial cells. However, cloning and characterization of ER(3 
suggest a re-evaluation of the estrogen-signaling system and function in the prostate. 
ERp is highly expressed in the luminal epithelial cells of the rat prostate (Kuiper et al, 
1997)，but there are conflicting reports on the cellular localization of ERP in human 
prostate. Northern blot analysis demonstrate that ERp mRNA expression is only 
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marginal present or absent in human prostate (Enmark et al, 1997; Bonkhoff et al, 
1999). When using the immunohistocehmistry (IHC) technique, Royuela et al (2001) 
report that ERP is significantly expressed and localized in the nuclei of the basal cells 
population, whereas others detected a similar expression pattern in the nuclei of 
stromal cells, basal cells and the cytoplasm of glandular epithelial cells (Leav et al, 
2001; Pasquali et al, 2001). Nonetheless, Pasquali et al (2001) fail to detect ERp by 
iummunohistochemistry in normal and malignant tissues. On the other hand, using 
the in situ hybridization technique, Tsumsaki et al (2003) indicate that ERp is present 
in luminal epithelial, basal epithelial as well as stromal cells of both peripheral and 
transitional zones of human prostate. Besides, both the ER[3 mRNA and protein have 
been detected in vitro in several prostatic cancer cell lines and normal primary 
culture of human epithelial cells (Pasquali et al, 2001; Linja et al, 2003). 
Several studies documented that loss or down regulation of ERa and ERp 
in neoplastic human prostatic tissues (Pea). Hobisch et al (1997) and Brolin et al 
(1992) reveal that completely loss of ERa in malignant prostatic tissues. An inverse 
correlation is also found between ERa expression and histologic grade or pathologic 
stage of operable prostate cancers (Nativ et al, 1997). On the other hand, Fixemer et 
al (2003) and Leav et al (2001) discover that the loss of ERj3 expression is associated 
with progression from normal prostate to cancer, whereas those cancers that retain 
ERp expression are associated with a higher rate of recurrence. In addition, Linja et 
al (2003) document that ERp gene is barely detected in malignant primary cultures of 
human prostate epithelial cells or is expressed as the deletion variants. Latil et al 
(2001), using real-time quantitative reverse transcription-polymerase chain reaction 
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assays, report that there is a decrease in expression of ERp in clinically localized and 
ERs in hormone-refractory prostate cancers. One of the mechanisms involving the 
down regulation of ERs in prostate cancer is de novo methylation of cytosine-rich 
areas, termed "CpG islands", in the 5' regulatory regions of the ERs. Sasaki et al 
(2002) and Li et al (2000) illustrate that the frequency of ERs promoter methylation 
is significantly higher in prostate cancer, whereas treatment of ERs-negative prostate 
cell lines with demethylating agent can restore ERs mRNA expression. However, the 
functional role of ERs in neoplastic transformation and pathogenesis of prostate 
cancer cells remains to be established and is too early to be answered. 
1.3.5 Estrogen-modulated transgenic mice 一 functional studies of ERs in the 
prostate 
Four types of estrogen-modulated transgenic mice were developed 
including ERa knockout mice (aERKO), ERP knockout mice (PERKO), compound 
of ERa and ER(3 knockout mice (apERKO) and aromatase knockout mice (ArKO). 
The uses of these transgenic mice contribute to the understanding of the roles of 
estrogens and the specific functions of ERs isoforms in the prostate growth and 
development. 
a. ERa knockout mice (aERKO) 
Adult male aERKO mice show normal development and histology of the 
prostate but their prostates are enlarged upon aging (Couse and Korach, 1999). When 
intact adult aERKO, (3ERK0 or wild type mice have been treated with high-dose 
synthetic estrogen, diethylstilbestrol (DES)，there is no change in the prostate of 
aERKO, but PERKO and wild type mice show regression of the prostate and induce 
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squamous metaplasia (SQM) (Risbridger et al, 2001). After neonatal exposure with 
estrogens, PERKO and wild type mice show estrogen imprint effects as epithelial 
dysplasia is induced in ventral and doesolateral prostate with aging. In contrast, no 
evidence of estrogen imprinting is found in aERKO mice (Prins et al, 2001). Thus, 
above findings suggest that ERa is the predominant receptor mediating mitogenic 
estrogens action in the prostate. 
b. ERfi knockout mice (fiERKO) 
Krege et al (1998) and Weihua et al (2001) demonstrate that pERKO mice 
develop epithelial hyperplasia in the prostate with multiple hyperplastic foci in the 
ventral prostate. Nevertheless, the report of Prins et al (2001) and Couse et al (2000) 
do not agree with this observation. Hence, the antiproliferative role of ER(3 in the 
prostate is still controversial and remains to be clarified. 
b. Compound of ERa and ERp knockout mice (a/]ERKO) 
The results of Dupont et al (2000) and Couse et al (1999) show that there is 
no significant change in both histology or cell proliferation in ventral, dorsal and 
lateral protate of a(3ERK0 mice. These data suggest that factors other than the 
absence of ER(3 contribute to the development of prostatic hyperplasia in the study of 
Krege et al (1998) and Weihua et al (2001). Overall, deficiency of either one of the 
ERs or both does not prevent the normal prostate development. 
d. Aromatase knockout mice (ArKO) 
The prostate of ArKO mice is enlarged and hypertrophic. No evidence of 
hyperplasia or malignancy in the prostate lobes was reported by any age (Fisher et al, 
1998； Honda et al, 1998). However, the prostate phenotypes in the ArKo and 
apERKO mice are not indentical and this suggests that there might be other 
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mechanisms of estrogen action in these receptor-deficient mice. Those mechanisms 
may involve another ER subtype or the actions of estrogens that are not mediated 
through ERs (Jarred et al, 2002). To conclude, there may be secondary estrogens or 
ERs-related pathways that speculate or modulate the traditional ERs mediated genes 
regulation in human prostate during growth, development and carcinogenesis 
processes. 
1.4 Estrogen receptor-related receptors: orphan receptors 
Estrogen receptor-related receptors belong to the Class III of nuclear 
hormone receptor superfamily and consist of three isoforms (a, p and y). The 
phylogenetic tree of Class III receptors is shown in Fig 1.3. ERRa and ERRp are the 
first orphan receptors being cloned based on the sequences homology to estrogen 
receptor a. Nevertheless, all isoforms do not bind any physiological estrogens and 
they can activate the transcription of target genes in ligand-independent manner. 
Though initial studies of them indicate that their developmental and physiological 
roles are quite distinct from classical ERs, more recent results suggest that the two 
subfamilies are closely related and they can cross-talk to each others. 
1.4.1 Estrogen receptor-related receptors: Three isoforms 
Human estrogen receptor-related receptor a (hERRa, NR3B1) was isolated 
from kidney cDNA library in 1988 by the low stringency screening using the DBD 
of ERa as a cDNA probe (named hERRl) (Giguere et al, 1988). The deduced amino 
acids length is 521. Nonetheless, Yang et al (1996) later isolate a shorter spliced 
variant (named hERRa 1) with only 423 deduced amino acids and show that it is the 
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predominant expressed form of ERRa in human. Mouse ERRa (mERRa) was cloned 
from brain and kidney cDNA libraries using hERRal cDNA as a probe in 1997 
(Shigeta et al, 1997) and it is shares 97% amino acids identity to hERRal. Human 
ERRa gene is located at the centromere region of chromosome Ilql2-ql3 (Shi et al, 
1997; Sladek et al, 1997) and mouse ERRa gene is located at chromosome 19 
(Sladek et al, 1997). Besides, human ERRa pseudogene was cloned in 1997 and it 
locus to chromosome 13ql2.1 (Sladek et al, 1997). It is the only pseudogene 
discovered among the three isoforms of ERRs so far. The sequences comparison 
between ERRa and ERa shows 70% homology in DBD and 35% in LBD. 
Human estrogen receptor-related receptor p (hERRp, NR3B2) was isolated 
together with hERRa in 1988 (Giguere et al, 1988). It was cloned from heart cDNA 
library and the deduced amino acids length is 433 (named hERR2). Later, a longer 
form of hERRp (hERR|32) was isolated with 500 deduced amino acids (Chen et al, 
1999). Mouse ERR(3 (mERRP) was identified from embryonal carcinoma stem cells 
in 1996 (Pettersson et al, 1996). hERRP gene is mapped to chromosome 14q24.3 and 
mERRP gene is located at chromosome 12 (Sladek et al, 1997). ERR|3 shows 71% 
homology with ERa in DBD and 31% homology in LDB. 
On the other hand, human estrogen receptor-related receptor y (hERJly, 
NR3B3) was identified from fetal brain cDNA library by joining the 920 bp fragment 
to the 1612 bp overlapping expressed sequence tag (EST) at 1998 (Eudy et al, 1998). 
Heard et al, 2000 later indicate that hERRy mRNA is highly alternatively spliced at 
the 5'end, giving rise to a number of tissue-specific RNA and protein isoforms. The 
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deduced amino acids lengths of two major forms are 435 and 458 (named hERRyl 
and hERRY2). The ERRy mouse homologue (mERRy) was isolated in 1999 by 
yeast-two hybrid screening, using the transcriptional coactivator glucocorticoid 
receptor interacting protein 1 (GRIPl) as bait (Hong et al, 1999). hERRy gene is 
located at chromosome lq41 region (Eudy et al, 1998) whereas the chromosome 
mapping of mERRy is absent. ERRy shows 68% homology with ERa in DBD and 
32% homology in LBD. Based on the sequence comparison, ERRy is more closely 
related to ERRj3 than ERRa. The sequences comparisons of ERRs to the ERa are 
shown in Figure 1.4 
Apart from the ERRs in human and mouse, Ostberg et al (2003) 
demonstrate that the genome of Drosophila melanogaster encodes a single member 
of ERR ortholog (dERR). It indicates that all group III nuclear receptors might have 
originated from an ancestral ERR. 
1.4.2 Expression of ERRs in different tissues 
Both ERRa and ERRy are highly and widely expressed in human and 
mouse tissues while ERRP is expressed at low level within several restricted areas in 
adults. The gene encoding ERRa is broadly expressed in both the developing embryo 
and the adults. This expression begins at very early stages in ES cells and at E8.5 in 
the mesodermal cells of the visceral yolk sac in mouse (Boimelye et al, 1997). In 
addition, ERRa is expressed in mouse embryonic intestine, brown fat and heart 
(Vacacker et al, 1998). On the other hand, Shigeta et al (1997) and Sladek et al (1997) 
document that ERRa is highly expressed in heart, brain, and kidney and moderately 
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expressed in lung and liver in adult mouse. Moreover, the mRNAs of ERRa is 
present in human placenta and prostate as well as cerebellum, intestine, heart, 
hippocampus, hypothalamus, kidney and prostate in rat (Giguere et al, 1988). 
Bonnely et al (1997) also demonstrate that its expression coincides with bone 
formation. Shi et al, 1997 report that ERRa is highly expressed in heart, skeletal 
muscle and moderately expressed in placenta, kidney, pancreas small intestine and 
colon in human adults. Besides, ERRa is expressed in osteoblastic osteoscarcoma 
cell lines as well as in primary osteoblastic cell populations derived from normal 
human bone (Bonnely et al, 1997). ERR(3 is present early in the developing placenta 
in a subset of cells in extra - embryonic ectoderm destined to make up the chorion 
(Pettersson et al, 1996). One recent study showed that ERRp is specifically 
expressed in primordial germ cells (Mitsunaga et al, 2004). Nevertheless, ERRp 
synthesis is highly restricted in postnatal life and is detected at low levels in the liver, 
stomach, skeletal muscle, heart and kidney in human and rat (Giguere et al, 1988; 
Chen et al, 1999). On the other hand, the third isoform of ERRs family, ERRy, is 
widely expressed in different tissues. In mouse embryro, the synthesis of ERRy start 
as early as day 11 in central nervous system and the highest expression occurred 
around 11-15 day stages (Hong et al, 1999; Susens et al, 2000). Human ERRy 
transcripts can be detected at very high levels in fetal brains, kidney, heart and 
skeletal muscle (Heard et al, 2000). In adult tissues, Heard et al (2000) also show 
that the gene encoding ERRy is widely expressed and can be detected in heart, brain, 
placenta, skeletal muscle, kidney, pancreas, spleen, prostate, intestine, testis and 
retina. In mouse, Susens et al (2000) and Hong et al (1999) demonstrate that ERRy is 
highly expressed in heart, kidney, brain and skeletal muscles. In addition, Lorke et al 
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(2000) report that ERRy is differentially expressed in mouse brain. The transcripts 
are abundantly present in the isocortex, the olfactory system, cranial nerve nuclei and 
major parts of the coordination centers and its expression pattern is distinguished 
from ERRa, ERRP as well as ERs in mouse brain. Although the ERRs probably play 
specific roles in development and in adult tissues, the broad expression patterns of 
their genes, especially ERRa and ERRy, indicate that they can also influence a wide 
range of physiological processes, including some that are regulated by ERs (Giguere 
et al, 2002). 
1.4.3. Promoters binding and genes regulated by ERRs 
Group III nuclear hormone receptors bind DNA as dimers to hormone 
response elements containing two inverted repeats spaced by three nucleotides. AR, 
PR, MR and GR recognize response elements containing the consensus half-sites 
AGAACA. However, ERRs and ERs bind as homodimers to estrogen-response 
element (ERE: AGGTCArmnTGACCT, 'n' refer to any nucleotides) (Pettersson et al, 
1996; Lu et al, 2001; Johnston et al, 1997). This is a functional feature distinguishing 
the two branches of subfamily. ERRs can also bind as homodimers to the consensus 
extended half-site, ERR-response element (ERRE, also named SFRE: TnAAGGTCA, 
‘n’ refer to any nucleotides) (Pettersson et al, 1996; Bonnelye et al, 1997; Johnston 
et al, 1997; Hong et al, 1999; Vanacker et al, 1999; Hentschke et al, 2002). This 
class of binding site is also recognized by the orphan nuclear receptor steroidogenic 
factor-1 (SF-1). Besides, ERRs can bind the DNA response element as monomers 
and this kind of binding preferentially recognize the ERRE (Sladek et al, 1997; 
Johnston et al, 1997; Yang et al, 1996). 
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Among the three members of ERRs, genes that are regulated by ERRa 
isoform are the most widely studied. It has been demonstrated that ERRa is able to 
transactivate the human lactoferrin gene through the binding of imperfect estrogen 
response element as well as the steroidogenic factor binding element (SFRE), 
TCAACCTCATC, 26 bas pairs upstream from the ERE at the lactoferrin gene 
promoter in endometrium cells (Yang et al, 1996; Xie et al, 1999). Moreover, ERRa 
can stimulate the expression of the human thyroid hormone receptor (TRa) that 
consists of the SFRE in the promoter region (Vacacker et al, 1998). This isoform is 
also a transcriptional regulator of the human and mouse medium-chain acyl 
coenzyme A dehydrogenase (MCAD), a key enzyme involved in the mitochondrial 
fatty acid P-oxidation in brown adipocyte (Sladek et al, 1997; Vega et al, 1997). 
ERRa can bind to the single consensus half-site, ERRE at the MCAD nuclear 
receptor response element 1 (NRRE-1). In addition, ERRa interacts with the silencer 
element (SI), AAGGTCAGAAAT, which is situated between promoters 1.3 and II of 
the human aromatase gene and in turn modulates the aromatase expression level 
(Yang et al, 1998; Chen et al, 2002). Furthermore, Lu et al (2001) show that the three 
ERR isoforms can activate the estrogen-inducible pS2 gene, a human breast cancer 
prognostic marker, through the binding of ERE and ERRE in the promoter region of 
this gene. Furthermore, ERRa binds as a monomer specifically to the SFRE sequence 
and transactivates the promoter of the mouse osteopontin (OPN) gene, which is a 
marker of the late stages of osteoblastic differentiation (Bonnely et al, 1997; 
Vanacker et al, 1998). Additionally, the expression of human endothelial nitric oxide 
synthase (eNOS), a factor the affects the vascular homoestasis and protects against 
aterosclerosis, can be also modulated by ERRa through the classic ERE element 
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(Sumi et al, 2003). On the other hand, ERRa is not only a transcriptional activator, 
but also plays the role in repression mechanism. ERRa is a cellular repressor of 
transcription of the SV40 major late promoter that is responsible for the 
replication-dependent component of the early-to-late shift in SV40 gene expression 
(Wiley et al, 1993. Furthermore, Ichida et al (2002) discover that the expression of 
ERRa can dramatically repress peroxisome proliferator-activated receptor 
coactivator-la (PGC-la) transcriptional activity. 
Unlike ERRa, the transactivation-target genes of ERRp and ERRy are 
much less studied. It has been known that both of them can modulate the expression 
pS2 gene as ERRa (Lu et al, 2001). ERRp can act as isoform-specific and 
cell-specific repressor of glucocorticoid receptor transcriptional activity in SK-N-MC, 
CV-1 and HeLa cells (Trapp and Holsboer, 1996). On the other hand, ERRy is able to 
activate the promoter of orphan nuclear receptor small heterodimer partner (SHP) 
gene, which is a repressor of transcriptional activities of a number of nuclear 
receptors including ERa. ERRy binds to specific response element, TCAAGGTTG, 
of the promoter of SHP and this element is differed from previously reported ERE 
and ERRE (Sanyal et al, 2002). 
1.4.4 Coregulators of ERRs 
Nuclear hormone receptors mediate gene transcription through interactions 
with coactivators and corepressors, a group of proteins that modulate chromoatin 
structure and recruit the basal trancription machinery (Mckenna et al, 1999). ERRs, 
which are classified as "orphan receptor", interact with some known coregulators. 
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The study of Xie et al (1999) demonstrate that the members of the pi60 family of 
nuclear receptor coactivators, including ACTR (activator of thyroid and retinoic 
acids receptors), GRJPl (glucocorticoid receptor interacting protein 1) and SRC-1 
(steroid receptor coactivator 1), potentiate the transcriptional activity by human 
ERRa and ERRp in mammalian cells. GRIP-1 can also bind to the AF-2 domain of 
ERRy and function as a transcriptional coactivator for ERRy in both yeast and 
mammalian cells (Hong et cd, 1999). Moreover, PNRC, a proline rich nuclear 
receptor, is a coregulatory protein that modulates the transcriptional activation of 
many class III receptors including AR, GR. It interacts with the orphan receptors SFl 
and ERRa in a ligand-independent manner (Zhou et al, 2000). In addition, Huss et al 
(2002) report that peroxisome proliferator-activated receptor coactivator-la (PGC-la) 
acts as a coactivator of ERRa since ERRa can bind to PGC-la in a yeast two-hybrid 
screen of a cardiac cDNA library. Besides, a search for novel coregulators of ERRy 
by Huss et al (2002) led to the identification of receptor interacting protein 140 
(RIP 140) as a potent corepressor and PGC-la as a potent coactivator of ERRy. So far, 
almost all coregulators can bind to ERRs in ligand-independent maimer and these 
observations suggest that ERRs are constitutive active nuclear hormone receptors. 
Apart from this, a recent study reveals that calmodulin, a predominant intercellular 
receptor for Ca^^ signals, acts as a mediator in the Ca2+ - dependent transactivation 
of ERRy (Hentschke et al, 2003). 
1.4.5 Ligands of ERRs 
Although ERRs are the first orphan receptors to be cloned, the identity of 
the natural and synthetic ERRs ligands remains unknown. Several studies 
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demonstrate that the three ERR isoforms could function as transcriptional activators 
in the absence of an exogenously added ligand (constitutively active). (Hong et al, 
1999; Xie et al, 1999; Zhang et al, 2000). However, other studies reveal that the 
presence of ERRs ligands that can regulate their transcriptional activity. Although 
ERRs are structural similar to ERs, they do not bind estradiol and other natural 
estrogens (Giguere et al, 1988; Yang et al, 1996). Crystal structure of the liganded 
ERa indicates that many amino acids that are crucial for estrogen binding are 
conserved among the ERRs (Shiau et al, 1998; Chen et al, 2001). It suggests that 
some ERs and ERRs ligands may be structurally related. The ligands of ERRs which 
have been found so far include diethylstilbestrol (DES), 4-hydroxytamoxifeii (OHT), 
two organochlorine persticides: toxaphene and chlordane as well as the unidentified 
serum component and peroxisome proliferator-activated receptor coactivator-la 
(PGC-la). 
First of all, DES is a synthetic estrogen that can act as an inverse agonist (if 
ERRs’ transcriptional activities are consititutive) or antagonists (if ERRs possess 
natural ligands) on all three isoforms of ERRs. DES is a potent synthetic estrogen 
that was used for the prevention of spontaneous abortions from 1940s to 1971s 
(Smith, 1999) and is still used for the treatment of advanced breast and prostate 
cancer (Ingle et al, 1981; Malkowicz, 2001). Nonetheless, the mechanisms of action 
of DES as an antiabortive agent and an antitiumor agent still remain to be elucidated. 
The study of Tremblay et al (2001) show that DES binding to the ERRs lead to the 
dissociation of coactivator proteins including steroid receptor coactivator-1 (SRC-1) 
and glucocorticoid receptor interacting protein 1 (GRIPl) in dose-dependent manner 
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and results in the loss of constitutive transcriptional activity of ERRs in vitro. 
Moreover, the treatment of DES trophoblast stem cells during early placentation in 
the mouse mimics the ERRP-deficient knockout mice phenotype. In addition, Lu et 
al (2001) report that the transcriptional activation of breast cancer marker, pS2 gene, 
by ERRs is completely abolished on treatment of DES. These discoveries define a 
novel pathway for the action of synthetic estrogen. 
In addition, selective estrogen receptor modulators (SERMs) are the drugs 
that display target site-specific estrogenic or antiestrogenic actions. The SERM 
tamoxifen (TAM) acts as an antiestrogen in breast cancer cells but stimulates uterine 
growth and maintains bone density (Jordan, 2001). Tremblay et al (2001) and 
Coward et al (2001) demonstrate that 4-hydroxytamoxifen (OHT), the active 
metabolite of TAM, functions as an isoform-specific ERRs inverse agonist or 
antagonist. It binds to ERRp and ERRy, disrupts the interaction between the 
coregulator protein, including SRC-1 and RIP 140, and abolishes the constitutive 
transcriptional activity in vitro. However, OHT does not recognize ERRa. These 
results demonstrate that the existence of novel receptor-based pharmacological 
pathways may contribute to the tissue-specific activities of OHT. The contrasting 
effects of DES and OHT on ERs and ERRs are shown in Figure 1.5 
Apart from the DES and OHT, two organochlorine pesticides, toxaphene 
and chlordane, can behave as the antagonists or inverse agonist of ERRa but not the 
others two isoforms. These two compounds are the endocrine disrupters that can 
display week estrogen-like activities. They can suppress the GRIPi 
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coactivator-induced ERRa transcriptional activity in vitro and reduce the aromatase 
activity in ERRa stable-transfected cells as aromatase expression is regulated in part 
by ERRa (Yang and Chen, 1999; Yang et al, 1998). 
Based on above studies, it is believed that some natural or synthetic inverse 
agonists could regulate the transcriptional activity of ERRs. This point of view is 
further supported by the study of Greschik et al (2002). He demonstrates that in the 
absence of a ligand, the ERRy LBD adopts a transcriptionally active conformation, 
while binding of DES or OHT in LBD requires a structural adaptation, which leads 
to an inverse agonist LBD conformation. It suggests that ERRs may represent 
ligand-inactivated rather than ligand-activated receptors. 
Nevertheless, an unidentified serum compound is necessary for ERRa 
transactivation function (Vanacker et al, 1999; Sumi et al, 2003). The study of 
Vanacker et al (1999) reveal that ERRa cannot activate the ERE response element 
under the charcoal treated serum condition. Sumi et al (2003) also show that ERRa 
fails to stimulate eNOS promoter-dependent luciferase activity in charcoal-treated 
serum. These data suggest that serum may contain some ERRa regulators or 
activators but not necessarily the small lipophilic ligands. 
Surprisingly, the most recent data suggests that the endogenous protein 
ligand of ERRa is present (Schreiber et al, 2003). Peroxisome proliferator-activated 
receptor coactivator-la (PGC-la) is a transcriptional coactivator of many nuclear 
receptors and it is implicated in the control of energy metabolism. PGC-la can 
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induce the expression of ERRa. Moreover, it interacts physically with ERRa and 
converts ERRa from a factor with little transcriptional activity to a potent regulator 
of gene expression. This indicates that ERRa is not a constitutively active receptor 
and the transformation into an active form is favored by binding to protein ligands, 
such as PGC-la, rather than small lipophilic ligands. 
1.4.6 Functional roles of ERRs 
Transcription factors of the nuclear hormone superfamily control 
numerous cellular processes during development and maintenance of homeostasis in 
animals. Several functional roles of ERRs, especially the ERRa isoform, were 
explored during the researches of last two decades. The wide expression pattern of 
ERRa in human, rat and mouse indicates that it plays some important physiological 
roles. First of all, more and more evidences agree that ERRa is related to human 
breast cancer. This ERR isoform is showed potential as a biomarker of unfavorable 
clinical outcome and its expression levels in breast cancer is correlated with 
expression of ErbB2, an indicator of aggressive tumor behavior (Ariazi et al, 2002). 
ERRa can also modulate the expression of aromatase and pS2, the gene related to 
breast cancer (Lu et al, 2001; Yang et al, 1998; Chen et al, 2002). Therefore, ERRa 
might have some roles in breast cancer development and progression. 
Furthermore, ERRa functions as a metabolic regulator in body. Firstly, using the 
knockout mice model, Luo et al (2003) demonstrate that mice lacking ERRa are 
resistant to a high-fat diet-induced obesity and show alteration in the expression of 
genes regulating adipogenesis as well as energy metabolism. Secondly, the 
medium-chain acyl coenzyme A dehydrogenase (MCAD)，a key enzyme involved in 
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the mitochondrial fatty acid P-oxidation in brown adipocyte, is the transcriptional 
target of ERRa (Sladek et al, 1997; Vega and Kelly, 1997). Thirdly, ERRa interacts 
with PGC-la in vitro and the latter is implicated in the control of energy metabolism. 
The levels of ERRa mRNA in vivo are higher in PGC-1 expressing tissues, such as 
heart, kidney and muscle (Huss et al, 2002). These three lines of evidences conclude 
that ERRa controls the energy metabolisms in the body. On the other hand, several 
studies suggest that ERRa plays the role in bone development and metabolism. 
Bonnely et al (1997) and Vanacker et al (1998) report that ERRa are expressed in 
bones formed by endochondral and intramembranous routes as well as osteoblastic 
osteosarcoma and the primary osteoblastic cells. It also acts as a cell-specific 
transcriptional activator of the mouse osteopontin (OPN) gene that is a marker of the 
late stages of osteoblastic differentiation. Comparing to the both ERa and ER(3, 
ERRa mRNA is expressed at high level in rat calvaria (RC) in vivo and rat bone 
marrow (REM) cells in vitro (Bonneiye and Aubin, 2002). Furthermore, Bonnelye et 
al (2002) revealed that ERRa is regulated by estrogens in bone and ERRa may play a 
functional role at several levels (osteoblasts, adipocytes and osteoclasts) in estrogen 
deficiency diseases such as osteoporosis. 
Apart from ERRa, the functional roles of other two isoforms still remain to 
be farther explored. It is only known that ERRp has an important role in early 
placentation because the homozygous mutant embryos generated by targeted 
disruption of the ERRp gene have severely impaired placental formation and 
abnormal chorion development, and they die at 10.5 days post-coitum (Luo et al, 
1997). For the ERRy, it has been demonstrated that this isoform is related to breast 
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cancer as it associates with favorable biomarkers in human breast cancer and is a 
proposed candidate target for therapeutic development (Ariazi et al, 2002) 
1.4.7 Cross talk between ERRs and ERs 
ERRs and ERs belong to Class III nuclear hormone superfamily and they 
are highly homology in their gene structures especially the DNA-binding domain. 
Accumulated evidences show that ERRs might cross talk to the classical ERs and 
regulate overlapping transcription pathways. ERRs can bind to the ERE and ERRE 
sequences in the promoter region of targeted gene. ERa dimers but not ERp dimmers 
can also recognize a functional ERRE (Vanacker et al, 1999). Therefore, they are 
almost complete overlapping in their binding specificity and the gene they regulated. 
Among the three members of ERRs, the relationship between ERRa and classical 
ERs is mostly studied. It has been demonstrated that ERRa and ERa might regulate 
the same target gene independently as well as interfering each other's functional 
activity by competition of binding site (Zhang and Teng, 2001). Additionally, ERRa 
and ERa bind to the same coactivators (SRC family) and compete with each other 
since most coregulators are limiting factors within the cells (Zhang and Teng, 2001). 
Moreover, Johnston et al (1997) and Yang et al (1996) reveal that the bacterially 
synthesized ERRa and ERa can physically interact and heterodimerize in vitro under 
specific condition. However, there are no reports that they can form functional 
heterodimers in vivo. On the other hand, several studies demonstrate that ERRa is an 
estrogen-responsive gene and downstream target of ERa in some specific cells. Liu 
et al (2003) and Shigeta et al (1997) show that estrogens enhance the ERRa level in 
mouse uterus and heart as well as human breast and endometrial cell lines. Bonnelye 
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et al (2002) also find that estrogen can up regulate the ERRa mRNA level during 
osteoprogenitor proliferation in bone. The major estrogen response of ERRa is 
mediated by a 34-bp DNA element containing multiple steroid hormone response 
element half-sites (MHREs) that are conserved between the human and mouse ERRa 
gene promoters (Liu et al, 2003). The presence of nuclear receptor binding elements 
in ERRa promoter indicates that this gene may also respond to a number of distinct 
nuclear receptor regulated signaling pathways. Nonetheless, the presence of this 
response element in other two ERR isoforms are still unknown. 
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Class Receptor Denomination isoform Ligand 
Class I TR Thyroid hormone a, |3 Thyroid hormone (T3) 
receptor 
RAR Retinoic acid receptor a,(3,y Retinoic acid 
VDR Vitamin D receptor / l-25(OH)2 vitamin D3 
PPAR Peroxisome proliferator a,(3,y Benzotriene B4, Wy 14.643 




Polyunsaturated fatty acids 
PXR Pregnane X receptor / Pregnanes, C21 steroids 
CAR Constitutive androstane a,(3 Androstanes: 1,4-bis 
receptor (2-(3,5-dichloropyridyloxy)) 
benzene 
LXR Liver X receptor a,p Oxysterols 
FXR Famesoid X receptor / Bile acids 
RevErb Reverse ErbA a,(3 Unknown 
RZR Retinoid Z receptor a,(3,y Unknown 
UR Ubiquitous receptor / Unknown 
Class II RXR Retinoid X receptor a,(3,y 9-Cw-retinoic acids 
COUP-TF Chicken ovalbumin a,p,y Unknown 
upstream promoter 
transcription factor 
HNF-4 Hepatocyte nuclear a,P,Y Fatty acyl-CoA thioesters 
factor 4 
TLX Tailles-related receptor / Unknown 
PNR Photoreceptor-specific / Unknown 
nuclear receptor 
TR2 Testis receptor a,p Unknown 
Class III GR Glucocorticoid receptor / Glucocorticoids 
AR Androgen receptor / Androgens 
PR Progesterone receptor / Progestins 
ER Estrogen receptor a,(3 Estradiol 
ERR Estrogen receptor a,(3,y unknown 
-related receptor 
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Class IV NGFI-B NGF-induced clone B a，|3,y Unknown 
Class V SF-1 Steroidogenic factor 1 Afi Oxysterols 
Class VI GCNF Germ cell nuclear Unknown 
factor 
Class 0 SHP Small heterodimeric Unknown 
partner 
DAX-1 Dosage-sensitive sex Unknown 
reversal 
Table 1.1 Subfamilies of mammalian nuclear hormone receptors (adopted from 
Aranda and Pascual, 2001) 
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Ligand binding 
A/B I C D E i r ^ C Q O H ^ 
M - 1 D i m binding： AP-2 
Figure 1.1 A typical stmcture of a nuclear homione receptor is composed of several 
functional domains (A/B, C. D, E andF regions). The ligand-independent 
trans criptioml activation domain (AF -1) and ligand-dependent 
transaGtivation domain are contained with A/B and E region respectively 
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ERa A/B C D E/F 
I / / f 1 -r / / / 
: 30% i 96% Ams/' 53% , 
I > / ‘ / { I J / / / 1 / ^ I ! t i r 
ERp Am C D E/F 
1 149 214 248 530 a. a 
Figure 1.2 Gomparis on of tiie structures b etween human ERa and ERp. The fonctional 
A to F domains are shQwn,. with the numbers ofanimo acid indicated. 
Percentage of amino acid identity is also represented 
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Figure 1.3 Phylogenetic tree of Class HI nuclear hormone reeeptor superfknily. 
Sequence comparsion analyses have shown that the ERs and the ERRs 
form one bmnch, whereas the four other steroid hormone rec eptors form 
another. 
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1 185 250 314 546 595 a a • • • + . 
ERa A/B C D E F 
1 79 144 198 423 a.a 
ERRa A/B 68% D 36% 
1 102 168 211 433 a.a 
ERRp Am 73% D 37% 
1 123 207 230 458 a.a 
E R R y A/B 6 9 % D 3 6 % 
Figure 1.4 Ammo： acid sequence compai^ion among humM ERa, ERRa, ERRp, and 
ERR-y. Mumbers in the bars indicate the pereentage of amino acid sequence 
in DNA-binding domain (C region) and ligand-binding domain (E region) 
identity to ERct 
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Figure 1.5 Constrasting effects of 4-OHT and DES on ERs and ERRs. 4-OHT 
activates ER a in the uterus and bone, but acts as an estrogen antagonist in 
breast It also deactivates ERE-p. and ERRy. DES is a potent ER agonist ‘ 
and inhibits ERF.S transcriptional activities. 
39 
Chapter 2. Aims of the study 
Chapter 2. Aims of the study 
Estrogen receptor-related receptors (ERRa, ERRp and ERRy) are the 
orphan nuclear receptors, which are highly homologous to the classic ERs in many 
aspects including protein sequences, promoter binding, coactivator recruitment as 
well as transactivation targets. In vitro experiments also demonstrate that ERRs could 
physically interact with ERs forming heterodimer. It is hypothesized that ERRs 
might share some regulatory pathways as ERs in the prostate. In addition, study of 
ERRs in the prostate gland is absent since the first isoform of ERRs was cloned in 
1988. Therefore, the present study was aimed to investigate the functional roles of 
ERRs in the prostatic cells growth and carcinogenesis. The expression profiles of 
ERRs are firstly characterized and compared to the other steroid hormone receptors 
and prostatic specific markers in the human prostatic cells lines, tumor xenografts 
and prostatic tissues. Moreover, subcellular localization, transcriptional activities of 
ERRs together with the relationship to the ER expression are also investigated in the 
prostatic cells. Furthermore, the functional roles of ERRs in the prostatic cell growth 
are explored in the transient and stable-transfected prostatic cells. The results of 
above experiments are believed being able to reveal some functional roles of ERRs 
in the prostate and provide us the new insights in the treatment of prostate cancer. 
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Chapter 3. Methods and materials 
3.1 Expression patterns of ERRs and steroid hormone receptors in 
the human prostate cell lines, tumor xenografts and prostatic 
tissues 
3.1.1 Human prostatic tissues 
The human hyperplasic (BPH) and neoplastic (Pea) tissues used in this 
study were given by Dr L. W Chan, The Chinese University of Hong Kong. Nine 
benign hyperplastic tissues were obtained from patients with benign prostatic 
hyperplasia (BPH) by TURP whereas five neoplastic tissues were obtained by radical 
prostatectomy or ultrasound-guided needle biopsy from prostate cancer (Pea) patients. 
The removed tissues were stored at -70°C for subsequent total RNA extraction. 
3.1.2 Cell cultures 
Nine immortalized human prostatic cell lines (including RWPE-1, RWPE-2, 
PWR-IE, PZ-HPV-7, HPr-1, HPr-1 AR, PNTIA, PNT2, BPH-1), seven prostatic 
cancer cell lines (including CA-HPV-10, LNCaP, C4-2B, DU 145, PC-3, MDA Pea ‘ 
2b, CWR22Rvl) and one breast cancer cell line MCF-7 were used in this study. The 
origins, passage numbers, descriptions, culture media and references of these cell 
lines are listed in Table 3.1. All the cells were routinely grown at 37 °C with 5 % 
CO2 in an air atmosphere under saturated humidity. Subculture was performed when 
the cells were 80 to 90 % confluency. The total RNA or whole cell protein lysates 
were extracted from the cells when they were 80 to 90 % confluency. 
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3.1.3 Human prostate cancer xenografts 
Three human prostatic cancer xenografts, CWR22, CWR22R 
(CWR22-AIM) and CWR22-AIF were used in this study. The primary xenograft 
CWR22 was developed from the human primary prostatic carcinoma in 1992 
(Pretlow et al, 1993) and provided by Dr T.G. Pretlow, Case Western Reserve 
University. This xenograft was grown in male nude mice supplemented with one 
1-cm long testosterone-filled (T; Fluka, USA) Silastic tubling® (Dow Cowling, 
USA), transplanted subcutaneously. The androgen-independent sublines, CWR22R 
and CWR22-AIF, were derived from the original CWR22 xenografts by growing in 
castrated male nude mice or female nude mice respectively. When the xenografts 
grew to the desired sizes, the nude mice were scarified and the tumors were either 
frozen in liquid nitrogen immediately, stored at -70°C for total RNA extraction or 
transplanted and maintained in another nude mice. 
3.1.4 Full length clones of ERR isoforms 
Mammalian Expression vector pSG5 (Stratagene，USA) with the full :: 
,1 
length of human ERR isoforms cDNA inserts were given by Dr S. Chen, Beckman 
Research Institute of the City of Hope. The map of pSG5 vector and the DNA inserts 
are shown in Figure 3.1. The size of ERRa (hERRal), ERRp (hERR2) and ERRy 
(hERRy2) full length inserts are 1269bp, 1299bp and 1374bp respectively. 
Restriction cutting was performed in order to check the DNA insert. Briefly, ERR 
full length clone ( � 0 . 5 i^g) was mixed with lOX SuRE/Cut buffer H {(2 [il) (Roche, 
Germany)}, EcoRl restriction enzyme {(2 |il) (Roche, Germany)} and the final 
volume was adjusted to 20 |il by autoclaved milli-Q water. The mixture was 
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incubated at 37 °C for two hours and then chilled on ice. The cutted vector was 
resolved in 0.9 % agarose gel with ethidium bromide 
3.1.5 Reverse transcription-polymerase chain reactions (RT-PCR) 
A. RNA extraction 
Total RNA were extracted from cell lines, human prostatic tissues and 
tumor xenografts by using the Trizol® reagent (Invitrogen, USA) according to 
manufacturer's procedure. When the cells were grown to 80 - 90 % confluency in 
60-mm culture dish, the growth medium was removed and the cells were washed 
briefly with Hank's solution. (GibcoBRL, USA). Trizol� reagent (1 ml) was then 
added and the cells were lysed in situ. The cell lysate in Trizol® reagent was 
collected after 10 minutes incubation. On the other hand, the frozen human prostatic 
tissues or xenografts were ground with the pestles in small mortars with liquid 
nitrogen. About 100 mg homogenized tissue was incubated with 1 ml Trizol® reagent 
and further homogenized by shearing using 23G needle and 10 ml syringe. The 
homogenate was collected and further incubated for 5 minutes. Chloroform (200 |il) 
.1 
was added to the cell lysate or tissue homogenate and the mixture was shaken ^ 
vigorously for 2 minutes. After 10 minutes incubation at room temperature, the total 
RNA was separated from DNA and protein by centrifugation at 12000 g for 15 
minutes at 4°C. The colourless supernatant containing the total RNA was collected 
and mixed with isopropyl alcohol (0.5 ml). The mixture was incubated at room 
temperature for 10 minutes in order to precipitate the total RNA. The white RNA 
pellet was then isolated by centrifugation at 12000 g for 15 minutes at 4°C, The 
pellet containing the extracted RNA was gently washed with 70% ethanol, air dried 
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briefly and re-dissolved in 20 to 50 |il diethyl-pyrocarbonate (DEPC) treated water. 
Concentration of RNA was quantified by measuring its absorbance at 260nm using a 
UV spectrophotometer (Bio-photometer, Eppendorf, Germany). 
B. Reverse transcription (RT) 
Total RNA isolated from the prostatic cell lines, human tissues and 
xenografts was digested by DNase before the reverse transcription in order to remove 
the genomic DNA contamination. Total RNA (10 jig), DNase-I {(2 |il) (10 U尔 1, 
RNase free, Boehringer Mannheim, Germany)} and lOx PGR (2 jil) buffer were 
mixed and the final volume was adjusted to 20 jil by DEPC-treated water. The 
mixture was incubated at 37 for 30 minutes for DNA digestion and then incubated 
at 65 °C for further 30 minutes in order to inactivate the DNase activity. The mixture 
was then mixed with oligo d(T)i2-i8 primer {(2 |il) (1 jig/ul, Invitrogen, USA)} and 
incubated at 70 for 10 minutes and quickly chilled on ice afterwards. RT master 
mix {lOx PGR buffer (2 [xl), 50 mM MgCb (2 pJ), lOmM dNTP mix (2 i^l), O.IM 
DTT (4 jil), DEPC-treated water (7 jil)} was added to the mixture and pre-warmed at 
I 
42�C. After 5 minutes, reverse transcriptase {(1 jil) (M-MLV, RNase H, point mutant, ^ 
200U/|il, Promega, USA) was added to the pre-warmed RNA mixture and further 
incubated at 42 °C for 90 minutes in order to synthesize the first strand 
complementary DNA cDNA). The RT reaction was stopped at 70 for 15 
minutes. The reversely transcribed cDNA was stored at -20 °C until the subsequent 
PGR reaction. 
C. Polymerase Chain Reaction fPCR) 
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The expression levels of twelve genes were examined in the human 
prostatic cells lines and xenografts including estrogen receptor-related receptor a 
(ERRa), estrogen receptor-related receptor (3 (ERRp), estrogen receptor-related 
receptor y (ERRy), estrogen receptor a (ERa), estrogen receptor p (ER(3), androgen 
receptor (AR), progesterone receptor (PR), glucocorticoid receptor (GR), aromatase, 
prostatic specific antigen (PSA/hK3), kallilrein 2 (KLK2/hK2) and pS2. The mRNA 
levels of ERRa, ERRf3 and ERRy were also studied in human prostatic tissues. PGR 
reaction was performed in the mixture of cDNA (1 |al), lOx PGR buffer (2.5 jil), 50 
mM MgCh (0.75 lOmM dNTP mix (0.5 |il), forward primer (0.5 jil), reverse 
primer (0.5 jil), autoclaved milli-Q water (19 jil) and Taq DNA polymerase {(0.25 
(5U/jal, Invitrogen, USA)} using a thermal cycler (programmable thermal 
controller-100, MJ Research, Inc, USA). The sequences of oligonucleotide primers 
and the conditions of PGR are listed in Table 3.2. The amplification of P-actin was 
served as internal control of cDNA amount and quality. Control reactions for PGR 
were performed by replacing RNA sample during RT reaction with DEPC-treated 
water (no RNA control), using RNA sample that was not reverse transcribed to 
i 
cDNA (no RT control) and replacing cDNA with autoclaved milli-Q water (no 1 
cDNA control). To visualize the PGR product, the sample was subjected to 
electrophoresis in 1.2 % agarose gel with ethidium bromide in Ix TAE buffer (40mM 
Tris-acteate, ImM EDTA) and the image was captured under UV transillumination. 
(Flow chem., Alpha Innotech Corporation, USA) 
3.1.6 Semi-quantitative RT-PCR analysis 
Semi-quantitative RT-PCR of ERRa, ERRp, ERRy, ERa and ERp mRNA 
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levels were performed and compared w i t h p-act in m R N A levels in the prostatic cell 
lines and xenografts. PCR condit ions were same as described above and summarized 
in Table 3.2. The opt imal PCR condi t ion was determined previously so that the 
ampl i f ica t ion was w i t h i n the exponential phase wi thout saturation. Separate reaction 
was performed in parallel using pr imer o f p-act in for comparative measurement. 
A f te r PCR, the product was resolved on a 1.2 % agarose gel w i t h ethidium bromide 
and the image was captured under U V transi l lumination. (F low chem., A lpha 
Innotech Corporation, U S A ) The intensity o f the band was converted into digital ized 
signal w i t h an image scanner and quanti f ied by a gel documentation program 
(F lowChem analysis software, A lpha Innotech Corporation, USA) . Signal intensities 
o f the ERRa, ERRp, ERRy, ERa and ERP products were normalized to the p-actin 
products in order to produce arbitrary units o f relative expression levels. The mean 
values 士 S.D. obtained f rom three independent experiments were plotted. 
3.1.7 Southern blot analysis 
A. Preparation of membrane ofDNA blot 
i 
,i 
The PCR products o f ERRa, ERRp and ERRy ampl i f ied f rom the prostatic i 
cell lines and xenografts were separated by 1.2% agarose gel electrophoresis. The gel 
was soaked in denaturing buffer (0.5N NaOH, 1.5M NaCl) at room temperature 
under the gentle agitation for 30 minutes w i t h two changes. Af terward, the denatured 
gel was neutralized by soaking the gel i n neutralization buffer (0 .5M Tr is-HCl, 1.5M 
NaCl , p H 7.5) at room temperature under the gentle agitation for 30 minutes w i th 
two changes. The D N A in the neutralized gel was then transferred onto a 
posit ively-charged ny lon membrane w i t h pore size 0.45 | im (Boehringer Mannheim, 
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Germany) using a vacuum suction blotter w i t h 0.4 bar suction force (MasterBlot , 
Uniequip , U S A ) for 2 hours. The blotted D N A fragment was cross-l inked w i t h the 
membrane by an UV-cross l inker (CI-1000 Ul t rav io let crosslinker). The cross-l inked 
D N A membrane was stored at 4 °C in a clean zip bag. 
B. Synthesis the DIG-labelled DNA probe 
ERRa, ERR(3 and ERRy c D N A probes were synthesized by PGR, using 
the fo rward and reverse primers l isted in table 3.2 and the pSG5 vectors containing 
the fa l l - length human ERRs c D N A inserts as templates. The D N A fragment was 
pur i f ied by Sephaglas BandPrep k i t (Pharmacia Biotech, U S A ) according 
manufacturer 's procedure. Br ie f ly , PGR product was separated by 1.2 % agarose gel 
electrophoresis and excised. Gel solubil izer (〜3 00 | i l ) was added to the cutted gel and 
then incubated at 60 unt i l the gel was completely dissolved. Sephaglas BP 
suspension was then added to the mixture, mixed wel l and incubated at room 
temperature for 5 minutes. The pellet obtained after 2 minutes centri fugation at 
12000 g was washed three times w i t h wash buffer and resuspended in 20 j i l 
autoclaved m i l l i -Q water. The mixture was then centrifuged at 12000 g for addit ion 2 • 
minutes and the supernatant containing pur i f ied D N A was collected and stored at -20 
°C unt i l subsequent labeling reaction. DIG-labeled c D N A probe was generated by 
random primer ol igo-label ing method using the D I G - D N A labeling k i t (Roche, 
Germany) according the manufacturer's procedure. Br ief ly , pur i f ied D N A (1.5 \xg) 
was heated at 100 °C fo l lowed by chi l led on ice for 5 minutes in order to denature the 
double strands D N A . Hexanucleotide m ix (2 ul), lOX D I G - D N A labeling m ix (2 j i l ) , 
k lenow enzyme {(2 }il), (2U/| i l , Roche, Germany)} were then added to the denatured 
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D N A template and incubated at 37 °C for 6 hours for D N A labell ing. Af terward, 4 M 
L i C l (2.5 j i l ) and 100% ethanol (75 | i l ) were added to the reaction mixture and placed 
at -20 °C overnight i n order to precipitate the labeled c D N A probe. The D N A was 
then pelleted by centr i fugat ion at 12000 g for 30 minutes at 4 °C , resuspended in 40 
| i l autoclaved m i l l i - Q water and stored at -20。C unt i l the hybridizat ion. 
C. Hybridization of membrane and colorimetric detection 
The ny lon membranes transblotted w i t h the ERRa, ERR(3 and ERRy D N A 
fragments were f i rst pre-hybridized w i t h 3 m l o f DIG-Easy H y b solut ion (Roche, 
Germany) i n a hybr id izat ion tube (diameter x length = 1 5 m m x 120 mm) at 60 °C for 
1 hour under gentle agitat ion ( 5 - 1 0 rpm). A t the same t ime, the DIG-labeled ERRa, 
ERR(3 and ERRy c D N A probes were denatured by heating at 100 °C for 5 minutes 
and chi l led on ice immediately. The denatured probes were applied to the blotted 
membranes together w i t h the 5 m l DIG-Easy Hyb solution in a f inal concentration 75 
ng/ml. The membrane was hybridizated to the c D N A probe at 60 °C overnight under 
gentle agitat ion (5-10 rpm). Af ter overnight hybridization, the unbound and : 
non-specific b inding c D N A probe was removed by washing the membrane w i t h 2 X i 
SSC, 0.1% SDS then I X SSC, 0.1% SDS for 15 minutes each at room temperature. 
The membrane was f inal ly washed w i t h O. IX SSC, 0.1% SDS for 30 minutes at 68 
Af ter hybr id izat ion wash, the membrane was blocked w i th blocking solution 
(blocking reagent, Roche, Germany) for one hour at room temperature. The 
membrane was then incubated w i th ant i-DIG-alkal ine phosphatase antibody diluted 
1:5000 in b locking solution (Roche, Germany) for one hour at room temperature in 
order to identi f icat ion o f hybridized DIG-labeled c D N A probe. Af ter the unbound 
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antibody was removed by washing in wash buffer ( I X maleic acid buffer, 0.3% 
Tween-20) for 2 times, the hybr idizat ion signal was detected by colorimetic method. 
Br ief ly , the membrane was incubated in substrate buffer (100 m M Tris-HCI, lOOmM 
NaCl , 50 m M M g C ^ - H i O ) for 10 minutes and then soaked in 10 m l substrate buffer 
containing substrates o f alkaline phosphase {45 j i l o f p-nitro-blue tetrazol iym 
chloride (NBT) , 75 mg/ml in N,N-dimethyl - formamide ( D M F A ) and 35 j i l o f 
5-bromo-4-chloro-3- indoly l phosphate (BCIP), 50 mg/ml in 
N,N-d imethy l - fonnamide ( D M F A ) } . The colorimetic reaction was stopped by 
r insing the membrane w i t h running tap water and the membrane was dried by the 
blot t ing w i t h f i l ter paper. 
3.1.8 Generation and characterization of polyclonal antibodies 
A. Peptides design 
Polyclonal antibodies against human ERRa, ERRp and ERRy were 
generated using the synthetic peptide approaches. A l l the synthetic peptides were 
purchased f rom Peptron Inc, (Korean) including peptides synthesis and modifications. 
Peptide N H 2 - K A E P A S P D S P K G S S E T E T E C - C 0 0 H representing amino acids 14-32 . 
o f h E R R a l (423 a.a) was synthesized and keyhole l impet hemocyanin ( K L H ) was 
cross-linked via the C-terminal additional cysteine. Peptides 
A c N H 2 - Y E D C T S G I M E D S A I K - C O N H 2 representing amino acids 76-90 o f hERRp 
(433 a.a) and ACNH2 -YDDCSSTIVEDPQTK -CONH2 representing amino acids 
101-115 o f hERRy2 (458 a.a) were synthesized w i th modif icat ion including 
N-terminal acetylation and C-terminal amidation. Keyhole l impet hemocyanin ( K L H ) 
was cross-linked via the C-terminal lysine. 5 mg of each K L H conjugated synthetic 
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peptide was purchased w i t h addit ional 1 m g ovalbumin (OVA) conjugated and 100 
j ig free peptide. The powder f o rm o f synthetic peptide was dissolved in m i l l i -Q water 
and adjusted to 600 j ig/ml . The dissolved peptide was aliquot to 0.5 ml / tube and 
store at -70 °C unt i l injection. 
B. Generation of antibodies 
Male N e w Zealand Whi te rabbit w i t h age around 3 months and weight 
between 2 to 3 kg was used to generate the polyclonal antibodies against the ERRs. 
They were bred in the Laboratory An ima l Services Centre, The Chinese Universi ty 
o f Hong Kong. Three rabbits were used for each antibody product ion w i t h total ly 
four peptide injections per rabbit at three weeks intervals. For each injection, 0.5 m l 
conjugate (300 j ig) was premixed w i t h 0.5 m l Freund's Adjuvant {complete for f irst 
and second injections, incomplete for th i rd and fourth injections, (Sigma, U S A ) } 
using the three ways stopper for 10 minutes. The mixture was then injected into 
rabbit subcutaneously at two different sites. Ten days after th i rd injection, 5 m l whole 
b lood (booster I I ) was taken f rom the rabbit through the large ear vein. Around 60 - 丨 
i 
i 
80 m l whole b lood (booster I I I ) was taken f rom the rabbit directly through the heart j 
chamber ten days after the fourth inject ion and the rabbit was scarified. The removed 
whole b lood was centrifuged at 4000 g for 30 minutes at 4 ° C after the b lood was 
clotted at room temperature for 30 minutes. The clear supernatant, represent the 
serum fract ion o f the whole blood, was collected and aliquoted before stored at -20 
oc. The sera o f booster I I and booster I I I were directly used to 
immunohistochemistry and western blot analysis. 
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C. Preparation of preabsorbed antibodies 
The free ERRa , E R R p and ERRy synthetic peptides were dissolved i n I x 
PBS to f ina l concentrat ion 5 j ig /ml . The dissolved peptides were m i x e d w i t h 
correspondent rabbi t antisera against ERRa , ERRp and ERRy in 1:1 vo lume ratio 
and incubated at 4 °C overnight under gentle shaking. The I g G fractions speci f ical ly 
recognize the ERRs i n the antisera were bound to the ERRs free peptides and fo rmed 
the complexes. A f te r overnight incubat ion, the mix ture was centr i fuged at 13000 g 
for 10 minutes at 4 °C i n order to precipitate the pept ide-ant ibody complex. The 
supernatant, represent the f ract ion o f preabsorbed antiserum (1 fo ld d i lu t ied) was 
col lected, al iquoted and stored at -20 °C. 
D. Construction of 6xHis-ERR fusion plasmids 
Polyhist id ine prokaryot ic prote in expression vector, pRSETA ( Invi t rogen, 
U S A ) contain ing 6 h ist id ine coding sequences at the N- termina ls o f cloned sequence, 
was g iven by D r K . B Wong, The Chinese Univers i ty o f Hong Kong. The map o f 
p R S E T A vector and the D N A inserts are shown in Figure 3.2. The polyhis t id ine -
ERRa, ERRP and ERRy fus ion prote in constructs were generated by subcloning the ] 
f u l l length PGR products o f ERRa, ERRp and ERRy ampl i f ied f r om pSG5-ERRs 
vectors into pRSETA vector through the B a m H l and E c o R l restr ict ion cut t ing sites. 
The pr imers used for PGR o f E R R a were as fo l l ow : the forward pr imer w i t h B a m H l 
l inker, 5 ' - A A T C G G A T C C A T G T C C A G C C A G G T G G T G G G —3，； the reverse pr imer 
w i t h EcoR l l inker, 5 ' - T A C C G A A T T C T C A G T C C A T C A T G G C C T C G A -3，. The 
pr imers used for PGR o f ERRp were as fo l l ow : the forward pr imer w i t h B a m H l 
l inker, 5 ' - T G C A G G A T C C A T G T C G T C C G A A G A C A G G C A - 3 ' ; the reverse pr imer 
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w i t h EcoRl l inker, 5 ' - A T C C G A A T T C T C A C A C C T T G G C C T C C A G C A - 3 , . The 
primers used for PGR o f ERRy were as fo l low: the forward pr imer w i t h BamHl 
l inker, 5 ' - T G C A G G A T C C A T G G A T T C G G T A G A A C T T T G - 3 ’； the reverse pr imer 
w i t h EcoRl l inker, 5 , - A T C C G A A T T C T C A G A C C T T G G C C T C C A A C A - 3 , . The 
translational start and stop codons were underlined. PGR was performed as fo l low: 
94。C 5 minutes and 25 cycles o f 94 1 minutes, 65。C 1 minutes, 72 °C 1 minutes 
using the Expand H i g h Fidel i ty PGR System (Roche, Germany) in order to reduce 
the copying error dur ing the PGR reaction. The ampl i f ied ERRa, ERRp and ERRy 
fu l l length D N A were pur i f ied by Sephaglas BandPrep k i t (Pharmacia Biotech, U S A ) 
as descried in section 3.1.7. The pur i f ied PGR products and pRSETA vectors were 
then cutted by restrict ion enzymes B a m H l and E c o R l and the products were pur i f ied 
using the Sephaglas BandPrep k i t (Pharmacia Biotech, U S A ) again. Af terward, 
l igat ion was performed as fo l low: M l lengths o f ERRa, ERRp and ERRy (4 pi ) were 
m ixed w i t h pRSETA vector (2 | i l ) , 5x l igat ion buffer (4 \xl), T4 ligase {(4 | i l ) 
(G ibcoBRL, U S A ) } and autoclaved M i l l i - Q water (6 |i l). The mixture was ligated at 
16°C overnight and l igat ion product was directly used to transform the D H 5 a E.coli 
competent cells. The colony that grew on L B agar plate containing ampic i l l in ( L B A , 
100 j ig /ml) was isolated, expanded and pur i f ied using the rapid plasmid miniprep 
system (Invitrogen, U S A ) according the manufacture's procedure. The isolated 
pRSETA-ERRs vectors were checked by restriction cutting and PGR using the genes 
specific primers that are shown in Table 3.2, in order to conf i rm the correct insert. 
E. Expression ofrecomhinant 6xHis-ERR fusion proteins 
The ampic i l l in resistant colonies o f pRSETA-ERRa, ERRp and ERRy 
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t ransformed C41 E.coli competent cells were picked and grown in L B A med ium 
(5ml ) at 37 °C overnight under continuous shaking (250 — 280 rpm). 0.5 m l overnight 
culture was expanded into 50 m l L B A and incubated at 37 °C under continuous 
shaking (250 - 280 rpm) unt i l OD600 reached 0.4-0.8 ( 3 - 4 hours). Isopropyl 
p -D -1 -thiogalactopyranoside ( IPTG) was then added to the exponential phase culture 
to f ina l concentrat ion 0.2 m M in order to induce the recombinant ERRs protein 
expression. A f te r incubat ion the bacteria culture at 25 °C 4 hours under continuous 
shaking (250 - 280 rpm), the bacteria was pelleted by centri fugation at 5000g for 10 
minutes at 4 ° C and lysed by 10 fo ld volume o f 2 X SDS protein loading buffer (100 
m M Tr i s -HCI p H 6.8, 200 m M DTT, 4% SDS, 0.2% bromophenol blue and 20% 
glycerol) w i t h I m M (Phenylmethylsul fonyl f luor id) PMSF proteinase inhibitor. The 
whole bacteria lysates w i t h the ERRs recombinant proteins were boi led for 10 m i n at 
95°C before al iquoted and stored at -70 °C 
F. Western Blot analysis of 6xHis-ERR recombinant proteins 
The bacteria whole lysates containing ERRa, ERRP and ERRy 
recombinant proteins were denatured by heating at 95。C for 10 minutes and 
separated by 1 m m thick, 10% sodium dodecyl sulfate polymacylamide gel 
electrophoresis (SDS-PAGE) using a min i -gel apparatus (Bio-Rad, USA) . The 
Protein was loaded at 3 | i l per lane and separated at 100 V constant voltages in I x 
running buffer (25 m M Tris-base, 0.2 M glycine, 0.1% SDS) for 1.5 hours unt i l 
bromophenol blue just arrived at the bot tom o f the gel. The apparent molecular size 
o f the protein was determined by referring to the board range pre-stained protein 
marker (Bio-Rad, USA) . Af ter electrophoresis, the protein on the gel was 
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electrophoretically transferred onto the polyvinl idene dif luoride (PVDF) membrane 
(0.2 j im, Westran® S, Schleicher & Schuell) i n I x transfer buffer (10% methanol, 25 
m M Tris-base, 0.25 M glycine) at 55 V at 4 overnight. The PVDF membrane was 
pretreated w i t h methanol for 5 seconds and soaked into I x transfer buffer at least 15 
minutes before blott ing. Af ter overnight transfer, the PVDF membrane containing the 
transferred protein was pre-blocked by 1% PBST ( I x PBS w i th 1% Tween-20) for 1 
hour at room temperature. Membrane was then incubated w i th primary antibodies 
{antiserum against ERRa, 1:1000; antiserum against ERRP, 1:1000; Mouse 
monoclonal antibody against polyhistidine, 1:2000 (Ant i -HisG antibody, Invitrogen, 
USA) }d i l u ted in 0.1% PBST containing 4% non-fat dry m i l k overnight at room 
temperature w i t h gentle shaking. The unbound antibody was removed by washing 
the membrane w i t h 0.1% PBST for 4 times w i th 15 minutes each. The membrane 
was then incubated w i t h alkaline phosphatase (AP) conjugated secondary antibodies 
(AP-conjugate goat anti-mouse antibody, 1:3000 and AP-conjugated goat anti-rabbit 
antibody, 1:2000, Zymed, USA) di luted in 0.1% PBST containing 4% non-fat dry 
m i l k for 1 hour at room temperature. Af ter washing the membrane w i th 0.1% PBST 
for 4 times w i t h 15 minutes each, the antigen-antibody binding site was detected by 
colorimetric reaction. Brief ly, the membrane was incubated in substrate buffer (100 
m M Tr is -HCI ,100mM NaCl, 50 m M MgCls.HzO) for 10 minutes and then soaked in 
50 m l substrate buffer containing substrates o f alkaline phosphase {45 | i l o f 
p-nitro-blue tetrazoliym chloride (NBT) , 75 mg/ml in N,N-dimethyl- formamide 
( D M F A ) and 35 | i l o f 5-bromo-4-chloro-3- indolyl phosphate (BCIP)，50 mg/ml in 
N,N -d imethyl - fonnamide ( D M F A ) } . The colorimetic reaction was stopped by 
rinsing the membrane w i th running tap water and the membrane was dried by the 
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blot t ing w i t h f i l ter paper. 
3.1.9 Western blot analysis 
A. Protein extraction from the prostatic cells 
RWPE-1, LNCaP, PC-3, DU145 and C W R 2 2 R v l prostatic cell lines were 
selected for the western blot analysis o f ERRs. Whole cell lysate was extracted when 
the cells grew to 80 — 90 % confluency in the 100-mm culture dish. Br ief ly , cells 
were washed br ief ly w i t h I x PBS, collected by trypsinization and washed w i t h cold 
I x PBS. The cells were then pelleted by centri fugation at 1500 g for 3 minutes. 
Who le cel l lysate was prepared by resuspending the cell pellet in ice-cold lysis buffer 
( 5 0 m M Tris-base, 5 0 m M NaCl , 1 m M DTT, I m M Sodium orthovanadate, I m M 
E D T A , 1 m M EGTA，1% NP-40, 0.5% SDS, p H 7.4). Af ter incubation on ice for 30 
minutes, the chromosomal D N A was sheared by repeated passages through 25G 
needle and 1 m l syringe. The protein lysate was then cleared by centri fugation at 
13000 g for 30 minutes at 4 and the protein concentration was determined by 
modi f ied lowery method w i t h bovine serum albumin (BSA) as a standard before 
al iquoted and stored at -70 °C unt i l electrophoresis. 
B. SDS-PAGE. Protein blottim and colorimetric detection 
Based on the results f r om the protein assay, equal amount o f protein 
sample was mixed w i t h 1/4 o f total volume o f 2X SDS protein loading buffer (100 
m M Tr is -HCI p H 6.8, 200 m M DTT, 4% SDS, 0.2% bromophenol blue and 20% 
glycerol) and adjusted to the equal f inal volume by lysis buffer. The protein was then 
denatured by heating at 95°C for 10 minutes and separated by 1 m m thick, 10% 
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sodium dodecyl sulfate polymacylamide gel electrophoresis (SDS-PAGE) using a 
min i -ge l apparatus (Bio-Rad, USA) . The apparent molecular size o f the protein was 
determined by referr ing to the board range perstained protein marker (Bio-Rad, 
USA) . The steps o f electrophoresis, protein b lot t ing and color imetic detection were 
same as descried i n section 3.1.8. The antibodies used including rabbit antiserum 
against ERRa 1:1000, rabbit antiserum against ERRj3 1:1000, rabbit antiserum 
against ERRy 1:500 and monoclonal antibody against (3-actin 1:2000 (Act in , pan 
Ab-5 , Neomarkers, USA) . 
3.1.10 Immunohistochemistry 
The normal, dysplastic and neoplastic human prostates paraf f in sections 
were dewaxed i n xylene, hydrated i n a decreasing series o f ethanol unt i l 80% ethanol. 
The hydrated section was treated w i t h 0.35 % hydrogen peroxide (H2O2) in absolute 
methanol for 30 minutes in order to remove the endogenous peroxidase act iv i ty and 
then rinsed i n dist i l led water for 2 times. To retrieve and expose the immunoreactive 
sites o f some antigens, section was incubated in retrieval buffer (O . IM Tr is-HCI, 5% 
urea, p H 9.5) at 95 °C for 15 minutes and left in the same buffer at room temperature 
for addit ional 15 minutes. Af ter r insing w i t h I x PBS for 2 times, the section was 
blocked w i t h the blocking solut ion (PBS w i th 1 % BSA, 0.1 % Tr i ton-X 100, 0.05% 
NaNs) at room temperature for 30 minutes. The section was then incubated w i th 
pr imary antibodies {rabbit antiserum against ERRa 1:400; rabbit antiserum against 
ERR(3, 1:400, rabbit antiserum against ERRy 1:200 and monoclonal antibody against 
H igh Molecular Weight keratin, 1:50 (Keratin, H M W Ab-2, Neomarkers, USA) } 
di luted in b locking solution in a humid chamber at room temperature overnight. For 
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negative control, section was incubated w i t h preabsorbed antisera against ERRa, 
ERRp and ERRy in b lock ing solution. A f te r overnight incubation, the unbound 
antibody was removed by washing the section w i t h I x PBS for 3 times w i t h 15 
minutes each. The section was then incubated w i t h biot inylated secondary antibodies 
di luted 1:200 i n b lock ing solution. {biot in-Sp-conjugated goat anti-rabbit IgG, 
biot in-Sp-conjugated donkey anti-mouse IgG, (Jackson ImmunoResearch 
Laboratories, U S A ) } for 1 hour at room temperature. Af ter washing the section w i t h 
I x PBS for 3 t imes w i t h 15 minutes each, peroxidase-conjugated streptavidin di luted 
1:200 (Jackson ImmunoResearch Laboratories, U S A ) was applied to the section and 
incubated for one hour a room temperature. Section was then washed w i th I x PBS 
for 3 t imes w i t h 15 minutes each and soaked in 0.1 M acetic buffer (pH 6) for 10 
minutes. The antigen-antibody binding sites in the section were revealed by a glucose 
oxidase -d iaminobenzidine (DAB) -n icke l intensi fy ing procedure. Brief ly, the section 
was incubated w i t h a n i cke l -DAB solution (240 ml ) containing nickel ammonium 
sulphate hexahydrate (9.6 g), ammonium chloride (96 mg), P-D-glucose (480 mg) 
and D A B (120 mg) dissolved in 0.1 M acetic buffer (pH 6) for 10 minutes. Glucose 
oxidase (1 ml , 3.75 mg/ml ) was then added in order to generate the H2O2 and 
immunosignal. The peroxidase reaction was stopped by running tap water and the 
section was dehydrated in a graded series o f ethanol, cleared w i th xylene and 
mounted w i t h Permount® before histological examination. 
3.2 Relationship of ERR and ER expressions in the prostatic cells 
3.2.1 Expression vectors of ERRa, ERRy and ERa 
Mammal ian expression vector pSG5, containing the fu l l length o f human 
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E R R a and human ERRy were descried in section 3.1.4. The mammal ian expression 
vector p c D N A 3 . 1 (Invitrogen, U S A ) , containing the fu l l length o f w i l d type human 
ERa (pcDNA3 .1 -ERa) was given by Dr L .K . Leung, The Chinese Univers i ty o f 
Hong Kong. The map o f pcDNA3 .1 vector and the D N A insert are shown in Figure 
3.3. Restr ict ion cutt ing was performed in order to check the D N A insert through the 
B a m H l and Xho 1 restr ict ion sites. The vector that was used for transfection 
experiment was isolated, expanded and pur i f ied f rom the bacteria using the rapid 
p lasmid min iprep system (Invitrogen, U S A ) according the manufacture's procedure. 
Several tubes o f autoclaved M i l l i - Q water eluted D N A were pooled together and the 
concentration was quanti f ied accurately by measuring its absorbance at 260nm using 
a U V spectrophotometer (Bio-photometer, Eppendorf, Germany). 
3.2.2 Transient transfection of ERRa, ERRy and ERa expression vectors in 
PC-3 cells 
PC-3 cell l ine was used to exam the relationship o f ERR and ER 
expressions in the prostatic cell. I t was cultured and maintained in 100-mm culture 
dish and subculture was performed at 70 — 80% confluency in order to maintain the 
cells i n the exponential growth condit ion. 24 hours before transfection, cells were 
seeded at density o f 2.5 x 10) cells i n 6-wel l plates. Cells were transfected either w i th 
1 |ig pSG5-ERRa, pSG5-ERRy, pSG5 (empty vector), pcDNA3.1-ERa and 
pcDNA3.1 (no inserts) using Fugene 6 reagent (Roche, Germany) according the 
manufacture's protocol. Br ief ly, Fugene reagent (3 j i l ) was diluted in 25 | i l 
O P T I - M E M medium (GibcoBRL, USA) . The D N A was then added to the diluted 
Fugene reagent and mixed gently. Af ter 30 minutes incubation at room temperature, 
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the DNA-Fugene complexes w i t h O P T I - M E M medium was direct ly added to the 
wel l . Tr iplate experiments were done by transfected three independent wel ls by the 
same vector. 24 hours after transfection, the med ium containing transfection reagent 
was removed and either fresh growth med ium (pSG5-ERRa, pSGS-ERRy, pSG5 
transfected cells) or fresh growth med ium containing 10 n M P-estradiol (Fluka, U S A ) 
(pcDNA3 .1 -ERa and p c D N A 3 . 1 transfected cells) was added to the wel l . A f ter 
further incubated for 24 hours, cells were lysed by Tr izo l® reagent (Invitrogen, U S A ) 
and store at -70 °C unt i l the subsequent R N A extraction. 
3.2.3 Semi-quantitative RT-PCR analysis 
Total R N A was extract and reverse transcripted to the first strand c D N A 
f r o m the PC-3 cells transfected w i t h either pSG5-ERRa, pSGS-ERRy, pSG5, 
pcDNA3 .1 -ERa or pcDNA3 .1 expression vectors. The detail procedures o f R N A 
extraction and reverse transcription were descried in section 3.1.5. For 
semi-quantitative RT-PCR analysis, Signal intensities o f the ERRa, ERRy, ERa and 
ERp products were normal ized to those o f P-actin products in order to produce 
arbitrary units o f relative expression levels. The mean values 士 S.D. obtained f rom 
three independent experiments were plotted. PGR conditions were described and 
summarized in Table 3.2. 
3.3 Intracellular Trafficking and transcriptional activity of 
GFP-tagged ERRs in the prostatic cells 
3.3.1 Construction of GFP-tagged ERR fusion plasmids 
Green fluorescence protein expression vector, pEGFP-Cs (Clontech, USA) , 
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conta in ing a red-shi f ted var iant o f w i l d - t y p e GFP at the N - te rm ina l o f c loned 
sequence, was g iven by D r X . G . Yao, The Chinese Univers i ty o f H o n g Kong . The 
map o f pEGFP-Cs vector and the D N A inserts are shown i n Figure 3.4. The 
GFP-tagged E R R a , ERRP and ERRy fus ion prote in constructs were generated by 
in- f rame subcloning o f the f u l l length PCR products o f ERRa, ERRp and ERRy 
amp l i f i ed f r o m pSG5-ERRs vectors. The pr imers used for P C R o f E R R a were as 
f o l l o w : the f o rward pr imer w i t h H i n d l l l l inker, 5 ' -
TATGAAGCTTATGTCC A G C C A G G T G G T G G G - 3 ’ ； the reverse primer with 
B a m H l l inker, 5 ' - C A T A G G A T C C T C A G T C C A T C A T G G C C T C G A - 3 , . The pr imers 
used for P C R o f ERR(3 were as f o l l ow : the fo rward pr imer w i t h X h o l l inker, 5 ' -
T A T G C T C G A G A T G T C G T C C G A A G A C A G G C A —3’； the reverse pr imer w i t h 
BamHl linker, 5,- TATAGGATCCTCACACCTTGGCCTCCAGCA-3’. The primers 
used for P C R o f ERRy were as f o l l ow : the fo rward pr imer w i t h X h o l l inker, 5 ' -
G T C G C T C G A G A T G G A T T C G G T A G A A C T T T G - 3 ’ ； the reverse pr imer w i t h 
B a m H l l inker, 5， -TATCGGATCCTC A G A C C T T G G C C T C C A A C A - 3 , . The 
translat ional start and stop codons were underl ined. PCR were per formed as fo l l ow: 
94。C 5 minutes and 25 cycles o f 94 °C 1 minutes, 65。C 1 minutes, 72 °C 1 minutes 
using the Expand H i g h F ide l i ty PCR System (Roche, Germany) i n order to reduce 
the copy ing error dur ing the PCR reaction. The ampl i f ied ERRa, ERRP and ERRy 
fu l l length D N A w i t h l inkers were pur i f ied by Sephaglas BandPrep k i t (Pharmacia 
Biotech, U S A ) as descried i n section 3.1.7. The pur i f ied PCR products and 
pEGFP-Cs vector were then cutted by restr ict ion enzymes and l igated together as 
descried i n section 3.1.8. The colonies that grew on L B agar plates containing 
karamyc in ( L B K , 50 j ig /ml ) were isolated, expanded and pur i f ied using the rapid 
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p lasmid min ip rep system ( Inv i t rogen, U S A ) according the manufacture's procedure. 
The isolated pEGFP-Cs-ERRa, pEGFP-Cs-ERRp and pEGFP-Cs-ERRy vectors were 
checked by restr ic t ion cut t ing and PGR using the genes specif ic pr imers that are 
shown i n Table 3.2 i n order to con f i rm the correct insert. 
3.3.2 Examination of transcriptional activity of GFP-tagged ERRs by 
luciferase assay 
A. Plasmids 
Fi re f l y reporter vectors, pGL3-basic (Promega, U S A ) containing three 
estrogen response elements (pGL3 -EREx3-Luc ) and three steroidogenic factor-1 
response element ( p G L 3 - S F l x 3 - L u c ) at the N- te rmina l o f luciferase prote in were 
g iven by D r S. Chen, Beckman Research Institute o f the Ci ty o f Hope. The reni l la 
reporter vector, p R L - C M V (Promega, U S A ) containing the C M V enhancer and early 
promoter elements i n order to provide h igh- level expression o f reni l la luciferase, was 
g iven by D r L . K Leung, The Chinese Univers i ty o f Hong Kong. These vectors were 
used to per fo rm the luciferase assay by co-transfection to the culture cells. 
I 
t: 
B. Luciferase assay 
PC-3, a human prostate carcinoma cel l l ine, was cultured and maintained i n 
100-mm culture dish and subculture were performed at 70 — 80% confluency i n order 
to mainta in the cells i n the exponential growth condit ion. 24 hours before 
transfection, cells were seeded at density o f 5 x 10 cells in the 24-wel l plates. Cells 
were co-transfected w i t h 0.125 ^ig pGL3-EREx3-Luc or pGL3 -SF l x3 -Luc , 0.125 |ig 
pEGFP-C3 -ERRa, pEGFP-Cs-ERRp, pEGFP-Cs-ERRy or pEGFP-Cs (no insert) and 
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0.0125 | ig p R L - C M V vectors us ing Fugene 6 reagent (Roche, Germany) according 
the manufacture 's protocol . The detai l procedures were described i n section 3.2.2 and 
0.75 jj-1 o f Fugene 6 reagent was used for each transfection. 48 hours after 
t ransfect ion, cells lysate was used to assay the luciferase ac i t iv i ty using the 
Dual-Luci ferase® Reporter Assay System (Promega, U S A ) according the 
manufacture 's protocol . Br ie f l y , cells i n the 24 -we l l plates were washed w i t h I x PBS 
and lysed by I x passive lysis buf fer (100 [d) for 10 minutes at r oom temperature 
under gent ly shaking. The plate was then placed at -70 °C for one hour before 
proceeded to next step. Cel ls were then scraped by rubber po l iceman and the cel l 
lysate was collected. A f te r centr i fugat ion at 13000 g for 1 minute, the supernatant 
(20 | i l ) o f each sample was transferred into the whi te 96-we l l plates ( B M G 
Labtechnologies G m b H , Germany). Luci ferase assay buffer II (50 [ lY) was then 
added to each w e l l and the luminance response o f f i re f l y luciferase act iv i ty o f 
GFP-tagged ERRs to the E R E and E R R E response elements was measured by 
Fluostar Galaxy plate reader ( B M G Labtechnologies GmbH, Germany). A t the 
meanwhi le , 5Ox reni l la luciferase substrate was di luted to I x i n stop and go® buffer. 
A f te r the f i re f l y luciferase act iv i ty was measured, stop and go® buf fer w i t h the I x ： 
substrate (50 }i l) was added immediate ly into each we l l and the luminance response 
o f reni l la luciferase act iv i ty was measured by Fluostar Galaxy plate reader ( B M G 
Labtechnologies GmbH，Germany) . The E R E or ERRE transactivation activit ies 
represented by f i re f ly luciferase l ight uni t was normal ized w i t h that o f reni l la 
luciferase l ight uni t to obtain the relat ive luciferase uni t ( R L U ) and the fo ld induct ion 
o f R L U compared to control (cells transfected w i t h pEGFP-Cs, empty vector) was 
calculated. Each transfection and luciferase assay was performed in tr ipl icate and the 
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mean 土 S.D. o f fo ld induct ion were plotted. 
3.3.3 Subcellular localization of GFP-tagged ERRs in the living prostatic cells 
24 hours before transfection, exponential growing PC-3 cells were seeded 
at density o f 9 x lO* cells on 25 m m polylysine coated coverslips in the metal rings. 
Cells were transfected either w i t h 0.5 j ig pEGFP-Cs-ERRa, pEGFP-Cs-ERRp, 
pEGFP-Cs-ERRy or pEGFP-Cs (empty vector) alone, using Fugene 6 reagent (Roche, 
Germany) according the manufacture's protocol. The detail procedures were 
described i n section 3.2.2 and 1.5 [ i l Fugene reagent was used for each transfection. 
Two groups o f experiment were done in this study. The cells in the first group were 
transfected and maintained in the presence o f 10% fetal bovine serum (FBS) whereas 
the cells i n the second group were transfected and maintained in the absence o f FBS 
(serum free medium). 48 hours after transfection, the l iv ing cells were directing 
examined (wi thout f ixat ion) using a B ioRad M R C 1024 confocal scanning 
microscope w i t h 488 m m excitat ion f i l ter and 518 m m fluorescein isothiocyanate 
(F ITC) emission filter. The green fluorescent and transmitt ion images were then 
I 
captured using either lOX, 20X or 40X magnif icat ion objectives. | 
fj 
3.2.4 Immunofluorescent staining GFP-tagged ERRs 
The exponential growing PC-3 cells were seeded at density o f 5 x cells 
on 13 m m polylysine coated coverslips placed in the 24-wel l plates 24 hour before 
transfection. Cells were transfected either w i th 0.25 j ig pEGFP-Cs-ERRa, 
pEGFP-Cs-ERRp, pEGFP-Cs-ERRy or pEGFP-Cs (empty vector) alone, using 
Fugene 6 reagent (Roche, Germany) according the manufacture's protocol. The 
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detai l procedures were described in section 3.2.2 and 0.75 )i l Fugene reagent was 
used for each transfection. 48 hours after transfection, cells were f ixed w i t h 40% 
paraformaldehyde in I x PBS for 2 hours at room temperature. A f te r r insing w i t h I x 
PBS for 3 t imes, cells transfected w i t h pEGFP-Cs-ERRs were incubated w i t h 
correspondent pr imary antibodies (rabbit antiserum against ERRa, 1:800; rabbit 
antiserum against ERR(3, 1:800; rabbit antiserum against ERRy 1:200) in the d i lu t ion 
buffer (PBS w i t h 1 % B S A , 0.1 % Tr i ton-X 100, 0.05% NaNs) at room temperature 
overnight under the gentle shaking. For control, cells transfected w i t h pEGFP-Cs 
(empty vector) were incubated w i t h pr imary antibodies against ERRs. Af ter 
overnight incubation, the unbound antibody was removed by washing the cells w i th 
I x PBS for 3 times w i t h 15 minutes each. Cells were then incubated w i t h 
conjugated donkey anti-rabbit I gG di luted 1:400 (Jackson ImmunoResearch 
Laboratories, U S A ) for 2 hours at room temperature. Af ter washing the cells w i t h I x 
PBS for 3 t imes w i t h 15 minutes each, the coverslip was removed f rom the 24-wel l 
plates and mounted on the slide w i t h glycerol. Cells were examined using a BioRad 
M R C 1024 confocal scanning microscope w i t h either 488 m m excitation f i l ter and 
518 m m F ITC emission f i l ter (green fluorescence) or 568 m m excitation f i l ter and 
596 Cy3 emission f i l ter (red fluorescence). The green fluorescent, red fluorescent 
and transmitt ion images were then captured using either lOX, 20X or 40X 
magni f icat ion objectives. 
3.4 The role of ERRs in the growth of the prostatic cells 
3.4.1 Evaluation the transfection efficiencies of PC-3 and PNT2 cells 
The transfection efficiencies o f PC-3, a human prostate carcinoma cell line 
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and PNT2, a normal prostate epithelial cel l immorta l ized by SV40 were tested using 
3-gal staining k i t ( Invi trogen, U S A ) before the subsequent experiments were 
performed. They were cultured and maintained in 100-mm tissue culture dish and 
subculture was per formed at 70 - 80% confluency in order to maintain the cells in 
the exponential g rowth condit ion. 24 hours before transfection, cells were seeded at 
density o f 5 x cells i n the 24-wel l plates. Cells were transfected w i t h 0.25 j ig 
pcDNA3.1H is /LacZ using using Lipofectamine 2 0 0 0 ™ and P lus™ reagent 
( Invi trogen, U S A ) according the manufacture's protocol. Br ief ly , D N A (0.4 j ig) was 
f irst d i luted i n 25 ii\ O P T I - M E M medium (GibcoBRL, U S A ) and P lus™ reagent (2 
j i l ) was added to the di luted D N A and incubated at room temperature for 15 minutes. 
The pre-complexed D N A was then combined w i t h the di luted Lipofectamine 2 0 0 0 ™ 
reagent (2 j i l i n 25 j i l O P T I - M E M medium), mixed gently and incubated at room 
temperature for further 15 minutes. Wh i le the complex was forming, the med ium on 
the cells was replaced by the normal growth medium without serum (0.2 ml) . The 
DNA-P lus™-L ipo fec tamine 2 0 0 0 ™ reagent complex w i t h O P T I - M E M was directly 
added direct ly to the cells. Af ter f ive hours incubation, the serum-free medium : 
containing the complex was replaced w i t h fresh, complete medium in order to : 
maximize the cell growth. 48 hours after transfection, the growth medium was 
removed and the cells were washed w i th I x PBS before f ixed by 0.3 m l I x f ixat ive 
solut ion (2% formaldehyde, 0.2% glutaraldehyde in IxPBS) for 10 minutes at room 
temperature. Cells were then stained by 0.25 m l staining solution (4 m M potassium 
ferricyanide, 4 m M potassium ferrocyanide, 4 m M magnesium chloride, 1 mg/ml 
X-ga l i n I xPBS) at 37 °C overnight. The successfully transfected cells that expressed 
the lacZ gene product, P-galactosidase were stained in blue colour and observed 
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under the inverted microscope. The transfection eff iciency in percentage was 
estimated by counting the tranfected cells in f ive random areas. 
3.4.2 Cells proliferation assays in ERRs transient transfected prostatic cells 
PC-3 and PNT2 cells were selected to exam the role o f ERRs in the 
prol i ferat ion o f prostatic cells under the transient expression condition. 24 hours 
before transfection, exponential growing cells were seeded at density o f 5 x cells 
i n the 24-wel l plates. Cells were transfected either w i th 0.4 | ig pSG5-ERRa, 
pSG5-ERRp, pSG5-ERRy or pSG5 (empty vector) alone using Lipofectamine 
2000™ and P l u s ™ reagent (Invitrogen, USA) according the manufacture's protocol. 
The detail procedures were described in section 3.4.1. 72 hours after transfection, 
cells were trypsinized and the number o f cells was counted directly using the 
hemocytometer under the invert microscope. The means o f cell number 士 S.D. o f 
four indiv idual measurements were plotted. 
3.4.3 Flow cytometry of ERRs transient transfected PC-3 cells 
Exponential growing PC-3 cells were seeded at density o f 2.5 x 10^ cells in : 
the 6-wel l plates 24 hours before transfection. Cells were transfected either w i th 2 j ig 
pSG5-ERRa, pSG5-ERR(3, pSG5-ERRy or pSG5 (empty vector) alone using 
Lipofectamine 2000™ and Plus™ reagent (Invitrogen, USA) according the 
manufacture's protocol. The detail procedures were described in section 3.4.1 but 10 
jj,l PlusTM reagent and Lipofectamine 2000™ reagent were used for each transfection. 
48 hours after transfection, cells were washed briefly w i th I x PBS, trypsinized and 
the cell pellet was collected. Af ter the pellet was washed w i th 0.9% NaCl, cells were 
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resuspend w i t h 0.9% N a C l (263 | i l ) . 95% ethanol (737 pJ) was then added to the cell 
suspension (the f ina l concentration o f ethanol is 70%) in order to f i x the cells. A f te r 
incubat ion for 30 minutes at 4°C, the f ixed cells were collected by centr i fugat ion at 
1500 g for 3 minutes and washed w i t h 0.9% NaC l to remove the residual ethanol. 
The f i xed cells were then re-suspend into 0.9% NaC l (900 |i l). The R N A o f the cells 
was digested by adding the RNase A (50 p i ) { (200 j ig /ml in 10 m M Tr is-HCI , p H 7.5 
and 15 m M NaC l ) (Sigma, U S A ) } wh i le the D N A o f the cells was stained by adding 
the propod ium iodide (50 j i l ) { (1 mg/ml ) (Sigma, U S A ) } . Af ter staining the D N A at 
room temperature for 30 minutes in dark, D N A content o f the cells was ready to 
analyze by Beckman Coulter EPICS A l t ra f l ow cytometer (Beckman Coulter, Inc, 
USA) . Immediately before running, cells were completely re-suspended and passed 
through the 70|j, ny lon membrane in order to remove the cell doublets. The 
fluorescence o f prop id ium iodine was measured by argon laser w i t h 488 m m 
excitat ion wavelength and 610 m m emission wavelength. The cell cycle distr ibut ion 
pattern was assessed by Expo32 software, Version 1.0 (Beckman Coulter, Inc, USA) . 
20000 single cells were analyzed f rom each sample and the mean percentage 士 S.D. 
o f GO/Gl , S, G 2 / M phases and ratio o f GO/Gl to G 2 / M phases o f three independent '也 
experiments were plotted. 
3.4.4 RT-PCR of cell cycle-related genes in ERRs transient transfected PC-3 
cells 
The expression levels o f cell cycle-related genes were studied in the ERRs 
transient transfected PC-3 prostatic cells including f ive cycl in dependent kinase 
( C D K ) inhibitors p i 6 , p i 8 , p i 9 , p21, p27 and a tumor suppressor gene p53. The 
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exponential g rowing PC-3 cells were seeded at density o f 3.5 x 10^ cells i n the 6-we l l 
plates 24 hours before transfection. Cells were transfected either w i t h 2 j ig 
pSG5-ERRa, pSG5-ERRp, pSGS-ERRy or pSG5 (empty vector) alone using 
L ipofectamine 2 0 0 0 ™ and P l u s ™ reagent (Invitrogen, U S A ) according the 
manufacture's protocol. The detail procedures were described in section 3.4.1 but 10 
j i l P l u s ™ reagent and Lipofectamine 2 0 0 0 ™ reagent were used for each transfection. 
Triplate experiements were done by transfected three independent wells by the same 
vector. Fourty-eight hours after transfection, total R N A was extracted f rom the cells 
and reversely transcripted to the f irst strand c D N A . PGR were performed according 
to the descript ion i n section 3.1.5. The sequences o f ol igonucleotide primers and the 
condit ions o f PGR are l isted in Table 3.2. For semi-quantitative RT-PCR analysis, 
signal intensity o f the p21 product was normalized to those o f P-actin product in 
order to produce arbitrary units o f relative expression level. The mean values 士 S.D. 
obtained f rom three independent experiments were plotted. 
3.4.5 Generation of PNT2 and DU145 cells stably transfected with ERRy 
A. Construction of ERRy stable expression plasmid ：功 
The pCI-neo-ERRy mammal ian expression vector was constructed by 
subcloning the fu l l length human ERRy directly f rom the pSG5-ERRy to pCI-neo 
vector (Promega, USA) . pCI-neo vector consists the neomycin resistant gene that can 
be used for stable transfection. Br ief ly , pSG5-ERRy vector was cutted by EcoR l 
restr ict ion enzyme and the result ing fragment, containing fu l l length o f human ERRy 
(1374 bp) was ligated to the E c o R l cutted pCI-neo vector. The l igat ion product was 
used to transform the D H 5 a E.coli competent cells. The colony that grew on L B A 
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agar plate was isolated, expanded and pur i f ied using the rapid plasmid miniprep 
system (Invi t rogen, U S A ) according the manufacture's procedure. The corrected 
or ientat ion o f isolated pCI-neo-ERRy was checked by D N A sequencing using B i g 
dye® version 3.1 sequencing k i t (App l ied Biosystems, USA) . Br ief ly , D N A vector (1 
j ig) was m ixed w i t h 5x B igDye sequencing Buf fer (4 j i l ) , Terminator Ready Reaction 
Premix (8 | i l ) , 0.5 | i l o f T? sequencing pr imer (5 ' - G T A A T A C G A C T C A C T A T A 
G G G C ) and autoclaved m i l l i -Q water was added to f inal ly 20 j i l volume. The 
sequencing PGR was then performed as fo l lowed: 94。C for 5 minutes fo l lowed by 40 
cycles o f 94°C, 55°C and 72°C for 1 minute each and f inal extension at 72°C for 10 
minutes using a thermal cycler (programmable thermal controller-100, M J Research, 
Inc, USA) . The PCR product was pur i f ied by ethanol precipitat ion as descried in 
section 3.1.7 and resuspended in 10 | i l template suppression reagent (Appl ied 
Biosystems, USA) . The sample was denatured by heating at 95°C for 5 minutes and 
then chi l led on ice immediately. The D N A at this step is ready to sequence by the 
A B I 310 sequencing machine (Appl ied Biosystems, U S A ) by capil lary 
electrophoresis sequencing method. The D N A sequence was analyzed by the 
[ 
DNAs is t Version 1.02 D N A sequence analysis software (Huge Patterton, USA) . The '' 
map o fpCI -neo vector and the D N A insert are shown in Figure 3.5. 
B. Generation of ERRy stable-transfected PNT2 and DU145 cells 
PNT2 cells and DU145 were selected to generate the ERRy 
stable-transfected cell. The cell l ine were cultured and maintained in 100-mm culture 
dish and subculture was performed at 70 - 80% confluency in order to maintain the 
cells i n the exponential growth condit ion. For the PNT2 cells, cells were seeded at 
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density o f 5 x 10^ cells i n the 60 -mm culture dish 24 hours before transfection. Cells 
were then transfected either w i t h 2 j ig pCI-neo-ERRy or pCI-neo (no inserts) alone 
using Fugene 6 reagent (Roche, Germany) according the manufacture's protocol. The 
detail procedures were described in section 3.2.2 and 6 | i l Fugene reagent was used 
for each transfection. For the DU145 cells, cells were seeded at density o f 1.375 x 
10^ cells i n the 100-mm culture dish 24 hours before transfection. Cells were then 
transfected either w i t h 10 j ig pCI-neo-ERRy or pCI-neo (no inserts) alone using the 
Lipofectamine 2 0 0 0 ™ and Plus^^ reagent (Invitrogen, U S A ) according the 
manufacture's protocol. The detail procedures were described i n section 3.4.1 and 50 
|j.l L ipofectamine 2 0 0 0 ™ and P lus™ reagent were used for each transfection. 24 
hours after transfection, pCI-neo-ERRy and pCI-neo transfected PNT2 and DU145 
cells were trypsinized and plated at a density o f 2 x 1CP in 60-mm culture dish and 
5.5 X 10^ in 100-mm culture dish respectively. 600 [ig/ml G418 and 1000 |^g/ml 
G418 (Promega, U S A ) was then added to the PNT2 and DU145 cells respectively 
after 24 hours in order to select the stable transfected cells by k i l l i ng the 
untransfected cells. A f te r 3 weeks selection, the G418 resistant stable clones (arising 
I . 
I J 
f r om single transfected cell) were r ing cloned using the small metal r ing (4 m m '』 
diameter). Br ief ly , the location o f G418 resistant clone was marked at the bot tom o f 
culture dish under the invert microscope. Cells were washed br ief ly w i t h Hank's 
solution. (GibcoBRL, U S A ) and the vasline dipped metal r ing was placed on the 
marked area. Trypinizat ion o f the single clone was then performed inside the metal 
ring. The isolated clone was plated in 24-wel l plates, grown and further expands 
under G418 pressure (300 \xg/m\ for PNT2 cells, 500 | ig/ml for DU145). When the 
cells reached 80-90 % confluency in 35- inm culture dish, total R N A was extracted 
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and R T - P C R o f ERRy was per formed i n order to detect the ERRy transcript levels in 
the stable-transfected clones. The detai l procedures o f R N A extract ion and RT-PCR 
were descried i n section 3.1.5. Two ERRy stable-transfected clones (pCI-neo ERRy 
clone 1 and pCI-neo ERRy clone 2) and two empty vector transfected clones 
(pCI-neo clone 1 and pCI-neo clone 2) o f P N T 2 and DU145 cells were generated and 
selected for subsequent studies. The isolated clone was g rown and maintained i n 
normal g rowth med ium w i t h 300 | ig /ml G148 for PNT2 transfected cells and 500 
M-g/ml G418 for D U 1 4 5 transfected cells. Semi-quanti tat ive RT-PCR o f ERRy was 
per formed i n order to detect the relat ive expression level o f ERRy i n the stable 
transfectants as compared to the control cells (empty vector transfected cells and 
parental cells). The sequences o f o l igonucleot ide pr imers o f ERRy and the condit ions 
o f PGR are l isted i n Table 3.2. 
C. Examination of transcriptional activity of ERRy stable-transfected PNT2 cells by 
luciferase assay 
For luciferase assay, 5 x 1 0 ^ cells f r o m exponential g rowing pCI-neo ERRy 
clone 1, pCI-neo ERRy clone 2, pCI-neo clone 1, pCI-neo clone 2 and parental PNT2 
cells were seeded i n the 24-we l l plates w i thout the presence o f G418. Cells were 
co-transfected w i t h 0.225 昭 pGL3=EREx3-Luc and 0.0225 fig p R L - C M V vectors 
using Fugene 6 reagent (Roche, Germany) and the luciferase act iv i ty o f was 
measured using Dual-Luciferase® Reporter Assay System (Promega，USA). The 
detai l procedures o f transfect ion and luciferase assay were described in section 3.3.2. 
Each transfect ion and luciferase assay was performed in tr ipl icate and the mean 士 
S.D. o f the fo ld induct ion o f R L U compared to control (parental PNT2 cells) were 
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plotted. 
3.4.6 Cell proliferation assay of ERRy stable-transfected PNT2 and DU 145 
cells 
For in vitro prol i ferat ion study, 5 x 10^ cells f rom each clone (pCI-neo 
ERRy clone 1, pCI-neo ERRy clone 2, pCI-neo clone 1 and pCI-neo clone 2) and 
parental cells PNT2 and D U 145 cells were seeded in the 24-wel l plates. Cells were 
then g rown in normal growth med ium wi thout G418 at 37 °C in a humid i f ied 
incubator w i t h 5% C〇2. For every 24 hours after seeding, cells were trypsinized and 
the number o f cells was counted directly using the hemocytometer under the invert 
microscope. A l l determinations were performed in tripl icate and the mean 士 S.D. o f 
cel l numbers were plotted against the t ime. Doubl ing t ime o f each clone and parental 
cells (the t ime required for doubl ing the number o f cells during exponential growth 
phase, Calaf and Russo, 1993) was also determined. 
3.4.7 Anchorage independent growth assay of ERRy stable-transfected PNT-2 j 
i. 
an DU 145 cells 
Soft agar assay (Macpherson and Montagnier, 1964) was used to test the 
anchorage independent growth o f PNT-2 and DU145 ERRy stable transfectants. 
When the cells grew to 70 — 80 % confluency, pCI-neo ERRy clone 1, pCI-neo ERRy 
clone 2, pCI-neo clone 1 and pCI-neo clone 2 and the parental cells were trypsinized 
for soft agar assy. Br ief ly, two layers o f agar were prepared in the 6-wel l plates. For 
the base agar, 1 % Noble agar (Di fco, U S A ) was melted and dissolved in the 
autoclaved dist i l led water by heating in the microwave oven for 1 minute. Melted 
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agar was kept at 56 °C water bath. 0.5% base agar w i t h I x R P M I or I x M E M w i th 
10% FBS was then prepared by m i x i n g the pre-warmed 2 fo ld growth med ium (2x 
R P M I or 2x M E M w i t h 20% FBS) w i t h 1 % melted noble agar (1:1; v/v). The mixed 
0.5% agar solut ion was added to 6 -we l l plates for 1 m l per wel l . The base agar was 
a l lowed to so l id i fy at room temperature for about 30 minutes and ready for setting o f 
top cell-agar layer. For the top cell-agar, 1.2 % Noble agar (Di fco, U S A ) was melted 
and dissolved i n the autoclaved dist i l led water by heating in the microwave oven for 
1 minute. Me l ted agar was kept at 56 °C water bath. The 1.2% agar solut ion and the 
pre-warmed 2x R P M I or 2x M E M w i t h 20% FBS were mixed in a ratio 1:1 (v/v). A n 
agar solut ion (0.6%) w i t h growth med ium was prepared and kept at 37 °C water bath. 
Cells were trypsinized and counted w i t h the hemacytometer under the invert 
microscope. 1 x 1 0 ^ / m l o f PNT2 cells and 0.5 x 10^ / m l o f D U 145 cells i n the 
growth med ium were mixed w i t h 0.6% top agar (1:1, v/v) to make a f inal density o f 
0.5 X l O V m l in I x R P M I or I x M E M w i t h 0.3% top agar. Top cell-agar suspension 
was then plated at 2 ml / we l l (1 x 10^cells or 0.5 x lO* cells) into the 0.5% base agar 
pre-plated 6-we l l plates. The plate was incubated at 37。C，in 5% CO2 atmosphere. j 
i, 
Af ter growing in soft agar for 8 weeks o f PNT2 cells and 6 weeks o f D U 145 cells, t 
cells were f ixed w i t h 10% formaldehyde for 10 minutes, stained in 0.1% cryustal 
v io let for 5 minutes and then destaining by r insing w i th tap water. The number o f 
stained colonies per we l l was counted under the dissecting microscope. Colony 
format ion eff iciency was determined as the number o f colonies w i th size larger than 
10 j i m in diameter formed in agar per total number o f cells seeded. Each soft agar 
assay was performed in triplicate and the mean 士 S.D. o f was determined. 
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3.4.8 Flow cytometry of ERRy stable-transfected PNT2 and DU 145 cells 
pCI-neo ERRy clone 1, pCI-neo ERRy clone 2, pCI-neo clone 1 and 
pCI-neo clone 2 and the parental PNT2 and D U 145 cells were seeded at density o f 5 
X 104 in 60 -mm culture dish wi thout the presence o f G418. 96 hours after seeding, 
the cells were prepared to analyze by flow cytometry. The detail procedures were 
described i n section 3.4.3. 20000 single cells were analyzed f rom each sample and 
the mean percentage 士 S.D. o f GO/Gl , S, G 2 / M phases and ratio o f GO/Gl to G 2 / M 
phases o f four independent experiments were plotted. 
3.4.9 RT-PCR of cell cycle-related genes in ERRy stable-transfected PNT-2 
and DU145 cells 
The expression levels o f cell cycle-related genes were studied in the ERRy 
stable-transfected PNT-2 and DU145 cells including cyclins (A, B l , Dl，D2, D3, E l , 
E2), c-myc, cyc l in dependent kinase ( C D K ) inhibi tor (p l6 , p l 8 , p l 9 , p21, p27) and 
p53. pCI-neo ERRy clone 1, pCI-neo ERRy clone 2, pCI-neo clone 1, pCI-neo clone 
2 and parental cells were seeded at density o f 1.375 x 10 into 100-mm culture dish [ 
I 
without the presence o f G418. 96 hours after seeding, total R N A was extracted f rom j, 
the cells and reversely transcripted to the first strand c D N A . PGR was performed 
according the description in section 3.1.5. The sequences o f oligonucleotide primers 
and the conditions o f PGR are listed in Table 3.2. For semi-quantitative RT-PCR 
analysis, signal intensities o f the p21 and p i 9 products were normalized to those o f 
3-actin products in order to produce arbitrary units o f relative expression levels. The 
mean values 士 S.D. obtained f rom three independent experiments were plotted. 
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3.4.10 Western blot analyis of p21 in ERRy stable-transfected PNT-2 cells 
pCI-neo ERRy clone 1, pCI-neo ERRy clone 2, pCI-neo clone 1, pCI-neo 
clone 2 and parental PNT-2 cells were seeded at density o f 1.375 x 10^ into 100-mm 
dishes wi thout the presence o f G418. 96 hours after seeding, the whole cell lysate 
was extracted according the description in section 3.1.9. Protein concentration was 
determined by mod i f ied lowery method w i t h bovine serum albumin (BSA) as a 
standard before al iquoted and stored at -70 °C unt i l electrophoresis. The steps o f 
electrophoresis, protein b lot t ing and color imetic detection were same as descried in 
section 3.1.8. The antibodies used including monoclonal antibody against human p21 
1:500 (p2lWAFi Ab-11, Neomarkers, U S A ) and monoclonal antibody against P-actin 
1:2000 (Act in , pan Ab-5 , Neomarkers, USA) . 15% and 10% SDS-PAGE were used 
for protein b lot t ing o f p21 and (3-actin respectively. For study the relative protein 
expression level, signal intensity o f p21 was normalized to those o f (3-actin in order 
to produce arbitrary units o f relative expression level. The mean values 土 S.D. 
obtained f rom three independent experiments were plotted. 
3.5. Statistical analysis , 
The results o f semi-quantitative RT-PCR, western blot analysis, luciferase 
assay, cell prol i ferat ion assay, f l ow cytometry, doubl ing t ime calculation and soft 
agar assay are represented as the mean (士 S.D.) o f three to four independent 
experiments. Statistical analysis was performed using the impaired Student's r-test. 
Values o f p<0.05 (2 tails) were considered statistically significant. 
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Table 3.1. In format ion o f cel l l ines 
Cell lines Passage Origins Description Culture media Referen 
no ce 
R W P E - 1 P 50-52 Amer ican Norma l prostate Keratinocyte-serum Bel lo et 
Type epithelial free medium al, 1997 
Culture immorta l ized by (GibcoBRL, U S A ) 
Col lect ion human supplemented w i t h 
(ATCC) papi l lomavirus 18 5 ng/ml human 
(HPV-18) recombinant EGF 
and 0.05 mg/ml 
bovine pitui tary 
extract 
RWPE-2 P 49-51 Amer ican Der ived f rom Same as RWPE-1 Bel lo et 
Type RWPE-1 by kirsten al, 1997 
Culture murine sarcoma 
Col lect ion virus ( K i - M S V ) 
(ATCC) transformation 
P W R - I E P 4-6 Amer ican Norma l prostate Same as RWPE-1 Webber 
Type epithelial et al. 
Culture immortal ized by 1996 
Col lect ion adenovirus 12-SV40 
(ATCC) hybr id v ims 
(Ad l2 -SV4Q) 
PZ-HPV-7 P 32-34 Amer ican Norma l peripheral Same as RWPE-1 Wei jerm | 
Type zone prostate an et al, [ 
Culture epithelial 1994 
Col lect ion immortal ized by 
(ATCC) human 
papil lomaviruse 18 
(HPV 18) 
HPr-1 P 22-24 Dr. Y C Norma l prostate Same as RWPE-1 Choo et 
Wong, epithelial al, 1999 
Universi ty immortal ized by 
o f Hong human 
Kong papil lomavirus 
(HPV) 
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HPr-1 A R P 14-16 Dr. Y C Der ived f r om HPr-1 Sane as RWPE-1 L i n g et 
Wong, by al, 2001 
Univers i ty replication-defective 
o f Hong retrovirus stably 
Kong transfected w i t h 
androgen receptor 
( m 
P N T I A P 64-66 European Norma l prostate RPMI1640 Degeorg 
Col lect ion epithelial (G i rboBRL, U S A ) es et al, 
o f Cel l immorta l ized by supplemented w i t h 1995 
Cultures SV40 10 m M HEPES, 
2mg/ml sodium 
bicarbonate, 10% 
FBS, 100 units/L 
penic i l l in G and 
100 ug/ml 
streptomycin 
PNT2 P 11-13 European Norma l prostate Same as P N T I A Degeorg 
Col lect ion epithelial es et al, 
o f Cel l immorta l ized by 1995 
Cultures SV40 
BPH-1 Norma l prostate RPMI1640 Hayward 
epithelial (Gi rboBRL, USA) etal, \ 
f 
immortal ized by supplemented w i th 1995 \ 
SV40 10 m M HEPES, 1 
2mg/ml sodium 
bicarbonate, 10% 
FBS, 100 units/L 
penic i l l in G and 
100 ug/ml 
streptomycin 
CA-HPv-10 P 11-13 American Prostate epithelial Same as RWPE-1 Wei jerm 
Type adenocarcinoma an et al, 
Culture immortal ized w i th 1994 
Col lect ion HPV-18 
(ATCC) 
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LNCaP P 25-27 Amer ican Prostate epithelial RPMI1640 Horosze 
Type carcinoma (GibroBRL, U S A ) w icz et 
Culture supplemented w i t h al, 1983 
Col lect ion 2.5 g glucose, 10 




FBS, 100 uni ts/L 
penic i l l in G and 
100 ug/ml 
streptomycin 
C4-2B P 20-22 Dr. E.T Der ived f rom T-medium W u et al， 
Keller, LNCaP, metastasis {80% D M E M 1994 
Univers i ty to bone (GibroBRl, U S A ) + 
o f 2 0 % F 1 2 K (Sigma, 
Mich igan U S A ) } 
supplemented w i t h 
5 | ig /ml insulin, 
13.6 pg/ml 
tr i iodothyronine, 5 
f ig/ml 
apo-transferrin, ; 
0.25 |ug/ml biot in, | 
25 [ig/ml adenine, 2 丨 
mg/ml sodium 
bicarbonate, 10% 
FBS, 100 units/L 
penic i l l in G and 
100 ug/ml 
streptomycin 
D U 145 P 14-16 Amer ican Prostate epithelial M E M (GibroBRL, M ickey 
Type carcinoma USA) supplemented et al, 
Culture established f rom a wi th 1 m M sodium 1977 
Col lect ion brain metastasis pyruvate, 1.5 mg/ml 
(ATCC) patient sodium bicarbonate, 
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IQo/oFBS, 100 
units/L penic i l l in G 
and 100 ug/ml 
streptomycin 
PC-3 P 4-6 Amer ican Prostate epithelial F12K (Sigma, Ka ighn 
Type carcinoma U S A ) supplemented et al, 
Culture established f rom a w i t h 1.5mg/ml 1979 
Col lect ion bone metastasis sodium bicarbonate, 
(ATCC) patient 10% FBS, 100 
units/L penic i l l in G 
and 100 ug/ml 
streptomycin 
M D A P c a P 8-10 Amer ican Prostate epithelial F12K (Sigma, Navone 
2b Type adenocarcinoma U S A ) supplemented et al, 
Culture established f rom a w i t h 25 ng/ml 1997 
Col lect ion bone metastasis cholera toxin, 10 
(ATCC) patient ng/ml epidermal 
growth factor, 0.005 
m M 
phosphoethanolami 
ne, 100 pg/ml 
hydrocortisone, 45 
n M selenious acid, 
0.005 mg/ml 丨 
insulin, 1.5 mg/ml y 
sodium bicarbonate, 
20% FBS, 100 
units/L penic i l l in G 
and 100 ug/ml 
streptomycin 
C W R 2 2 R v l P 12-14 Amer ican Prostate epithelial Same as LNCaP Sramkos 
Type carcinoma derived k i et al, 
Culture f rom CWR22 1999 
Col lect ion xenograft 
(ATCC) 
M C F - 7 P 7-9 Dr. L K Breast epithelial R P M I 1640 Brooks 
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Leung, adenocarcinoma (G ib roBRL , U S A ) et al, 
The supplemented w i t h 1973 
Chinese 10 | ig /ml insul in, 
Un ivers i ty 1.5 mg /m l sodium 
o f H o n g bicarbonate, 10% 
K o n g FBS, 100 uni ts /L 
pen ic i l l in G and 
100 ug /ml 
streptomycin 
Table 3.2 Sequences o f ol igonucleot ide pr imers and condit ions o f PGR 
Gene Nucleotide Products PCR condition GenBank 
sequences and size accession no. 
positions 
A . H u m a n (Forward) 5 , - T C G 5 0 2 bp 94。C for 1 m i n , N M — 0 0 4 4 5 1 
estrogen C T G T C T G A C 60。C for 1 min , 
receptor - re la ted C A G A T G T C 72。C for 1 m i n 
receptor a (934-953) (30 cycles) 
(ERRa) (Reverse) 5，-CCT 
C G A G C A T C T 
C C A A G A A C 
(1416-1435) i 
B . Human (Forward) 5 ' - C C C 4 8 6 b p 9 4 ° C for 1 min : X 5 1 4 1 7 ： ^ 
estrogen C T A CCT G A G C T T 60。C for 1 min , 
receptor-related A C A GAT T T 72。C for 1 m i n 
receptor j3 (682-684) (35 cycles) 
(ERRp) (Reverse) 5 ' - T A C 
A T T G A A T C T 
G A G T T G G C A A G 
— (1145-1167) 
C . H u a m n (Forward) 5 ' - A C C 4 7 0 b p 9 4 ° C for 1 min, AfD94518 
estrpgen A T G A A T GGC CAT 60°C for 1 min, 
receptor-related C A G A A (336-355) 72。C for 1 m i n (35 
receptor y (Reverse) 5,- A C C cycles) 
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(ERRy) A G C T G A G G G ‘ 
T T C A G G TAT 
(785-805) 
D. Human (Forward) 5 ' - CCT 395 bp 94。C for 1 min, NM—000044 
androgen GAT C T G T G G 60。C for 1 min , 
receptor ( A R ) A G A T G A A G C 72。C for 1 m i n (3 5 
T T C (2795-2818) cycles) 
(Reverse) 5 ' - T G T 
CGT GTC C A G 
C A C A C A CTA 
C A C (3166-3189) 
e. Human (Forward) 5 ' - A A C 476 bp 94。C for 1 min , XM—045967 
estrogen A C A A G C G C C 60。C for 1 min, 
receptor a A G A G A G A T 72。C for 1 m i n (35 
(ER a) (1159-1178) cycles) 
(Reverse) 5 ' - GAT 
CTC C A C CAT GCC 
CTC T A (1615-1634) 
f. Human (Forward) 5 ' - T G A 528 bp 94。C for 1 min, NM_001437 
estrogen A A A G G A A G G 60。C for 1 min, 
receptor (3 T T A G T G G G A 72。C for 1 m i n (35 
(ER p ) A C C (789-812) cycles) 
(Reverse) 5 ’ - T G G 
T C A GGG A C A 丨 
T C A T C A T G G N 
(1296-1316) 
^ h . Human (Forward) 5 ' - T C C 4 3 3 b p 9 4 。 C for 1 m i n , N M _ 0 0 0 9 2 6 
progesterone T T A CCT G T G 63。C for 1 min, 
receptor (PR) G G A GCT GT 72。C for 1 m i n (1 -5 
(3196-3215) cycles); 94。C for 1 
(Reverse) 5，- TGC min, 60°C for 1 
CTC T C G CCT A G T min, 72。C for 1 m in 
T G A T T (6-35 cycles) 
(3609-3628) 
i. Human (Forward) 5 , - T C G 4 2 9 b p 9 4 。 C for 1 min, M10901 
glucocort icoid A A T G A G G A C 55°C for 1 min, 
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receptor (GR) T G C A A G CC 72。C for 1 m i n (35 
(853-872) cycles) 
(Reverse) 5 ' - G A A 
G T T C A G A G T 
C C C C A G A G 
(1262-1281) 
j . H u m a n (Forward) 5 ' - C T C 258 bp 94。C for 1 m in , X13589 
aromatase A T T G C A A A G 55。C for 1 m in , 
C A C C C T A A T 72。C for 1 m i n (35 
(1085-1105) cycles) 
(Reverse) 5 ' - A A A 
C T C G A G T C T 
G T G C A T C C T 
(1322-1342) 
k. H u m a n (Forward) 5, - C C T 217 bp 94。C for 1 m in , NM—001648 
ka l l i l re in 3 C C T G A A G A A 58°C for 1 m in , 
( K L K 3 / h K 3 ) , T C G A T T C C T 72。C for 1 m i n (1-5 
Prostatic (333-353) cycles); 94。C for 1 
specif ic ant igen (Reverse)5'- G A G min , 55°C for 1 
(PSA) G T C C A C A C A min , 72。C for 1 m i n 
C T G A A G T T (6-25 cycles) 
(550-569) 
^ L . H u m a n (Forward) 5 ' - C T G 3 3 8 b p 9 4 。 C for 1 m i n , N M 一 0 0 5 5 5 1 : 
ka l l i l re in 2 CCC A T T G C C T A A 62。C for 1 m in , j 
( K L K 2 / h K 2 ) A G A A G (229-248) 72。C for 1 m i n (1-5 |；1 
(Reverse) 5 ' - G C T cycles); 94。C for 1 
C A C A C A C T G min , 60。C for 1 
A A G A C T C C T G min, 72。C for 1 m i n 
(545-566) (6-25 cycles) 
M . H u m a n pS2 (Forward) 5 C A C 2 7 0 bp 94°C for 1 min , X52003 
5 ' - Pr imer C A T G G A G A A 60。C for 1 min , 
C A A G G T G A 72。C for 1 m i n (30 
(46-65) cycles) 
(Reverse) 5 ' - G C A 
G A T CCC T G C 
A G A A G T G T 
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(296-315) ‘ “ 
N . H u m a n (Forward) 5 ' - A T G 249 bp 94。C for 1 min , NM—001101 
P -act in G A T G A T G A T A T C 55。C for 1 m in , 
G C C G C G (74-94) 72。C for 1 m i n (24 
(Reverse) 5 ' - C T C cycles) 
C A T G T C G T C C C A 
G T T G G T (302-322) 
O. H u m a n (Forward) 5 ' - C G T 4 0 6 bp 94。C for 1 min , M64349 
cyc l i n D 1 G G C C T C T A A G A T 60。C for 1 min , 
G A A G G (468-487) 72。C for 1 m i n (25 
(Reverse) 5 ’ - G C A cycles) 
G T C T G G G T C 
A C A C T T G A 
(854-873) 
R H u m a n (Forward) 5 ' - C T G 357 bp 94。C for 1 min , NM—001759 
cyc l in D 2 G G G A A G T T G 60。C for 1 min , 
A A G T G G A A 72。C for 1 m i n (25 
(699-718) cycles) 
(Reverse) 5 ' - A C G 
G T A C T G C T G 
C A G G C T A T 
(1036-1055) 
Q. Human (Forward) 5 ' - G G A 398 bp 94。C for 1 min , NM—001760 
cyc l in D3 A G A T G C T G G 60°C for 1 min , | 
C T T A C T G G 72°C for 1 m i n (25 丨 
(335-354) cycles) ” 
(Reverse) 5 ' - A C A 
G A G GGC C A A 
A A A G G T CT 
(713-732) 
R. Human (Forward) 5，-TAC 473 bp 94。C for 1 min, NM—001238 
cyc l in E l C C A A A C T C A 60°C for 1 min, 
A C G T G C A A 72。C for 1 m i n (25 
(442-461) cycles) 
(Reverse) 5 ' - A G G 
G G A C T T A A A 
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CGC C A C T T “ 
(893-912) 
S. Human (Forward) 5 ' - G A T 318 bp 94。C for 1 min, NM_057749 
cyc l in E2 G G T GCT T G C 60°C for 1 min, 
A G T G A A G A 72°C for 1 m i n (25 
(752-771) cycles) 
(Reverse) 5 ' - A C T 
GTC C C A CTC 
C A A A C C T G 
(1050-1069) 
^ T . Human (Forward) 5 ' - C C A 4 7 6 b p 9 4 ° C for 1 min, X51688 
cyc l in A T T C A T G T G G A T G 60。C for 1 min, 
A A G C A (406-425) 72。C for 1 m i n (25 
(Reverse) 5 ’ - A G T cycles) 
GCC C A C A A G 
C T G A A G T T 
(862-881) 
U. Human (Forward) 5, - GGC 440 bp 94°C for 1 min, NM—031966 
cyc l in B1 C A A A A T GCC TAT 60。C for 1 min, 
G A A G A (348-357) 72。C for 1 m i n (25 
(Reverse) 5 , - T G G cycles) 
CTC T C A T G T T T C 
C A G T G (768-787) i 
V. Human p 16 (Forward) 5 ’ - G G A 211 bp 94°C for 1 min, NM—058195 i 
G G G C T T CCT 60°C for 1 min, j:| 
G G A C A C (589-606) 72。C for 1 m i n (30 
(Reverse) 5 ' - T C A cycles) 
ATC G G G GAT 
GTC T G A G 
(781-799) 
W. Human p l 8 (Forward) 5 ' - A C G 384 bp 94。C for 1 min, NM_078626 
T C A A T G C A C 60。C for 1 min, 
A A A A T G G A 72。C for 1 m in (30 
(516-535) cycles) 
(Reverse) 5 ' - CCT 
G C A T C A GGC 
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T A A C A A CC 
(870-899) 
X . Human p i 9 (Forward) 5 ' - C T G 336 bp 94。C for 1 min, NM—001800 
C A G GTC A T G 60°C for 1 min, 
A T G T T T G G 72°C for 1 m i n (30 
(438-457) cycles) 
(Reverse) 5 ' - GAT 
GTC C A C G A G 
GTC C T G A G 
(754-773) 
Y. Human p21 (Forward) 5 ' - G A G 328 bp 94。C for 1 min, BC001935 
C G A T G G A A C 60。C for 1 min, 
T T C G A C T T 72°C for 1 m i n (30 
(219-238) cycles) 
(Reverse) 5 ' - GGC 
G T T T G G A G T 
GGT A G A A A 
(527-546) 
Z. Human p 2 7 ( F o r w a r d ) 5 ' - A G T 3 5 1 b p 9 4 ° C for 1 min, BC001971 
T A A CCC G G G 60°C for 1 min, 
A C T T G G A G 72。C for 1 m i n (30 
(496-515) cycles) 
(Reverse) 5 ' - T T G ； 
C A G GTC GCT i 
TCC T T A T T fj 
(827-846) ” 
A A . H u m a n ( F o r w a r d ) 5 ' - C C T 4 2 6 b p 9 4 。 C for 1 min, AF307851 
p53 C A C CAT CAT C A C 60。C for 1 min, 
A C T GG (888-907) 72。C for 1 m in (25 
(Reverse) 5 ' - T C T cycles) 
G A G T C A GGC 
CCT T C T GT 
(1294-1313) 
A B . H u m a n ( F o r w a r d ) 5 ' - C C T 4 8 4 b p 9 4 。 C for 1 min, BC058901 
c-myc A C C CTC T C A 60°C for 1 min, 
A C G A C A GC 72°C for 1 m in (25 
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( 6 7 0 - 6 8 9 ) cycles) 一 
( R e v e r s e ) 5'- C G C 
C T C T T G A C A T T C 
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T h . pS 纏 ¥ e c t e r 
, 斤 SV40/SV^C or； 
J - ‘ 《4 办 , , i 
w ( cefo "g i o b i n ！iitro n ！ 1 
I i f 象 
4 >J kB f r - — " " BamH i 
m 〜 、 
-5V40 pA 
A T G T G A 
E € � R 1 _ I m R a 1269 bp 
A T G T G A 
E c o R l — I ~ ERRj3 1299 bp [—EcoRl 
A T G T G A 
EcoRl—I e R R t 1374 bp | _ E c o R l 
』 ， . . . . 』 『 . . . . . [ i 
Figure 3 .1 The map of pSG5 mammaJian expression vector. Human ERR r^ , 
/5and； 7 were inserted thought the EcoRl - EcoRl restriction sites. 
This vector was used in transient expression experiments. 
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丨雙5道式:c线k,梦 
i pRSET , 
1 A i 
» 2 , 9 k b B 
ATG TGA 
BaitiHl—I E R R a 1269 bp 卜 E c o R l 
ATG •為-
B a m H l — ERR j3 1299 bp —EeoRl 
^TG TGA 
B a m H l — E R R j 13?4bp •EcoEl 
Figure 3.2 The map of pF-SETA prGkai^^otic protein expression vector. Human ，、 
ERE cr , 0 and 7 were inserted thought the BamHl - EcoRl 
restriction sites. The vectors were, used to generate the ERRs 
rec ombmant proteins in. the baeteria. 
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l + \ i c i ^ ^ i s i 
M pcDNA3.1 ( + / - ) , 
舊 542S/5427 bp 層 
ATG TGA 
BainHl——1~ ERgg 17S5bp 一 Xhal 
Hgure 3.3 The map of ptcil)麵L mammaJian expression vector； Human ER 
a was ins erted thought the BamHl: and Xho； 1: restnction sites. The 
vectors were us ed in transient expression exp eximents. 
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M m i 
'"、: SmB I 
/ , z — t r - i t m i l l = 6； 
M 
产〜. l i i i 
mmm 、〜1 wmmi 
T 『【尸 j 1 勵、 5 ‘； 
\ 卯、"7缘一 f y o 
11 / f Sxxm- 一 
Mmm m 
X.： u p y A - v \ 产5'浏 , Z / 、龙，. 
pglfl 
A T G T G A 
H i n d i n — j E K R q 1 2 6 9 b p B a n i H i 
A T G T G A 
X h o l — — E K R jg 1 2 9 9 b p — B a m H l 
A T G 職 
X t i o l — j E 皿 T i 3 7 4 b p 卜 B a m H l 
F i g u r e 3.4 The map of pEGFP-Cj mamrnalian green fluorescence:expiression 
vector. Human ERRa was inserted thoughtHndl l I and BamHl 
. . . . . . . . . . . . - . 
restriction sites and ERR /5 , r were mserted thought the Xho l -
BamHl restriction sites. The vector were used to Kcam the 
subcellular localization of ERRs in the culture cells. 
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( h & 
I r S \ 、；」 
H , \ 雄 
\ SV:“厂?hsncs'/ A / \ 72 T i 
A T G T G A 
E c o R l — E R R j 1 3 7 4 b p ~ 
F i g u r e 3.5 The majj of PCi-neQ inammalian expression vectcm: Human ERR 
y was inserted: thou动t the EcaRl - EcoRl r^triction sites. The 
vectofs: were used in stable trans fection exp eriment.. 
1 
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Chapter 4. Results 
4.1 Expression patterns of ERRs and steroid hormone receptors in 
the human prostate cell lines, tumor xenografts and prostatic 
tissues 
As the f irst step to study the potential roles o f ERRs in the prostate and 
prostate cancer, the expression prof i les o f the three ERR isoforms were investigated 
i n a broad panel o f immortal ized, carcinoma prostatic cell lines, pr imary prostate 
cancer xenografts as we l l as the cl in ical samples o f hyperplastic (BPH) and 
neoplastic prostates by RT-PCR. Their expression profi les were also compared to the 
expression o f other steroid hormone receptors and some prostatic markers i n order to 
reveal any correlat ion between them. Their expression patterns were also studied in 
M C F - 7 (a ER-posi t ive breast cancer cel l l ine) as a comparison. Besides, polyclonal 
antibodies against the ERRa, ERRp and ERRy were developed by the synthetic 
！ 
i 
peptide approaches. The antisera were used to study the protein expression o f ERRs ! 
i 
i n the prostatic cell lines and human prostates by Western blot analysis and i 
i 
I 
. 丨p Immunohistochemistry. 
4.1.1 mRNA expression patterns of ERR isoforms in the prostatic cell lines, 
prostate cancer xenografts and human prostatic tissues 
The results o f semi-quanti tat ive RT-PCR showed that all immortal ized 
human prostatic epithelial cell lines, cancer cell lines and three CWR22 xenografts 
expressed one to three isoforms o f ERRs (a, p and y) at the detectable levels (Figure 
4.2 A - B , Figure 4.3 A -B , Figure 4.4 A -B) . Among the three ERR isoforms, ERRa 
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(ampl i f ied after 30 cycles) transcripts were detected in all cell lines, xenografts and 
M C F - 7 cel l lines at variable levels. The highest expression levels o f ERRa were 
detected i n RWPE-1, Pz-HPV-7, BPH-1, PC-3 and C W R 2 2 R v l cell lines whi le the 
lowest expression levels were detected in two immortal ized cell lines P N T I A and 
PNT2, three prostatic xenografts as we l l as the MCF-7 cells (Figure 4.2 A -B) . On the 
contrary, the expression pattern o f ERRp in prostatic cell lines is completely different. 
For the immorta l ized cel l lines, four out o f nine (RWPE-1, RWPE-2, P W R - I E and 
Pz-HPV-10) showed relative h igh expression o f ERRp (ampl i f ied after 35 cycles). 
However, only weak or undetectable level o f ERRP transcripts were observed in the 
al l cancer cell lines, three cancer xenografts and MCF-7 breast cancer cells (Figure 
4.3 A -B ) . On the other hand, ERRy m R N A (ampl i f ied after 35 cycles) transcripts 
were detected at variable levels in different cell lines and prostatic xenografts. A l l 
cell lines except H P r - l - A R , PNT2, D U 145 ( low expression) and PNT2, M D A Pea 
2b (undetectable) showed relatively moderate to high expression levels o f ERRy. A l l 
CWR22 prostate cancer xenografts also showed relative high expression levels o f 
ERRy as similar to its in vitro subline, C W R 2 2 R v l (Figure 4.4 A-B) . The ERR D N A 
fragments ampl i f ied f rom the cell lines and xenografts were further analyzed by the “丨 
Southern blot analysis using the DIG-label led D N A probes that were prepared f rom 
the pSG5-ERRs vectors. The results showed that all PGR products were posit ively 
reacted w i t h the correspondent D N A probes (Figure 4.2 A , Figure 4.3 A , Figure 4.4 
A) . The results o f Southern blottings confirmed that the primers are gene-specific 
and i soform-speci f ic wi thout incorrect ampli f icat ion since the three ERR isoforms 
showed h igh homology in their D N A sequences. Addit ional ly, the expression o f ERR 
isoforms as detected by RT-PCR in cl inical samples o f human hyperplastic and 
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neoplastic prostatic tissues also exhibi ted similar patterns as shown in cel l lines and 
xenografts (Figure 4.5). ERRa transcripts were detected in al l hyperplastic and 
neoplastics samples, whereas ERRp (6 out o f 9 samples) and ERRy (6 out o f 9 
samples) m R N A were var iably expressed in hyperplastic tissues but weakly 
expressed (1 out 5 samples for ERRp, 2 out o f 5 samples for ERRy) or undetected in 
neoplastic tissues. The results demonstrated that the presence o f al l ERR isoforms 
m R N A in the non-cancerous human prostate (hyperplastic human prostate and 
immorta l ized epithel ial cel l l ines derived f rom normal prostate) as we l l as neoplastic 
prostate (prostate cancer cel l lines, xenografts and neoplastic human prostates) 
especially the ERRa since its m R N A was universally detected and present in al l 
tested samples. The results o f m R N A expression o f ERR isoforms as detected by 
RT-PCR are summarized i n Table 4.1. 
4.1.2 mRNA Expression patterns of steroid hormone receptors and prostatic 




The results o f semi-quantitative RT-PCR o f estrogen receptor a (ERa) | 
J 
(ampl i f ied after 35 cycles) showed that al l immortal ized cell lines derived f rom : 
normal prostate expressed moderate to h igh levels o f ERa (Figure 4.6 A-B) . 
However, on ly CA-HPV-10 , PC-3 and C W R 2 2 R v l cancer cell lines expressed this 
ER isoform, but not other cel l lines and xenografts where were derived f rom the 
prostate cancer. The results indicated that ERa is probably down regulated in the 
progression o f prostate cancer as compared to the normal prostate. MCF-7 , the 
posit ive control o f ERa expression, showed the highest expression among the all 
tested cel l lines. On the other hand, the expression pattern o f estrogen receptor (3 is 
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simi lar to ERRa since ER|3 m R N A transcripts (ampl i f ied after 35 cycles) were 
expressed in al l normal and cancer cel l l ines, xenografts as we l l as the M C F - 7 cell 
l ine (Figure 4.7 A - B ) w i t h the highest expression in PC-3 prostatic cel l l ine. Apart 
f r om ERs, the expression levels o f other class I I I steroid hormone receptors inc luding 
androgen receptor (AR) , progesterone receptor (PR), glucocort icoid receptor (GR) as 
we l l as aromatase were also demonstrated by RT-PCR (Figure 4.8). I n summary, 
most o f the cel l lines and the three tumor xenografts posit ively expressed A R (except 
RWPE-1, RWPE-2, PZ-HPV-10, HPr-1, P N T I A , CA-HPV-10 , DU145) , GR and 
aromatase. On the other hand, only P N T I A , LNCaP, C4 2B, D U 145, M D A Pea 2b, 
C W R 2 2 R v l and M C F - 7 (posit ive control) expressed PR at the detectable level after 
35 cycles PGR ampl i f icat ion. A m o n g the A R posit ive cell lines, a PGR product that 
was approximate 120 bp larger than predict size (395 bp) was detected in 
C W R 2 2 R v l (Figure 4.8). Besides f rom the steroid hormone receptors, the abundance 
o f m R N A transcripts o f two prostatic dif ferentiat ion markers (PSA/hK3 and 
K L K 2 / h K 2 ) and an estrogen-responsive gene (pS2) were also investigated by | 




cycle) and h K 2 (ampl i f ied after 30 cycle) were similar as they were highly expressed 
i n LNCaP, C4-2B, C W R 2 2 R v l , the three prostate cancer CWR22 xenografts and 
barely detected in D U 145 cell line. These expression patterns were posit ively 
correlated to the expression o f androgen receptor. Moreover, the expression o f pS2 
was also similar to PSA but i t was also detected in the RWPE-1, P W R - I E , HPr-1, 
PNT2, BPH-1, PC-3 as we l l as MCF-7 cell lines, the latter is the positive control o f 
pS2 gene. The results o f class I I I steroid hormone receptors and the prostatic 
di f ferentiat ion marker expression as detected by RT-PCR are summarized in Table 
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4.1. 
4.1.3 Characterization of antisera against human ERRs by ERR recombinant 
proteins 
The polyc lonal antibodies against cognate peptides o f human ERRa, ERRp 
and ERRy were developed by in ject ion o f synthetic peptides conjugated to carrier 
protein K L H into the N e w Zealand rabbits. As ERRs showed h igh homology in their 
amino acid sequences, the specif ic i ty o f sera removed after th i rd (booster I I ) and 
four th peptide in ject ion (booster I I I ) were evaluated by Western blot analysis o f ERR 
His-tagged recombinant proteins expressed i n a bacterial system before using them 
for the subsequent experiments. The molecular sizes o f the bacterial expressed ERR 
recombinant proteins in the denatured PAGE gel were f i rst ly determined using a 
monoclonal antibody against the polyhist idine (anti-HisG). The results showed that 
the apparent sizes o f ERRa, ERRP and ERRy recombinant proteins were 55 kDa, 49 
I 
kDa and 58 kDa respectively as referred to the standard protein marker (Figure 4.9) | 
I 
although the predicated protein size o f ERRP (433 a.a, 49 kDa) is actually larger than 丨 
ERRa (423 a.a, 46 kDa). Since the prokaryotic expression vector pRSETA consisted 
o f an addit ional sequence o f 108 bp, wh ich wou ld express a peptide w i t h predict 
protein size 4.2 kDa (36 amino acids, M R G S H H H H H H G M A S M T G G Q Q M G R 
D L Y D D D D K D R W G S ) at the N- termina l o f expressed ERR proteins. Thus, the 
actual size o f ERRa, ERRP, ERRy recombinant proteins were approximate 51 kDa, 
45 kDa and 54 kDa respectively. Western blot analysis was then performed using the 
antisera against ERRa, ERRP and ERRy synthetic peptides to the 6xHis-tagged ERR 
recombinant proteins. As shown in Figure 4.9, three antisera were able to recognize 
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the respective recombinant proteins specif ical ly wi thout cross-reacted to one another. 
The antisera were then used for subsequent Western blot analysis o f ERRa, ERRp 
and ERRy in the prostatic cel l lines and Immunohistochemistry o f the human 
prostate sections. 
4.1.4 Protein expression of ERR isoforms in the human prostatic cell lines 
The protein expression o f ERRa, ERR(3 and ERRy were studied in selected 
f ive prostatic cel l lines including one immorta l ized epithelial l ine (RWPE-1) and four 
prostate cancer cell l ine (LNCaP, D U 145, PC-3 and C W R 2 2 R v l ) using the antisera 
against E R R synthetic peptides. As shown in Figure 4.10, the immunoreactive 
signals o f ERRa protein (appoximately 53 kDa) were detected in al l tested cell lines 
w i t h higher expression in RWPE-1, LNCaP and PC-3 cells whereas the 
immunosignal o f ERRP protein (appoximately 48 kDa) was only detected in the 
RWPE-1 cells, but not in other tested cell lines. On the other hand, immunoreactive 
. I 
signals o f ERRy protein (appoximately 51 kDa) were detected in all tested cell lines, | 
except D U 145. The size o f native ERRa and ERRP proteins detected in the cell lines | 
1 
were matched to the His-tagged ERR recombinant proteins whi le the native ERRy 
protein was smaller than recombinant protein as detected by protein blott ing. The 
protein expression patterns o f three ERR isoforms in the prostatic cell lines were 
completely matched to the m R N A expression patterns. Therefore, the present results 
demonstrated that not only the m R N A transcripts, but also the functional proteins o f 
ERRs were expressed in the human prostatic cell lines. 
4.1.5 Immunolocalization of ERR isoforms in the normal, dysplastic and 
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neoplastic prostates 
The expression and local izat ion o f three ERR isoforms in normal and 
dysplastic prostates w i t h premalignant intraepithelial neoplasia lesions (PIN) as we l l 
as mal ignant prostates w i t h l o w graded, wel l-di f ferent iated and h igh graded, 
poor ly -d i f ferent iated lesions were examined using the antisera against the ERRs 
synthetic peptides. Intense nuclear expression o f ERRa was detected in the normal 
human prostate i n both lumina l and basal epithelial cells (Figure 4.11 A) . The exact 
locat ion o f basal epithelial cell layer was also determined by staining the normal 
prostate w i t h an antibody against the H i g h Molecular Weight keratin (specific basal 
cell marker) as shown in Figure 4.11 F. Similar to the normal prostate, strong nuclear 
ERRa immunoract iv i ty was also detected at the luminal epithelial cells in the 
dysplastic lesions (Figure 4.11 B). Besides, as shown in Figure 4.11 C-D, low to 
moderate expression o f ERRa was detected in the cancer cells o f the 
wel l -di f ferent iated and poorly-di f ferent iated adenocarcinoma as compared to the ； 
normal and dysplastic human prostates. Similar to the ERRa, the immunosignal o f | 
[ 
ERRp was detected at both the luminal and basal epithelial cells in the normal j 
i 
prostate as we l l as the dysplastic secretory epithelial cells in the P IN lesions. Some U 
stromal cells were also posit ively reacted (Figure 4.12 A-B) . In the 
wel l-di f ferent iated and poor ly differentiated prostate cancer lesions, ERRp was 
positively expressed at the nuclei of most of cancer cells (Figure 4.12 C-D) but less 
intense as seen in to the normal prostate. On the other hand, the expression o f ERRy 
was detected in both the cytoplasm and nuclei o f luminal epithelial cells in the 
normal prostate. In the dysplastic and neoplastic prostates, only few cells showed 
posit ive nuclear expression o f ERRy (Figure 4.13 A-D) . N o nuclear staining was 
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observed i n the sections that were incubated w i t h ERRa, ERRp and ERRy antisera 
preabsorbed w i t h their respective cognate peptides (Figure 4.11 E, Figure 4.12 E, 
Figure 4.13 E). The results o f control sections supported the specificities o f ERR 
immunohistochemistry. I n summary, ERRa, ERR|3 and ERRy were expressed and 
main ly local ized to the epithelial cells o f the normal human prostate, however, their 
protein expression were reduced in the progression f rom the normal to the dysplasia 
and further reduced in the prostate carcinoma. 
4.2 Relationship of ERR and ER expressions in PC-3 prostate 
cancer cells 
ERRs and ERs are the close relatives since they show high homology in 
their m R N A sequences and consist o f overlapped transcriptional mechanisms as we l l 
as the targeted genes. Several studies demonstrate that estrogen could stimulate the 
expression o f the ERRa gene in several estrogen-responsive organs and cultured cells ： 
I 
(Bonnelye et al, 2002; L i u et al, 2003). So far, study o f modulat ion o f gene 
expression o f ERs and ERRs by other members o f ERRs is absent, particularly in the 
prostatic cells. In this part o f study, the relationship o f ERR and ER at their 
transcriptional levels was investigated in the PC-3 prostate cancer cell l ine, wh ich 
expressed endogenously o f ERR (a, y) and ER (a, P). 
4.2.1 Expressions of ERRy, ERa and ERp in the ERRa transient transfected 
PC-3 cells 
PC-3 prostate cancer cell l ine was selected and used in this study as it 
possessed h igh transfection eff iciency and showed relatively high endogenous 
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expression o f ERRa, ERRy, ERa and ER(3 genes among the various cel l lines as 
detected by RT-PCR. In order to demonstrate whether the transcription o f two ER 
isoforms and ERRy could be regulated or modulated by ERRa, PC-3 cells were 
transfected w i t h the expression vector pSG5-ERRa containing the fu l l length o f 
human E R R a wh i le the m R N A levels o f ERa, ERp and ERRy in the transfected cells 
were evaluated by a semi-quantitative RT-PCR analysis . Transfection o f 
pSG5-ERRa vector greatly increased the transcript levels o f ERRa in the PC-3 cells 
as compared to the empty vector transfected cells (Figure 4.14 A -B ) , showing that 
E R R a gene was successfully delivered and expressed in the PC-3 cells. As shown in 
Figure 4.14 A , C, D and E, over-expression o f ERRa resulted in signif icant reduction 
I 
o f m R N A levels o f ERRy (p 二 0.0018) as we l l as ERa (p 二 0.0055) in the PC-3 cells 
as compared to the empty vector transfected control. However, the expression level 
o f another member o f ER, ERp, i n the PC-3 cells was not affected by the ERRa 
transient expression. The results demonstrated that transient over-expression o f ； 
ERRa could down-regulate or repress the expression o f ERa as we l l as ERRy in vitro. 




4.2.2 Expression of ERRa in the ERRy and ERa transient transfected PC-3 
cells 
To reverse investigate whether ERa or ERRy could regulate the expression 
o f ERRa, PC-3 cells were transfected w i t h either an expression vector pSGS-ERRy 
containing the fu l l length o f human ERRy or an expression vector pcDNA3.1-ERa 
containing the fu l l length o f w i l d type human ERa. As ERa is the ligand-dependent 
transcript ion factor, (3-estradiol (10 n M ) was added to the cultured cells that were 
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transfected w i t h p c D N A 3 . 1 - E R a and p c D N A 3 . 1 (empty vector). Transfection o f 
pSGS-ERRy vector and pcDNA3 .1 -ERa resulted in signif icant increased expression 
o f ERRy and ERa respectively i n the PC-3 cel l as compared to the empty vector 
transfected cells (Figure 4.15 A , B , C and E), showing that the ERRy and ERa genes 
were successfully del ivered and expressed in the PC-3 cells. As shown in Figure 4.15 
A , B , D and F, however, no signif icant change o f the ERRa transcript level was 
observed i n both ERRy and ERa over-expressed PC-3 cells as compared to the 
empty vector transfected control. These results, together w i t h previously described, 
i l lustrated that ERRa acts as the modulator o f expression o f ERRy as we l l as ERa at 
the transcript ional level. Nevertheless, the expression o f ERRa gene was independent 
to the ERRy and ERa. 
4.3 Intracellular trafficking and transcriptional activities of ERRs 
in the prostatic cells with fused green fluorescence protein -
ERRs i 
i 
A l though ERRs are classified as nuclear hormone receptors based on their 丨 
amino acid sequences, direct evidence o f their nuclear localization was absent 丨, 
especially i n the prostatic cells. In this part o f study, the subcellular local ization and 
the transcriptional activities o f ERRs to the estrogen-response element (ERE) and 
ERR-response element (ERRE or SF-1) were investigated in the PC-3 cells in the 
presence or absence o f serum. 
4.3.1 Transactivation of ERE response element - driven reporter by ERR 
isoform in the PC-3 cells in the presence or absence of serum 
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To trace the subcellular local izat ion o f ERRs in l i v ing cells, PC-3 cells 
were transfected w i t h fu l l length o f pEGFP-Cs-ERR expression vectors wh ich 
contained the fu l l length o f human ERRa, ERR(3 and ERRy tagged w i th the green 
fluorescence protein. The funct ional act iv i ty o f GFP-ERRs as the ligand-independent 
transcript ional factors was assayed w i t h an estrogen response element dr iven reporter 
gene (pGL3-EREx3-Luc) i n transient transfection experiment i n the PC-3 prostatic 
cells. Since PC-3 cells expressed endogenously ERs and ERRs, cells transfected w i th 
empty GFP vector and ERE promoter gene showed activated luciferase act iv i ty ( fo ld 
act ivat ion 二 1, control). As shown in Figure 4.16 A , the luciferase activities in the 
I 
cells that were transfected w i t h pEGFP-Cs-ERRa (p 二 0.034, 1.4 fo ld increased), 
I 
:i 
ERRp (p = 0.015, 2.9 fo ld increased) and ERRy (p = 0.015, 3.8 fo ld increased) were 
signif icant ly higher than i n cells transfected w i th empty vector. The same 
experiments were then repeated in the serum-free medium as Vanacker et al (1999) 
and Sumi and Ignarro (2003) previously demonstrate that requirement of an 
unknown serum factor for the transcriptional activation o f ERRa. As shown in 
Figure 4.16 B, the transcriptional activities o f the cells that were transfected w i th 
pEGFP-Cs-ERRa (p = 0.019, 1.3 fold increased), ERRp (p 二 0.043, 1.9 fold 
increased) and ERRy (p = 0.012, 3.7 fo ld increased) were also signif icantly higher 
than the empty vector transfected control. These results demonstrated that transfected 
GFP-ERRs were expressed in the PC-3 cells as the functional proteins w i th the 
ligand-independent transcriptional activities and constitutively active even in the 
absent o f serum. However, the transcriptional activity o f PC-3 cells transfected w i th 
ERRP in the absence o f serum was signif icantly lower (p = 0.040) than the cells 
transfected in the presence o f normal growth serum (Figure 4.16 C). This observation 
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indicated that serum might contain some factors that affected the ERR|3-mediated 
ERE transactivat ion but not the other two ERRs isoforms in PC-3 cells. Overal l , cells 
transfected w i t h pEGFP-Cs-ERRy could induce the strongest luciferase act iv i ty and 
pEGFP-Cs-ERRa exhibi ted the weakest response. The results showed that ERRy is 
the most active transcript ional factor toward the ERE promoter in the PC-3 cells 
among the three E R R isoforms. 
4.3.2 Transactivation of SF-1 response element driven reporter by ERR 
isoforms in the PC-3 cells in the presence or absence of serum [ 
I 
The experiment o f GFP-ERR dependent transcriptional activation was also 
！ 
performed on the SF-1 promoter (ERRE promoter, pGL3-SF lx3 -Luc ) under the 
normal serum and serum-free conditions in order to investigate the difference 
between GFP-ERR-mediated ERE and ERRE transcriptional activities. As shown in 
Figure 4.17 A and B, the transcriptional activities o f the cells transfected w i th 
pEGFP-Cs-ERRa (p - 0.035, 1.4 fo ld increased), ERRp (p = 0.0018, 2.8 fo ld 
increased) and ERRy (p — 0.021, 2.6 fo ld increased) were signif icantly higher than 
I 
the empty vector transfected control in normal growth medium. In the absence o f ,1』 
serum, the transcriptional activities o f the cells transfected w i th pEGFP-Cs-ERRa (p 
=0.033, 1.3 fo ld increased), ERR(3 (p - 0.010, 2.3 fo ld increased) and ERRy (p = 
0.012, 5.9 fo ld increased) were also signif icantly higher than the empty vector 
transfected control. These results were similar to the GFP-ERRs-mediated ERE 
transactivation and further conf irmed that GFP-ERRs were expressed as functional 
proteins since they could transactivate both the classical estrogen response element 
(ERE) as we l l as the ERR response element (SF-1) in a ligand-independent manner. 
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Compar ing the transactivation potential o f the three ERR isoforms in the presence or 
absence o f serum (Figure 4.17 C), the results were similar to previously described 
results as the transcript ional act iv i ty to the SF-1 promoter in the ERRp transfected 
PC-3 cells i n the absence o f serum was signif icant ly lower (p = 0.042) than the cells 
transfected i n the normal growth serum. This f ind ing il lustrated that the presence o f 
unknown factors in the serum that could enhance the ERRp-mediated transactivation. 
Interestingly, unexpected results were observed as the transcriptional act iv i ty to the 
SF-1 promoter i n ERRy transfected PC-3 cells in the absence o f serum was 
signi f icant ly higher (p=0.010) than the cells transfected in the normal growth serum. I 
i 
This phenomenon was not observed when the cells were transfected w i t h ERE 
promoter. The presence o f an ERRy antagonist towards the transactivation o f SF-1 
promoter i n the normal serum might be a possible reason o f this interesting 
observation. Overal l , the degree o f transactivation o f GFP-ERRs toward SF-1 
promoter was similar to the ERE promoter and ERRy is the most potent : 
transcriptional factor whi le ERRa is the weakest one among the three ERR isoforms. 
4.3.3 Subcellular localizations of three ERR isoforms in the PC-3 cells in the y 
presence or absence of serum 
In order to analyze whether ERRs are constitutively active and translocated 
to the nucleus, PC-3 cells were transfected w i th pEGPF-Cs vectors containing fu l l 
length o f ERRa, ERRp and ERRy under the conditions w i th or without serum. In the 
normal growth medium, the GFP-tagged ERRa, ERR(3 and ERRy fusion proteins 
were exclusively confined to the nuclei o f the transfected PC-3 cells (Figure 4.18, 
A-C) , i n contrast to the pEGPF-Cs (empty vector) transfected cells o f wh ich the 
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untagged GFP was evenly distr ibuted in the whole cells. The nucleol i were absent o f 
green fluorescence. As shown in Figure 4.19 A -C , the GFP-ERRs transfected cells 
were posi t ive ly reacted w i t h the respective ERR antisera. Both the immunosignals 
and the green fluorescent signal o f GFP-tagged ERRs were co-localized to the nuclei 
o f the transfected cells. I n contrast, the control cells, transfected w i t h empty vector 
showed absence o f immunosignals. These results showed that GFP-ERRs vectors 
were successfully translated and expressed in the PC-3 cells. Parallel experiments 
were also repeated in the serum-free condit ion. These results showed that the three 
E R R isoforms were predominant ly nuclear localized (Figure 4.19, A - C ) whi le the 
cells transfected w i t h empty vector showed homogenous green fluorescence in whole 
cell. These results agreed w i t h the reporter gene assays described in previous section 
that ERRs were consti tut ively active under conditions w i th or wi thout serum. 
A l though some discrepancy on transcriptional activities o f ERRp and ERRy was 
observed between the normal and serum-free conditions, no obvious change in ： 
i 




i ' f 
iiiia 
4.4 The role of ERRs in the growth of prostatic cells 
As ERRa was the f irst member o f ERR fami ly cloned in 1988. A l l studies 
conducted so far are aimed to investigate the expression, transactivation mechanism 
as we l l as the targeted genes o f these orphan receptors. No study ever published has 
focused on the role o f ERRs in the cell growth and proliferation, particularly in the 
prostatic cells. In this part o f study, the potential role o f ERRs in the prostatic cell 
growth was examined in both ERRs transient and stable-transfected prostatic cells. 
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4.4.1 The growth of ERRs transient transfected PC-3 and PNT2 prostatic cells 
The f irst step to investigate the role o f ERRs in the prostatic cell growth 
was to transient transfect the prostatic cells by ERR isoforms. The transfection 
eff iciencies o f di f ferent prostatic cells inc luding immortal ized and cancer cells were 
f i rst determined by transfecting the cells w i t h a lacZ expression vector 
p c D N A 3 . 1 His/Lacz, i n order to select suitable cel l lines for subsequent transfection 
experiments. A m o n g the dif ferent prostatic cell lines, only PNT2 (15-20%) and PC-3 
p V 
(30-40%) showed satisfactory h igh transfection efficiencies whereas most cell lines 
i 
j 
were not transfected very we l l by both Fugene 6 and Lipofectamine 2 0 0 0 ™ reagent 
(Figure 4.21 A and B). Therefore, these two cell lines were selected for the cell 
prol i ferat ion assay. Both PC-3 and PNT2 cells were transfected w i t h the expression 
vectors pSG5-ERRs containing the fu l l length o f the three ERR isoforms and the cell 
numbers were counted 72 hours after transfection. As shown in the Figure 4.22 A : 
and B, a common pattern o f reduction o f cell prol i ferat ion were observed i n al l ERRs 
j 
transfected PC-3 and PNT2 cells. Statistically, only ERRp (p = 0.030) and ERRy (p = 丨 
i . 
0.00025) overexpressed PC-3 cells resulted in significant reduction o f cell ( j 
prol i ferat ion, as compared to the empty vector pSG5 transfected cells. On the other 
hand, no signif icant difference on cell prol i ferat ion was observed in the ERRs 
transient expressed PNT2 cells (Figure 4.18 B). The observation on PNT2 cells may 
possibly due to the lower transfection eff iciency o f PNT2 cells (15-20%) than PC-3 
cells (30-40%). These results suggested that the ERRs may have an anti-proliferative 
funct ion in the PC-3 cells under the short-term over-expression condition. 
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4.4.2 Cell cycle analysis of ERRs transient transfected PC-3 cells 
To explore the mechanism whereby ERRs inhib i t the prol i ferat ion o f PC-3 
cells, the effect o f ectopic expression o f ERRs on the cel l cycle distr ibut ion pattern 
was studied. PC-3 cells transfected w i t h the expression vectors pSG5-ERRs 
containing the f u l l length o f three E R R isoforms and the D N A content i n the 
transfected cells were measured and analyzed by f l ow cytometry. The data obtained 
f r o m these studies demonstrated that transient over-expression o f the three ERR 
isoforms induced a GO/Gl cel l cycle arrest i n PC-3 cells. As shown in Figure 4.24 A , 
over-expression o f E R R a (p = 0.0034), ERRp (p = 0.0018) and ERRy (p = 0.000021) 
i 
i n PC-3 cells resulted i n a signif icant increase o f the cell f ract ion in GO/Gl phase as 
compared to the empty vector pSG5 transfected cells. In addit ion, the fractions o f 
cel l i n S (p = 0.0083) and G 2 / M phases (p 二 0.0021) o f ERRy transfected PC-3 was 
signi f icant ly decreased and increased respectively, as compared to the empty vector 
transfected cells. The GO/Gl cel l cycle arrest induced in ERR-transfected PC-3 cells 
j i 
was f l i r ther conf i rmed as the ratio o f GO/Gl to G 2 / M phase o f ERRa (p : 0.047), | 
ERRp (p 二 0.021) and ERRy ( p= 0.0025) transient expressed PC-3 cells were j 
:| :: I ‘丨 iJ 
significantly higher than the empty vector transfected cells (Figure 4.24 B). The [J 
GO/Gl cel l cycle arrest o f ERRs transfected cells can be clearly demonstrated in the 
overlap plot of cell cycle distribution (Figure 4.23). These results indicated that 
ERRs inhib i ted prol i ferat ion o f PC-3 cells by causing a GO/Gl cell cycle arrest 
leading to cel l cycle wi thdrawal under the short-term over-expression condit ion. 
4.4.3 Expression of cyclin-dependent kinase (CDK) inhibitors and p53 in the 
E R R S transient transfected PC-3 cells 
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Since ectopic over-expression o f ERRs could reduce the cell prol i ferat ion 
and disturb the cel l cycle distr ibut ion o f PC-3 cells, the expression pattern o f several 
cycl in-dependent kinase ( C D K ) inhibi tors and the tumor suppressor gene p53, wh ich 
control the cel l cycle progression, were examined in order to evaluate whether 
over-expression o f ERRs might modulate these cell cycle-related genes. RT-PCR o f 
p l 6 , p i 8 , p l 9 , p21, p27 and p53 expressions were performed in the pSG5-ERRs and 
pSG5 empty vector transfected PC-3 cells. Transfection o f pSG5-ERR vectors 
showed a signif icant increase in expression o f the respective ERR isoforms as 
compared to the empty vector transfected cells (Figure 4.25 A ) and conf i rmed that 
E R R genes were successfully delivered and expressed in the PC-3 cells. As shown in 
Figure 4.25 B and C, p21 m R N A transcript level was signif icantly increased in the 
ERRa (p = 0.040)，ERR(3 (p = 0.040) and ERRy (p = 0.0083) transient transfected 
PC-3 cells as compared to the empty vector transfected cells. On the other hand, no 
signif icant change on the expression o f other cell cycle-related genes were observed 
(Figure 4.25 B). Therefore, the present results demonstrated that the GO/Gl cell cycle ！ 
i ( 
arrest i n ERRs transfected PC-3 cells were possible due to the induction o f p21 gene |.r 
expression. U 
4.4.4 Establishment of ERRy stable-transfected PNT2 and DU145 cells 
The results o f transient expression showed that all ERR isoforms inhibited 
PC-3 cel l growth by inducing a GO/Gl arrest particularly more signif icantly by the 
ERRy isoform. Therefore, the next step performed was to exam the cell growth o f the 
ERRy stable-transfected prostatic cells. Since both PNT2, a immortal ized prostatic 
cells and D U 145, a androgen independent cells, expressed endogenously relative low 
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levels o f ERRy among the various prostatic cel l lines as determined by RT-PCR, they 
were selected to generate the ERRy stable transfected cells using the pCI-neo vector 
containing f u l l length o f human ERRy gene for subsequent experiments. Ten pCI-neo 
ERRy transfectants and f ive pCI-neo (empty vector) transfectants were selected by 
neomyc in G418 pressure and r ing-cloned. Two out o f ten pCI-neo ERRy 
transfectants o f both PNT2 and DU145 cells showed signif icantly h igh ectopic ERRy 
expression, together w i t h 2 pCI-neo clones (empty vector) and the parental cells 
( total ly 3 control cells) were used for subsequent growth experiments. The loss o f the 
ectopic expression o f ERRy in the transfected cells has not been observed in f ive ” 
generations after clonal selection and the transfectants were used for the subsequent 
i 
experiments. B y semi-quantitative RT-PCR analysis (Figure 4.26 A -D) , expression I 
o f ERRy m R N A transcripts i n the ERRy stable-transfected o f PNT2 and DU145 cells | 
！ 
(clone 1 and clone 2) were signif icant ly higher than the empty vector transfected 
cells (clone 1 and clone 2) and the parental cells. No significant change in ERRy 
m R N A level was observed in the empty vector transfected cells (clone 1 and clone 2) 
and the parental cells. Morphological ly , PNT2 and DU145 cells stably transfected 
w i t h the ERRy (clone 1 and clone 2) exhibited similar cell shape and size as 丨 
compared to the empty vector transfected (clone 1 and clone 2) and the parental cells, 
w i t h al l PNT2 transfectants and parental cells were nearly oval in shape w i th a 
centrally located nucleus (Figure 4.27 A -E ) whi le all DU145 transfectants and 
parental cells were irregular in shape w i t h the centrally located nuclei (Figure 4.27 
F-J). 
110 
Chapter 4. Results 
4.4.5 Transcriptional activation of ERE response element in ERRy 
stable-transfected PNT2 cells 
Al though the ectopic h igh expression o f ERRy m R N A were detected in the 
transfected cells, the expressed ERRs were further ver i f ied for their funct ional i ty or 
transcript ional activit ies towards ERE response element. Therefore, lucifierase gene 
reporter assay was performed to test the transactivation potential o f ERRy in PNT2 
ERRy stable transfected (clone 1 and clone 2) towards the ERE promoter gene 
(pGL3-EREx3-Luc ) and compared to the empty vector transfected (clone 1 and clone 
2) and parental PNT2 cells. Since the PNT2 cells exhibited endogenous expression | 
o f ERs and ERRs, the luciferase act iv i ty detected in parental PNT2 cells transfected 
w i t h ERE promoter gene were served as the control ( fo ld activation = 1). As shown 
i j 
i n Figure 4.28, the transcript ional activit ies to ERE-luciferase reporter in ERRy i 
I 
； I 
stable-transfected clone 1 (2.8 fo ld increased, p = 0.011 to empty vector clone 1, p 二 
0.0018 to empty vector clone 2, p = 0.0031 to parental PNT2) and ERRy 
stable-transfected clone 2 (2.8 fo ld increased, p = 0.020 to empty vector clone 1, p = 
0.010 to empty vector clone 2, p = 0.0070 to parental PNT2) were signif icantly 
higher than both the empty vector transfected cells (clone 1 and clone 2) and parental 丨 
II y 
cells. N o signif icant difference in luciferase activities were observed between the two 
ERRy transfected clones or between the empty vector transfected cells (clone 1 and 
clone 2) and the parental PNT2 cells. The results demonstrated that the transfected 
ERRy gene was expressed as the functional protein in the two ERRy stable 
transfected clones since it could bind and activate the ERE promoter i n order to 
produce the luciferase signal. Similar experiment could not be repeated in the ERRy 
stabe-transfected DU145 cells as DU145 cells were di f f icu l t to transfect using both 
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Fugene 6 and the L ipo fec tamine 2 0 0 0 ™ reagents. 
4.4.6 Effect of over-expression of ERRy on the growth of PNT2 and DU145 
stable-transfected cells 
A s over-expression ERRy could inh ib i t the g rowth o f transient transfected 
PC-3 and P N T 2 cells, the cel l pro l i ferat ion parameters inc lud ing growth curves and 
doub l ing t ime were also examined i n the ERRy stable-transfected PNT2 and DU145 
cells. A s shown i n Figures 4.29 and 4.30, slower growth patterns shown i n cel l 
g rowth curves were observed i n the ERRy stable-transfected PNT2 and DU145 cells 「 
i 
i 、 
(clone 1 and clone 2) as compared to the empty vector transfected cells (clone 1 and 
clone 2) and parental P N T 2 and DU145 cells. Therefore, the doubl ing t ime ( D T ) o f 
: i 




required for the ERRy transfected PNT2 cells (clone 1 and clone 2), empty vector 
transfected cells (clone 1 and clone 2) and parental cells to double its cel l numbers 
dur ing the log phase (72 hours to 120 hours after seeding) were 36.14 士 3.26, 34.58 土 
2.74, 26.23 土 3.87, 25.95 土 2.07 and 25.28 土 3.53 respectively. The doubl ing t ime o f 
ERRy stable-transfected clone 1 (p 二 0.0078 to empty vector clone 1，p = 0.0033 to 
empty vector clone 2, p = 0.0040 to parental PNT2) and ERRy stable-transfected 
clone 2 (p = 0.017 to empty vector clone 1, p = 0.0024 to empty vector clone 2, p = 
0.0059 to parental PNT2) were s igni f icant ly longer than the both empty vector 
transfected cells and parental PNT2 cells. Simi lar ly, as shown in Table 4.3, the 
doubl ing t ime o f ERRy transfected DU145 cells (clone 1 and clone 2), empty vector 
transfected cells (clone 1 and clone 2) and parental cells were 27.96 士 2.44, 28.79 士 
2.66，23.15 士 1.08, 23.42 士 1.17 and 23.25 士 1.29 respectively. The doubl ing t ime o f 
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E R R y stable-transfected clone 1 (p = 0.023 to empty vector clone 1，p = 0.029 to 
empty vector clone 2, p = 0.019 to parental D U 1 4 5 ) and ERRy stable-transfected 
clone 2 (p=0.017 to empty vector clone 1, p=0.021 to empty vector clone 2, p=0.020 
to parental D U 1 4 5 ) were s ign i f icant ly longer than the both empty vector transfected 
cells and parental D U 1 4 5 cells. These results showed that g rowth o f transfectants 
were af fected and s lowed d o w n by the ectopic ERRy expression in both P N T 2 and 
D U 1 4 5 prostat ic cells. Th is observat ion agreed to the previous results on transient 
expression study and demonstrated that ERRy might be invo lved as a negative 
manner i n the g rowth regulat ion o f both immor ta l i zed and cancerous prostatic cells. 
4.4.7 Efficiencies of colony formation of ERRy stable-transfected PNT2 and 
DU145 cells 
Besides the doub l ing t ime, the eff ic iencies o f colony format ion in the soft 
agar were also evaluated in the ERRy stable-transfected PNT2 and DU145 cells. This 
assay is the most common method to study the anchorage independent g rowth and 
degree o f t ransformat ion o f the cul tured cells. The ERRy stable-transfected PNT2 
and DU145 cells (clone 1 and clone 2, empty vector transfected (clone 1 and clone 2) 
and parental cells were seeding at density 1 x 10^ and 0.5 x 10"^  in the semi-sol id 
med ium (soft agar) in 6- we l l plates respectively. A f te r growing for 8 weeks for 
P N T 2 cells and 6 weeks for D U 145 cells, cell aggregated clonal ly developed f rom 
the single cel l w i t h size o f approximately larger than 10 u in diameter was considered 
and counted as a single colony. As shown in Figures 4.31 and 4.32. the empty vector 
transfected and parental PNT2 and D U 145 cells could form colonies in soft agar and 
demonstrated that PNT2 and D U 145 cells are transformed prostatic cell l ine as the 
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fo rmer cel l l ine was immor ta l i zed by the S imian v ims 40 T antigen wh i le and the 
latter was der ived f r o m a prostate cancer patient metastatic to the brain. However, 
ectopic over-expression o f ERRy gene i n the P N T 2 and D U 145 cells suppressed the 
fo rmat ion o f co lony i n soft agar. As shown i n Table 4.2 and 4.3, the colony format ion 
eff ic iencies for the ERRy transfected P N T 2 cells (clone 1 and clone 2), empty vector 
transfected cells (clone 1 and clone 2) and parental cells were determined to be 0%, 
0%, 1.12 % 士 0.25, 0.92 % 士 0.33, 1.07 % 士 0.16 respectively whereas the ERRy 
transfected D U 145 cells (clone 1 and clone 2), empty vector transfected cells (clone 
1 and clone 2) and parental cells were determined to be 0.093% 士 0.023, 011% 士 
0.081, 1.16% ± 0.24, 0.93% 土 0.083 and 0.96%土 0.33 respectively. Statistical ； 
I 
analysis o f the data showed that the co lony- forming capacities o f the ERRy ： 
j 
j 
transfected P N T 2 and D U 145 cells were suppressed as compared to the empty I 
vector transfected and parental P N T 2 cells. Therefore, the present data demonstrated 
that the ERRy gene not on ly reduced the cel l prol i ferat ion rate but also the anchorage 
independent g rowth o f P N T 2 and D U 145 prostatic cells. 
4.4.8 Cell cycle analysis of ERRy stable-transfected PNT2 and DU145 cells f,| 
II d 
The results o f cel l cycle analysis f rom the transient transfection 
experiments demonstrated that a l l three E R R isoforms induced a GO/Gl cel l cycle 
arrest i n the PC-3 cells. This cel l g rowth retardation by the transfected ERRs was 
further ver i f ied in the ERRy stable-transfected PNT2 and D U 145 cells. The ERRy 
stable-transfected, empty vector transfected and parental cells were seeded at density 
o f 5 X 10^ into 60- m m culture dish. Four days after seeding (cells are growing in the 
log phase), D N A content o f the tested cells was measured by f l o w cytometry. The 
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data obtained f rom these studies demonstrated that the ectopic expression o f ERRy 
induced a GO/Gl cell cycle arrest in the PNT2 ERRy stable transfectants but a G 2 / M 
cel l cycle arrest i n the D U 145 ERRy stable transfectants. As shown in Figure 4.34 
A - B , the f ract ion o f cells o f ERRy stable-transfected PNT2 cells clone 1 (p = 0.0050 
to empty vector clone 1, p = 0.0011 to empty vector clone 2, p = 0.0046 to parental 
PNT2) and ERRy stable-transfected PNT2 cells clone 2 (p = 0.00075 to empty vector 
clone 1, p = 0.00016 to empty vector clone 2, p = 0.00051 to parental PNT2) in 
GO/Gl phase were signif icant ly higher than both the empty vector transfected cells 
and parental cells. The results also showed that the ratio o f GO/Gl to G 2 / M phase in 
ERRy stable-transfected PNT2 clone 1 (p = 0.011 to empty vector clone 1, p = 
0.0091 to empty vector clone 2, p = 0.020 to parental PNT2) and ERRy 
stable-transfected PNT2 clone 2 (p = 0.0078 to empty vector clone 1, p = 0.0062 to 
empty vector clone 2, p -— 0.015 to parental PNT2) were signif icantly higher than 
both the empty vector transfected cells and parental PNT2 cells. A l though the 
fract ion o f cells o f ERRy PNT2 transfectants in G 2 / M phase were lower than the 
control, statistical analysis o f the data was insignif icant. The GO/Gl cell cycle arrest 
o f ERRs transfected PNT2 cells can be clearly shown in the overlap plot o f cell cycle 
distr ibut ion (Figure 4.33 A) . On the other hand, as shown in Figure 4.35 A - B , the 
fract ion o f cells o f ERRy stable-transfected DU145 cells clone 1 (p 二 0.00011 to 
empty vector clone 1, p = 0.000080 to empty vector clone 2, p 二 0.00011 to parental 
DU145) and ERRy stable-transfected DU145 cells clone 2 (p = 0.0000080 to empty 
vector clone 1, p 二 0.000005 to empty vector clone 2, p = 0.00011 to parental DU145) 
in GO/Gl phase were signif icantly lower than both the empty vector transfected cells 
and parental cells. Besides, the fraction o f cells o f ERRy stable-transfected DU145 
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cells clone 1 (p 二 0.0054 to empty vector clone 1，p 二 0.000067 to empty vector 
clone 2, p = 0.0011 to parental DU145) and ERRy stable-transfected DU145 cells 
clone 2 (p = 0.0018 to empty vector clone 1, p = 0.000067 to empty vector clone 2, p 
二 0.00069 to parental DU145) in G 2 / M phase were signif icant ly higher than the both 
empty vector transfected cells and parental cells. Moreover, the results also showed 
that the ratio o f GO/Gl to G 2 / M phase o f ERRy stable-transfected clone 1 (p 二 
0.0028 to empty vector clone 1, p = 0.00089 to empty vector clone 2, p = 0.0011 to 
parental DU145) and ERRy stable-transfected clone 2 (p = 0.0025 to empty vector 
clone 1, p 二 0.00054 to empty vector clone 2, p = 0.0012 to parental DU145) were 、 
signi f icant ly lower than both the empty vector transfected cells (clone 1 and clone 2) ! 
i 
and parental cells. The results indicated the inh ib i t ion o f cell prol i ferat ion in DU145 : 
i i 
ERRy transfectants was due to a G 2 / M phase cell cycle arrest. The G 2 / M cell cycle ! 
arrest o f D U 145 ERRy transfectants can be clearly shown in the overlap plot o f cell 
cycle distr ibut ion (Figure 4.33 B). The present observations agreed w i t h previous 
results on transient expression study, that over-expression o f ERRy inhibited 
prol i ferat ion o f prostatic cells by inducing a cell cycle arrest i n both short-term and 
long-term ectopic expression conditions. However, the observation on this part o f 丨 
Study showed that the mechanism of ERJly-mediated growth arrest in 
SV40- immorta l ized PNT2 cells was different to the prostate cancer DU145 cells 
since over-expression o f ERRy induced different phase o f cell cycle arrest shown in 
these two cell lines. 
4.4,9 Expression of cell cycle-related genes in the ERRy stable-transfected 
PNT2 and DU 145 cells. 
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Since previous transient transfection experiments showed that transient 
expression o f ERRs i n PC-3 caused growth arrest through (or part ial ly through) 
induct ion o f p21, the possible involvement o f cel l cycle-related genes in the growth 
retardation o f PNT2 and D U 145 ERRy stable-transfected cells was also investigated. 
The expression o f cycl ins ( D l , D2, D3, E l , E2, A , B l ) , C D K inhibitors ( p l 6 , p l 8 , 
p l 9 , p21, p27), c-myc (an early cel l prol i ferat ion oncogene) and p53 were evaluated 
by RT-PCR in ERRy stable-transfected, empty vector transfected and parental cells. 
As shown in Figure 4.36 A - C , the relative expression level o f p21 m R N A in the 
ERRy stable-transfected PNT-2 clone 1 (p = 0.079 to empty vector clone 1, p = 0.022 
I 
to empty vector clone 2, p = 0.020 to parental PNT2) and ERRy stable-transfected 
j 
clone 2 (p = 0.0026 to empty vector clone 1, p = 0.0038 to empty vector clone 2, p = 
i 
i 
0.0033 to parental PNT2) were signif icant ly higher than both the empty vector 
transfected cells and parental cells. This f ind ing was further conf irmed by Western 
blot analysis that expression o f p21 protein was increased in the ERRy 
stable-transfected PNT-2 cells (Figure 4.37 A -B) . The relative expression o f p21 
protein in the ERRy stable-transfected PNT-2 clone 1 (2 fo ld increased, p 二 0.0050 to 
empty vector clone 1，p = 0.015 to empty vector clone 2, p = 0.0023 to parental 
PNT2) and ERRy stable-transfected clone 2 (3 fo ld increased, p = 0.0074 to empty 
vector clone 1, p = 0.0069 to empty vector clone 2, p = 0.00042 to parental PNT2) 
were signif icant ly higher than both the empty vector transfected cells and parental 
cells. N o signif icant changes in expression o f other cell cycle-related genes observed 
as demonstrated by RT-PCR and protein blott ing. On the other hand, the expression 
o f p l 9 m R N A in the ERRy stable-transfected D U 145 cells clone 1 (p = 0.00074 to 
empty vector clone 1, p = 0.0011 to empty vector clone 2, p 二 0.0051 to parental 
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PNT2) and ERRy stable-transfected clone 2 (p = 0.0018 to empty vector clone 1, p = 
0.0035 to empty vector clone 2, p = 0.011 to parental PNT2) were signif icantly lower 
than the both empty vector transfected cells and parental cells. (Figure 4.38). These 
observations demonstrated that growth retardation o f ERRy transient expressed PC-3 
cells and ERRy stable-expressed PNT2 were probably through similar mechanism 









Chapter 4. Results 
Figure 4.1 Restriction cutting of pSG5-ERRs, pRSETA-ERRs, pEGFP-C3-ERRs, 
pCI-neo-ERRy and pcDNA3.1-ERa vectors to verify the correct sizes of 
inserts cloned into the respective vectors 
(A) Restriction cutting of mammalian expression vector pSG5 containing the full 
length inserts of ERR isoforms. The empty vector (4.1 kb) and the respective 
full lengths of ERRa (1 ,269 bp), ERR~ (1 ,299 bp) and ERRy (1 ,374 bp) are 
indicated. 
(B) Restriction cutting of prokaryotic expression vector pRSETA containing the full 
length inserts of ERR isoforms. The empty vector (2 .9 kb) and the respective 
full lengths of ERRa (1 ,269 bp), ERR~ (1 ,299 bp) and ERRy (1,374 bp) are 
indicated. 
(C) Restriction cutting of mammalian green fluorescence protein expression vector 
pEGFP-C3 containing the full length inserts of ERR isoforms. The empty vector 
(4.7 kb) and the respective full lengths of ERR a (1,269 bp), ERR~ (1,299 bp) and 
ERR y (1,374 bp) are indicated. 
(D) Restriction cutting of mammalian expression vector peI-neo containing the full 
length insert of ERRy. The empty vector (5.4 kb) and the full length of ERRy 
(1,374 bp) are indicated. 
(E) Restriction cutting of mammalian expression vector pcDNA3.l containing the 
full length insert of ERa. The empty vector (5.4 kb) and the full length of ERa 
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Chapter 4. Results 
Figure 4.2 Semi-quantitative RT -PCR analysis of ERRa in the human prostatic cell 
lines and xenografts 
(A) Expression pattern of human ERRa in a panel of prostatic cell lines and 
xenografts as determined by RT -PCR. The first panel shows the expression of 
ERRa (30 cycle, 502 bp), in seventeen prostatic cell lines, three prostate cancer 
xenografts and one breast cancer cell line (MCF -7). Three lanes on the right side 
are the negative controls without templates, including absence of total RNA (no 
RNA), reverse transcriptase (no RT) and cDNA templates (no cDNA). No 
signal is shown in the controls. The transcripts of ERRa are detected in all cell 
lines, xenografts and MCF -7 cells at variable levels. The second panel shows 
the expression of ~-actin mRNA (24 cycle, 249 bp) in the same samples as the 
internal standard. The third panel shows the Southern blotting of the PCR 
products of ERRa, probed with a human ERRa DIG-labeled DNA probe in 
order to confirm the PCR products amplified in the first panel are human ERRa. 
(B) Relative abundance of human ERRa mRNA transcripts in the prostatic cell lines 
and xenografts as determined by a semi-quantitative RT -peR analysis. Signal 
intensities of the ERRa are normalized to those of ~-actin in order to produce 
arbitrary units of relative expression levels. The mean values ± S.D. obtained 
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Chapter 4. Results 
Figure 4.3 Semi-quantitative RT -peR analysis of ERR~ in the human prostatic cell 
lines and xenografts 
(A) Expression pattern of human ERR~ in a panel of prostatic cell lines and 
xenografts as determined by RT -peR. The first panel shows the expression of 
ERR~ (35 cycle, 486 bp), in seventeen prostatic cell lines, three prostate cancer 
xenografts and one breast cancer cell line (MeF -7). Three lanes on the right side 
are the negative controls without templates including absence of total RNA (no 
RNA), reverse transcriptase (no RT) and cDNA templates (no cDNA). No 
signal is shown in the controls. The transcripts of ERR~ are highly expressed in 
RWPE-l, RWPE-2, PWR-IE, PZ-HPV-7 immortalized cells but weakly 
expressed or being undetectable in other cell lines and xenografts. The second 
panel shows the expression of ~-actin mRNA (24 cycle, 249 bp) in same 
samples as an internal standard. The third panel shows the Southern blotting of 
the peR products of ERR~, probed with a human ERR~ DIG-labeled DNA 
probe in order to confirm the peR products amplified in the first panel are 
humanERR~. 
(B) Relative abundance of human ERR~ mRNA transcripts in the prostatic cell lines 
and xenografts as determined by a semi-quantitative RT-PCR analysis. Signal 
intensities of the ERR~ are normalized to those of ~-actin in order to produce 
arbitrary units of relative expression levels. The mean values ± S.D. obtained 



















































































































































































































































































































































































































































































































































































































































































































Chapter 4. Results 
Figure 4.4 Semi-quantitative RT -PCR analysis of ERRy in the human prostatic cell 
lines and xenografts 
(A) Expression pattern of human ERRy in a panel of prostatic cell lines and 
xenografts as determined by RT -PCR. The first panel shows the expression of 
ERR y (35 cycle, 4 70 bp), in seventeen prostatic cell lines, three prostate cancer 
xenografts and one breast cancer cell line (MCF -7). Three lanes on the right side 
are the negative controls without templates, including absence of total RNA (no 
RNA), reverse transcriptase (no RT) and cDNA templates (no cDNA). No 
signal is shown in the controls. The transcripts of ERRy are moderately to 
highly expressed in all cell lines and xenografts except in HPr-l AR, PNT2 and 
DU 145 (low expression) or PNT1A and MDA Pca 2b (undetectable) . The 
second panel shows the expression of ~-actin mRNA (24 cycle, 249 bp) in same 
samples as an internal standard. The third panel shows the Southern blotting of 
the PCR products of ERRy, probed with a human ERRy DIG-labeled DNA 
probe in order to confirm the PCR products amplified in the first panel are 
humanERRy. 
(B) Relative abundance of human ERRy mRNA transcripts in the prostatic cell lines 
and xenografts as determined by a semi-quantitative RT -PCR analysis. Signal 
intensities of the ERRy are normalized to those of ~-actin in order to produce 
arbitrary units of relative expression levels. The mean values ± S.D. obtained 



























































































































































































































































































































































































































































































































































































































Chapter 4. Results 
Figure 4.5 
RT-PCR of ERRu, ERR~ and ERRy in human hyperplastic and neoplastic prostatic 
tissues. The first panel shows the expression of ERRu (40 cycle, 502 bp), the second 
panel shows the expression of ERR~ (40 cycle, 486 bp) and the third panel shows the 
expression of ERRy (40 cycle, 4 70 bp). Three lanes on the right side are the negative 
controls without templates, including absence of total RNA (no RNA), reverse 
transcriptase (no RT) and cDNA templates (no cDNA). No signal is shown in the 
controls. The transcripts of ERRu are detected in all hyperplastic and neoplastic 
tissues samples whereas ERR~ and ERRy are variably detected. The lower panel 
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Chapter 4. Results 
Figure 4.6 Semi-quantitative RT-PCR analysis of ERa in the human prostatic cell 
lines and xeno grafts 
(A) Expression pattern of human ERa in a panel of pro static cell lines and xenografts 
as determined by RT-PCR. The upper panel shows the expression of ERa (35 
cycle, 476 bp) in seventeen prostatic cell lines, three prostate cancer xenografts 
and one breast cancer cell line (MCF -7) . Three lanes on the right side are the 
negative controls without templates including absence of total RNA (no RNA), 
reverse transcriptase (no RT) and cDNA templates (no cDNA). No signal is 
shown in the controls. The transcripts of ERa are detected in all immortalized 
cell lines but variably expressed in cancer cell lines and xenografts. MCF-7, the 
positive control of ERa, shows the highest expression among the all tested cell 
I 
I·· ,' " '" 
": '1 
lines. The lower panel shows the expression of ~-actin mRNA (24 cycle, 249 bp) 
,I,,,, 
in the same samples as an internal standard. 
(B) Relative abundance of human ERa mRNA transcripts in the prostatic cell lines 
and xenografts as determined by semi-quantitative RT -peR. Signal intensities of 
the ERa are normalized to those of ~-actin in order to produce arbitrary units of 
relative expression levels. The mean values ± S.D. obtained from three 
















































































































































































































































































- N· ~ c.. ~ ~ ., ~ ... =
 
















































































































































































Chapter 4. Results 
Figure 4.7 Semi -quantitative RT -PCR analysis of ER~ in the human prostatic cell 
lines and xenografts 
CA) Expression pattern of human ER~ in a panel of pro static cell lines and xenografts 
as determined by RT -PCR. The upper panel shows the expression of ER~ (35 
cycle, 528 bp) in seventeen prostatic cell lines, three prostate cancer xenografts 
I f 
and one breast cancer cell line (MCF -7). Three lanes on the right side are the 
negative controls without templates including absence of total RNA (no RNA), 
reverse transcriptase (no RT) and cDNA templates (no cDNA). No signal is 
shown in the controls. The transcripts of ER~ are detected in all cell lines, 
xenografts and MCF-7 cells at variable levels. The lower panel shows the 
expression of ~-actin mRNA (24 cycle, 249 bp) in the same samples as an 
internal standard. 
(B) Relative abundance of human ER~ mRNA transcripts in the prostatic cell lines 
and xenografts as determined by semi-quantitative RT -PCR. Signal intensities 
of the ER~ are normalized to those of ~-actin in order to produce arbitrary units 
of relative expression levels. The mean values ± S.D. obtained from three 










































































































































































































































































































































































































Chapter 4. Results 
Figure 4.8 
RT-PCR of AR, PR, GR, aromatase, PSA, hK2 and pS2 genes in the prostatic cell 
~ )I; 
I ' 
lines and xenografts. The first panel shows the expression of AR (35 cycle, 395 bp) . 
The second panel shows the expression of PR (35 cycle, 433 bp). The third panel 
shows the expression of GR (35 cycle, 429 bp). The fourth panel shows the 
expression of aromatase (35 cycle, 258 bp). The fifth panel shows the expression of 
PSA (30 cycle, 217 bp) The sixth panel shows the expression of hK2 (30 cycle, 338 
bp) The seventh panel shows the expression of pS2 (35 cycle, 270 bp) Three lanes on 
the right side are the negative controls without templates including absence of total 
RNA (no RNA), reverse transcriptase (no RT) and cDNA templates (no cDNA). No 
signal is shown in the controls. The lowest panel shows the expression of ~-actin (24 
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Chapter 4. Results 
Figure 4.9 
Western blot analysis of His tagged-ERR recombinant proteins expressed in a 
bacterial system (pRSETA-ERRs) by a monoclonal anti-HisG antibody and 
polyclonal anti-ERRs antisera. The first panel shows the detection of 6xHis-ERR 
recombinant proteins by monoclonal anti-hisG antibody, showing the 6xHis-ERRa, 
6xHis-ERR~ and 6xHis-ERRy with the size of 55 kDa, 49 kDa and 58 kDa 
respectively. The second panel shows the detection of 6xHis-ERRa by antiserum 
against ERRa synthetic peptide. The immunosignals of 6xHis-ERRa protein, but not 
6xHis-ERR~ or 6xHis-ERRy is detected. The third panel shows the detection of 
6xHis-ERR~ by antiserum against ERR~ synthetic peptide. The immunosignals of 
6xHis-ERR~ protein, but not 6xHis-ERRa or 6xHis-ERR y is detected. The fourth 
panel shows the detection of 6xHis-ERRy by antiserum against ERRy synthetic 
peptide. The immunosignals of 6xHis-ERRy protein, but not 6xHis-ERRa or 
6xHis-ERR~ is detected. 
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Chapter 4. Results 
Figure 4.10 
Western blot analysis of ERRs in the five selected human prostatic cell lines. The 
first panel shows the expression of ERRa detected by ERRa antiserum. The 
immunosignals (----- 53 kDa) are detected in all cell lines. The second panel shows the 
expression of ERR~ detected by ERR~ antiserum. The immunosignal (----- 48 kDa) is 
detected in RWPE-l cells only. The third panel shows the expression of ERRy 
detected by ERRy antiserum. The immunosignals (----- 51 kDa) are detected in all cell 
lines except DU 145 cells . The lowest panel shows the expression of ~-actin as the 
control of protein amount. 
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Chapter 4. Results 
Figure 4.11 Immunohistochemistry of ERRa in the normal, dysplastic and neoplastic 
prostates with low-grade and high-grade lesions, using the anti-ERRa 
antiserum. (200x, bar = 1 O~) 
(A) Normal prostate. A strong nuclear staining of ERRa is shown in the luminal 
(secretory) epithelial cells. Some basal epithelial cells also show positive 
nuclear staining 
(B) Prostate with prostatic intraepithelial neoplasia lesion (dysphasia). ERRa IS 
expressed in the nuclei of the dysplastic secretroy epithelial cells. 
(C) Low-grade, well-differentiated prostatic adenocarcinoma. Few cancer cells show 
positive nuclear staining. 
(D) High-grade, poorly differentiated adenocarcinoma. Infiltrating mass of cancer 
cells, with only little glandular organization, show positive staining in some 
cancer cells. 
(E) Control section, uSIng preabsorbed anti-ERRa antiserum, shows absence of 
nuclear staining. 
(F) Normal prostate. The cytoplasm of basal epithelial cell layer is stained by a 
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Chapter 4. Results 
Figure 4.12 Immunohistochemistry of ERR~ expression in the normal, dysplastic 
and neoplastic prostates with low-grade and high-grade lesions using the 
anti-ERR~ antiserum. (200x, bar = lOll) 
(A) Normal prostate. Luminal (secretory) epithelial cells show intense nuclear 
staining. The nuclei of basal epithelial cells also positively stained. 





Dysplastic prostate with prostatic intraepithelial neoplasia lesion (dysplasia). 
Acini with micropapillary form of PIN show the expression of ERR~ in the 
nuclei of the dysplastic secretory epithelial cells . 
L 
(C) Low-grade, well differentiated prostatic adenocarcinoma. A strong nuclear 
staining of ERR~ is shown in the cancer cells. 
(D) High-grade, poorly differentiated adenocarcinoma. Low to moderate nuclear 
ERR~ expression can be seen in the cancer cells. 
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Chapter 4. Results 
Figure 4.13 Immunohistochemistry of ERRy expression in the normal, dysplastic 
and neoplastic prostates with low-grade and high-grade lesions using the 
anti-ERRy antiserum. (200x, bar = 1 O~) 
(A) Normal prostate. Majority of luminal (secretory) epithelial cells show both 
cytoplasmic and nuclear staining. 
(B) Prostate with prostatic intraepithelial neoplasia lesion (dysplasia). Cytoplasmic 
staining is shown in the dysplastic secretory epithelial cells. 
(C) Low-grade, well differentiated prostatic adenocarcinoma. Cytoplasmic staining 
can be observed in the cancer cells with few of them show nuclear staining. 
(D) High-grade, poorly differentiated adenocarcinoma. Most of the cancer cells show 
weak cytoplasmic staining. 
(E) Control section, using the preabsorbed anti-ERRy antiserum, shows absence of 
cytoplasmic and nuclear staining. 
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Chapter 4. Results 
Figure 4.14 Semi-quantitative RT-PCR of ERR a, ERRy, ERa and ER~ in the ERRa 
transient transfected PC-3 cells. 
(A) Representative results of RT-PCR of ERRa, ERRy, ERa and ER~ in ERRa 
transient transfected PC-3 cells. The first, second, third and fourth panels show 
the expression of ERRa (30 cycle, 502 bp), ERRy (35 cycle, 470), ERa (35 
cycle, 476 bp) and ER~ (35 cycle, 528 bp), respectively. Three lanes on the 
right side are the negative controls without templates including absence of total 
RNA (no RNA), reverse transcriptase (no RT) and cDNA templates (no ' 
cDNA). No signal is shown in the controls. The lowest panel shows the 
expression of ~-actin mRNA (24 cycle, 249 bp) in the same samples as an 
internal standard. 
(B) - (E) Relative abundance of human ERRa, ERRy, ERa, ER~ mRNA transcripts 
In ERRa transient transfected PC-3 cells as determined by 
semi-quantitative RT-PCR. Signal intensities of the ERRa, ERRy, ERa, 
ER~ are normalized to those of ~-actin in order to produce arbitrary units 
of relative expression levels. The mean values ± S.D. obtained from three ' 
independent measurements are plotted. ERRa level in the ERRa 
transfected cells is significantly higher than the empty vector transfected 
cells. ERRy and ERa levels in the ERRa transfected cells are significantly 
lower than the empty vector transfected cells (*, p<0.05 vs pSG5 empty 
vector transfected cells). No significant difference ofER~ level is observed 
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Chapter 4. Results 
Figure 4.15 Semi-quantitative RT-PCR analysis of ERRa in the ERRy and ERa 
transfected PC-3 cells. 
(A)RT-PCR of ERRy and ERRa mRNA levels in ERRy transient transfected PC-3 
cells. The first and second panels show the expression of ERRy (35 cycle, 470) 
and ERRa (30 cycle, 502 bp), respectively. The lowest panel shows the 
expression of ~-actin (24 cycle, 249 bp) in the same samples as an internal 
standard. 
(B)RT-PCR of ERa and ERRa mRNA levels in ERa transient transfected PC-3 cells 
in the presence of 10 nM estrogen. The first and second panels show the 
expression of ERa (35 cycle, 476 bp) and ERRa (30 cycle, 502 bp), respectively. 
The lowest panel shows the expression of ~-actin (24 cycle, 249 bp) in the same 
samples as an internal standard. 
(C) - (F) Relative abundance of ERRy (Figure C) and ERRa (Figure D) mRNA 
transcripts in ERRy transient transfected PC-3 cells and ERa (Figure E) 
and ERRa (Figure F) mRNA in ERa transient transfected PC-3 cells as 
determined by semi-quantitative RT-PCR. Signal intensities of the ERRy, 
ERa and ERRa are normalized to those of ~-actin in order to produce 
arbitrary units of relative expression levels. The mean values ± S.D. 
obtained from three independent measurements are plotted. ERRy level in 
the ERRy transfected cells is significantly higher than the empty vector 
transfected cells. ERa level in the ERa transfected cells is significantly 
higher than the empty vector transfected cells (*, p<O.05 vs pSG5 empty 
vector transfected cells). No significant difference in ERRa level IS 
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Chapter 4. Results 
Figure 4.16 GFP-ERRs dependent transcriptional activation of the ERE-containing 
reporter gene pGL3-EREx3-Luc in the PC-3 cells in the presence of or 
absence of serum. Cells were transfected with 0.125 Jlg 
pEGFP-C3-ERRs, 0.125 Jlg pGL3-EREx3-Luc and 0.0125 Jlg 
pRL-CMV. Cells were harvested after 48 hours, and firefly and renilla 
luciferase activities of lysates were measured. The mean values ± S.D. 
obtained from three independent measurements are plotted. 
(A) Transactivation of ERE response element by pEGFP-C3-ERR isoforms in the 
PC-3 cells in the presence of serum. The relative luciferase activities in cells 
transfected with pEGFP-C3-ERRu, pEGFP-C3-ERR~ and pEGFP-C3-ERRy are 
significantly higher than in cells transfected with pEGFP-C3 (empty vecto~) (*, 
p<0.05). 
(B) Transactivation of ERE response element by pEGFP-C3-ERR isoforms in the 
PC-3 cells in the serum-free condition. The relative luciferase activities in cells 
transfected pEGFP-C3-ERRu, pEGFP-C3-ERR~ and pEGFP-C3-ERRy are 
significantly higher than cells transfected with pEGFP-C3 (empty vector) (*, 
p<O.05). 
(C) Comparison of transactivation of ERE response element by pEGFP-C3-ERR 
isoforms in the PC-3 in the presence or absence of serum. The relative luciferase 
activities in cells transfected with pEGFP-C3-ERR~ in serum-free medium is 
significantly lower than cells transfected in the presence of normal growth 
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Chapter 4. Results 
Figure 4.17 GFP-ERRs dependent transcriptional activation of the SF -1 containing 
reporter gene pGL3-SF-1x3-Luc in the PC-3 cells in the presence or 
absence of serum. Cells were transfected with 0.125 ~g 
pEGFP-C3-ERRs, 0.125 ~g pGL3-SF1x3-Luc and 0.0125 ~g 
pRL-CMV. Cells were harvested after 48 hours, and firefly and renilla 
luciferase activities of lysates were measured. The mean values ± S.D. 
obtained from three independent measurements are plotted. 
(A) Transactivation of SF-l response element by pEGFP-C3-ERR isoforms in the 
PC-3 cells in the presence of serum. The relative luciferase activities in cells 
transfected with pEGFP-C3-ERRu, pEGFP-C3-ERR~ and pEGFP-C3-ERRy are 
significantly higher than cells transfected with pEGFP-C3 (empty vector) (*, 
p<0.05). 
(B) Transactivation of SF-1 response element by pEGFP-C3-ERR isoforms in the 
PC-3 cells in the serum-free medium. The relative luciferase activities in cells 
transfected with pEGFP-C3-ERRu, pEGFP-C3-ERR~ and pEGFP-C3-ERRy are 
significantly higher than cells transfected with pEGFP-C3 (empty vector) (*, 
-" . p<0.05). 
(C) Comparison of transactivation of SF-l response element by pEGFP-C3-ERR 
isoforms in the PC-3 cells in the presence or absence of serum. The relative 
luciferase activities in cells transfected with pEGFP-C3-ERR~ in serum-free 
medium is significantly lower than in cells transfected in the presence of serum. 
(* , p<O.05). On the other hand, the relative luciferase activity in cells transfected 
with pEGFP-C3-ERRy in serum-free medium is significantly higher than in cells 
transfected in the presence of serum. (*, p<O.05). 
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Chapter 4. Results 
Figure 4.18 Subcellular localization of GFP-tagged ERR isoforms in the PC-3 cells 
in the presence of serum. PC-3 cells were transfected with 0.5 ~g of 
GFP-ERRs expression vectors, pEGFP-C3-ERRs and cultured on 
coverslips for 48 hours before visualization by confocal microscope 
with a standard set of FITC filter (left panel) or transmittion light (right 
panel). (1,200x, bar = 1~) 
(A) Cells transfected with pEGFP-C3-ERRu, the green fluorescence is localized to 
the nucleus of transfected cell. 
(B) Cells transfected with pEGFP-C3-ERR~, the green fluorescence is localized to 
the nucleus of transfected cell. 
(C) Cells transfected with pEGFP-C3-ERRy, the green fluorescence is localized to 
the nucleus of transfected cell. 
(D) Cells transfected with pEGFP-C3 (empty vector), both cytoplasm and nucleus of 
transfected cell show the green fluorescent signal. 
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Figure 4.19 Immunofluorescence of GFP-tagged ERR isoforms in the PC-3 cells. 
pEGFP-C3-ERRs transfected PC-3 cells were incubated with antisera 
against ERRs followed by an anti-rabbit Cy3 antibody before 
visualization by confocal microscope with a standard set of FITC filter 
(left panel), transmittion light (middle panel) or Cy3 filter (right panel) . 
(1,200x, bar = 1 !l). 
(A) Cells transfected with pEGFP-C3-ERRa and incubated with anti-ERRa 
antiserum, immunosignal is detected at the nucleus of transfected cell. 
(B) Cells transfected with pEGFP-C3-ERR~ and incubated with anti-ERR~ antiserum, 
immunosignal is detected at the nucleus of transfected cell. 
(C) Cells transfected with pEGFP-C3-ERRy and incubated with anti-ERRy antiserum, 
immunosignal is detected at the nucleus of transfected cell. 
(D) - (F) Cells transfected with pEGFP-C3 (empty vector) and incubated with 
anti -ERRs antisera, no nuclear immunosignal is detected in the transfected cells. 
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Chapter 4. Results 
Figure 4.20 Subcellular localization of GFP-tagged ERR isoforms in the PC-3 
cells in the serum-free condition. PC-3 cells were transfected with 0.5 
j.lg of GFP-ERRs expression vectors, pEGFP-C3-ERRs and cultured 
on covers lips for 48 hours before visualization by confocal 
microscope with a standard set of FITC filter (left panel) or 
transmittion light (right panel). (1,200x, bar = 1 j.l) 
(A) Cells transfected with pEGFP-C3-ERRu, the green fluorescence is localized to 
the nucleus of transfected cell. 
(B) Cells transfected with pEGFP-C3-ERR~, the green fluorescence is localized to 
the nucleus of transfected cell. 
(C) Cells transfected with pEGFP-C3-ERRy, the green fluorescence is localized to 
the nucleus of transfected cell. 
(D) Cells transfected with pEGFP-C3 (empty vector), both cytoplasm and nucleus of 
transfected cell show the green fluorescent signal. 
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Chapter 4. Results 
4.21 Evaluation of the transfection efficiencies of PC-3 and PNT2 cells. Cells were 
transfected with 0.25 ~g pcDNA3.1His/LacZ mammalian expression vector in 
24-well plates. After 48 hours, the transfected cells were fixed and stained in 
blue colour by ~-gal histochemistry. (100x. bar = 1 0 ~) 
(A) PC-3 prostatic cells transfected with pcDNA3.1His/LacZ. The transfection 
efficiency is determined to be approximately 30 - 40 0/0. 
(B) PNT2 prostatic cells transfected with pcDN A3.1 His/LacZ. The transfection 
efficiency is determined to be approximately 15 - 20 %. 
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Chapter 4. Results 
Figure 4.22 Effect of transient expression of ERRs in prostatic cell growth. Cells 
were transfected with 0.4 Ilg of pSG5-ERRs expression vectors or 
empty vector. The cell numbers were counted 72 hours after 
transfection. The mean values ± S.D. obtained from four independent 
measurements are plotted. 
(A) The growth effects of overexpression of ERR isoforms in the PC-3 cells. The cell 
number of ERR~ and ERRy transfected cells are significantly lower than the 
empty vector transfected cells (control). (*, p<0.05 vs pSG5 empty vector 
transfected cells) 
(B) The growth effects of overexpression of ERR isoforms in the PNT2 cells. No 
significant difference is observed between ERRu, ERR~ and ERRy and empty 
vector transfected cells (control). 
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Chapter 4. Results 
Figure 4.23 Cell cycle analysis of ERRu, ERR~, ERRy transient transfected PC-3 
cells. Cells were seeded at density of 2.5 x 105 in 6-well plates and 
transfected with 2 J.lg of pSG5-ERR expression vectors. After 48 hours 
post incubation, cells were fixed and analyzed by the flow cytometry. 
The overlap plot of pSG5-ERRu, pSG5-ERR~, pSG5-ERRy, pSG5 
(empty vector) transfected PC-3 cells is shown. 
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Chapter 4. Results 
Figure 4.24 Cell cycle analysis of ERRs transient transfected PC-3 cells. The mean 
percentage ± S.D. of GO/G 1, S, G2/M phases and ratio of GO/G 1 to 
G2/M phases of three independent experiments are plotted. 
(A) Distribution of GO/G2, S and G2/M phases of pSG5-ERRu, pSG5-ERR~, 
pSG5-ERRy and pSG5 (empty vector) transfected PC-3 cells. The percentage of 
cells in GO/G 1 phase of ERRu, ERR~ and ERRy transfected cells and G21M 
phase of ERRy transfected cells are significantly higher than empty vector 
transfected cells. The percentage of cells in S phase of ERR)' transfected cells is 
significantly lower than empty vector transfected cells. (* , p<O.05 vs pSG5 
empty vector transfected cells). 
(B) The ratio GO/G 1 to G2/M phases of ERRu, ERR~ and ERR)' transfected cells are 
significantly higher than the empty vector transfected cells. (*, p<O.05 vs pSG5 
empty vector transfected cells). 
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Chapter 4. Results 
Figure 4.25 Determination of ERRs, CDK inhibitors and p53 mRNA expression by 
RT-PCR and semi-quantitative RT-PCR analysis of p21 in the ERRs 
transient transfected PC-3 cells. 
CA) - (B) Detection of ERRs, CDK inhibitors and p53 mRNA transcripts in the 
ERRs and empty vector transient transfected PC-3 cells by RT-PCR. In (A), 
the first, second and third panels show the expression of ERRa (30 cycle, 
502 bp), ERR~ (35 cycle, 486 bp), ERRy (35 cycle, 470 bp) respectively 
while in (B), the first, second, third, fourth, fifth and sixth show the 
expression of p 16 (30 cycle, 211 bp), p 18 (30 cycle, 3 84 bp), p 19 (30 cycle, 
336 bp), p21 (30 cycle, 328 bp), p27 (30 cycle, 351 bp), p53 (25 cycle, 426 
bp) respectively. Three lanes on the right side of each panel are the 
negative controls without templates including absence of total RNA (no 
RNA), reverse transcriptase (no RT) and cDNA templates (no cDNA). No 
signal is shown in the controls. The lowest panels in (A) and (B) show the 
level of expression of ~-actin mRNA (24 cycle, 249 bp) in the same 
samples as an internal standard. 
CC) Relative abundance of p21 mRNA transcripts in the ERRs transient transfected 
PC-3 cells as determined by semi-quantitative RT -PCR. Signal intensity of the 
p21 is normalized to those of ~-actin in order to produce arbitrary units of 
relative expression levels. The mean values ± S.D. obtained from three 
independent measurements are plotted. The level of p21 mRNA in ERRs 
transient transfected PC-3 cells is significantly higher than the empty vector 
transfected cells. (*, p<O.05) 
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Chapter 4. Results 
Figure 4.26 Semi-quantitative RT-PCR of ERRy in the ERRy stable-transfected 
PNT2 and DU 145cells. 
(A) - (B) RT-PCR of ERRy mRNA level in PNT2 and DU 145 pCI-neo ERRy 
clone 1 , pCI-neo ERRy clone 2, pCI-neo clone 1, pCI-neo clone 2 and 
parental cells (untransfected) . The first panel shows the expression of 
ERRy (30 cycle or 35 cycle, 470 bp). Three lanes on the right side are the 
negative controls without templates including absence of total RNA (no 
RNA), reverse transcriptase (no RT) and cDNA templates (no cDNA). No 
signal is shown in the controls. The second panel shows the level of 
expression of ~-actin mRNA (24 cycle, 249 bp) in the same samples as an 
internal standard. 
(C) - (D) Relative abundance of human ERRy mRNA transcripts in the ERRy 
stable-transfected PNT2 and DU 145 cells as determined by 
semi-quantitative RT-PCR. Signal intensity of the ERRy is normalized to 
those of ~-actin in order to produce arbitrary units of relative expression 
levels. The mean values ± S.D. obtained from three independent 
measurements are plotted. The levels of ERRy mRNA in PNT2 and DU 
145 ERRy stable-transfected cells (clone 1 and clone 2) are significantly 
higher than the empty vector transfected cells (clone 1 and clone 2) and 
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Chapter 4. Results 
Figure 4.27 Morphology of ERRy stable-transfected, empty vector stable-transfected 
and parental PNT2 and DU 145 cells. No obvious morphological 
change is observed (1 OOx, bar = 10).1). 
(A) PNT2 peI-neo ERRy clone 1 
(B) PNT2 peI-neo ERRy clone 2 
(C) PNT2 peI-neo clone 1 
(D) PNT2 peI -neo clone 2 
(D) Parental PNT2 
(E) DU 145 peI-neo ERRy clone 1 
(G) DU 145 peI-neo ERRy clone 2 
(H) DU 145 peI-neo clone 1 
(1) DU 145 peI-neo clone 2 







Morphology of the ERR r Stable-Transfected 
PNT2 and DU 145 cells 
(F) 
PNT2 pcr -neo ERR r clone 1 DU 145 pCr-neo ERR r clone 1 
(G) 
PNT2 pCr-neo ERR r clone 2 DU 145 per -neo ERR r clone 2 
(H) 
PNT2 per-neo clone 1 DU 145 per -neo clone 1 
(I) 
PNT2 per -neo clone 2 DU 145 per-neo clone 2 
(J) 
Parental PNT2 Parental DU 145 
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Figure 4.28 
Transcriptional activation of the ERE-containing reporter gene pGL3-EREx3-Luc in 
the ERRy stable-transfected PNT2 cells. Cells were co-transfected with 0.225 J..Lg 
pGL3-EREx3-Luc and 0.0225 J..Lg pRL-CMV. Cells were harvested after 48 hours, 
and firefly and renilla luciferase activities of lysates were measured. The mean 
values of fold of luciferase activation ± S.D. obtained from three indepenten~ 
measurements are plotted. The relative luciferase activities of ERRy 
stable-transfected cells (clone 1 and clone 2) are significantly higher than the empty 
vector stable-transfected and the parental PNT2 cells (*, p<0.05). No significant 
difference is observed between the empty vector transfected cells (clone 1 and clone 
2) and the parental PNT2 cells. 
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Figure 4.29 
The growth curves of ERRy stable-transfected PNT2 cells (clone 1 and clone 2), 
empty vector stable-transfected cells (clone 1 and clone 2) and the parental PNT2 
cells. Cells were seeded at 5,000 cells per well in 24-well plates and the cells were 
counted at 24 hr intervals. Slower growth patterns are observed in the ERRy 
stable-transfected PNT2 cells (clone 1 and clone 2) 
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Figure 4.30 
The growth curves of ERRy stable-transfected DU145 cells (clone 1 and clone 2), 
empty vector stable-transfected cells (clone 1 and clone 2) and the parental DU 145 
cells. Cells were seeded at 5,000 cells per well in 24-well plates and the cells were 
counted at 24 hr intervals. Slower growth patterns are observed in the ERRy 
stable-transfected DU 145 cells (clone 1 and clone 2) 
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Figure 4.31 Anchorage independent growth of ERR)' stable-transfected cells (clone 
1 and clone 2), empty vector stable-transfected cells (clone 1 and clone 2) 
and parental PNT2 cells in the soft agar. The micrographs on the left side 
at high magnification show the cells grow singly or as colonies (SOx, bar 
= 10J.l) while the micrographs on the right side show the view of whole 
well. 
(A) -- (B) The growth ofPNT2 pCI-neo ERR)' clone 1 in the soft agar. Cells grow 
Individually as single cells. No colony is formed 
(C) - (D) The growth of PNT2 pCI-neo ERR)' clone 2 in the soft agar. Cells grow 
individually as single cells. No colony is formed 
(E) - (F) The growth of PNT2 pCI-neo clone 1 in the soft agar. Some cells grow as 
colonies. 
(G) - (H) The growth of PNT2 pCI-neo clone 2 in the soft agar. Some cells grow as 
colonies. 
(I) - (J) The growth of parental PNT2 cells in the soft agar. Some cells grow as 
colonies. 
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Chapter 4. Results 
Figure 4.32 Anchorage independent growth of ERRy stable-transfected cells (clone 
1 and clone 2), empty vector stable-transfected cells (clone 1 and clone 2) 
and parental DU 145 cells in the soft agar. The micrographs on the left 
side at high magnification show the cells grow singly or as colonies (50x, 
bar = 10/-l) while the micrographs on the right side show the view of 
whole well. 
(A) -- (B) The growth of DU 145 peI-neo ERRy clone 1 in the soft agar. Few cells 
grow as colonies in a smaller size. 
(C) - (D) The growth of DU 145 peI-neo ERRy clone 2 in the soft agar. Few cells 
grow as colonies in a smaller size. 
(E) - (F) The growth of DU 145 peI -neo clone 1 in the soft agar. Some cells grow as 
colonies. 
(G) - (H) The growth of DU 145 peI-neo clone 2 in the soft agar. Some cells grow 
as colonies. 
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Chapter 4. Results 
Table 4.2 Summary of the growth parameters of the ERRy stable-transfected PNT2 
cells. 
Doubling time Colony formation 
(hour) a efficiency (%) a, b 
PNT2 pCT-neo 36.14 o * 
ERRy clone 1 ± 3.26* 
PNT2 pCT-neo 34.58 o * 
ERRy clone 2 ± 2.74* 
PNT2 pCT-neo clone 1 26.23 1.12 ± 0.25 
(empty vector) ± 3.87 
PNT2 pCT-neo clone 2 25.95 0.92 ± 0.33 
(empty vector) ± 2.07 
PNT2 parental 25.28 1.07 ± 0.16 
± 3.53 
a Data are mean values ± S.D. obtained from three separate measurements 
b Results are expressed as the percentage of the number of colonies formed from 
10,000 cells 
*, p<0.05 , significantly different from the empty vectors transfected (clone 1 and 
clone 2) and parental cells 
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Table 4.3 Summary of the growth parameters in the ERRy-stably transfected DU145 
cells. 
Doubling time Colony formation 
(hour) a efficiency (%) a, b 
DU145 pCI-neo 27.962 0.093 
ERRy clone 1 ± 2.44 * ± 0.023 * 
DU145 pCI-neo 28.79 0.11 
ERRy clone 2 ± 2.66 * ± 0.081 * 
DU145 pCI-neo clone 1 23.15 1.163 
(empty vector) ± 1.08 ± 0.24 
DU145 pCI-neo clone 2 23.42 0.93 
( empty vector) ± 1.17 ± 0.083 
DU1 45 parental 23.25 0.96 
± 1.29 ± 0.33 
a Data are mean values ± S.D. obtained from three separate measurements 
b Results are expressed as the percentage of the number of colonies formed from 
5,000 cells 
*, p<0.05, significantly different from the empty vectors transfected (clone 1 and 
clone 2) and parental cells 
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Figure 4.33 Cell cycle analysis of PNT2 and DU 145 ERRy stable-transfected cells. 
Cells were seeded at density 5 x 104 in 60-nun dish. After 96 hours of 
growth, cells were fixed and analyzed by the flow cytometry. 
(A) The overlap plot of PNT2 pCI-neo ERRy clone 1, PNT2 pCI-neo ERRy clone 2, 
PNT2 pCI-neo clone 1, PNT2 pCI-neo clone 2 and Parental PNT2 is shown . . 
(B) The overlap plot of DU 145 pCI-neo ERRy clone 1, DU145 pCI-neo ERRy clone 
2, DU145 pCI-neo clone 1, DU145 peI-neo clone 2 and Parental PNT2 is shown. 
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Chapter 4. Results 
Figure 4.34 Cell cycle analysis of PNT2 ERRy stable-transfected cells. The mean 
percentage ± S.D. of GO/G 1, S, G2/M phases and ratio of GO/G 1 to 
G2/M phases of four independent experiments were plotted. 
(A) Distribution of GO/G2, S, G2/M phases of ERRy stable-tranfected cells (clone 1 
and clone 2), empty vector stable-transfected cells (clone 1 and clone 2) and the 
parental PNT2 cells. The percentage of cells in GO/G 1 phase of ERRy stable-
tranfected cells (clone 1 and clone 2) are significantly higher than the empty 
vector stable-transfected and parental PNT2 cells. (*, p<O.05). 
(B) The ratio of GO/G 1 to G2/M phases in ERRy stable-tranfected cells (clone 1 and 
clone 2) are significantly higher than the empty vector stable-transfected and 

















































































































































































































































































































































































Chapter 4. Results 
Figure 4.35 Cell cycle analysis of DU145 ERRy stable-transfected cells. The mean 
percentage ± S.D. of GO/G 1, S, G2/M phases and ratio of GO/G 1 to 
G2/M phases of four independent experiments are plotted. 
(A) Distribution of GO/G2, S, G21M phases of ERRy stable-tranfected cells (clone 1 
and clone 2) , empty vector stable-transfected cells (clone 1 and clone 2) and the 
parental DU 145 cells. The percentage of ERRy stable-tranfected cells (clone 1 
and clone 2) in GO/G 1 phase are significantly lo\ver while the percentage of cells 
in G2/M phase are significantly higher than the empty vector stable-transfected 
and parental DU 145 cells respectively. (*, p<O.05). 
(B) The ratio of cells in GO/G 1 to G2/M phases in ERRy stable-tranfected cells 
(clone 1 and clone 2) are significantly lower than the empty vector 





































































































































































































































































































































































Chapter 4. Results 
Figure 4.36 Detection of cell cycle-related genes mRNA transcripts by RT -PCR and 
semi-quantitative RT-PCR analysis of p21 In the ERRy 
stable-transfected PNT2 cells. 
(A) Detection of cyclins, CDK inhibitors, p53 and c-myc mRNA transcripts in the 
ERRy stable-transfected, empty vector stable-transfected and parental PNT2 
cells by RT -PCR. Panels 1-7 in the left column show the expression of cyclin 
D 1 (25 cycle, 406 bp), cyclin D2 (25 cycle, 3 57 bp), cyclin D3 (25 cycle, 398 
bp), El (25 cycle, 4 73 bp), E2 (25 cycle, 318 bp), cyclin A (25 cycle, 476 bp) 
and cyclin B 1 (25 cycle, 440 bp) respectively. Panel 1-7 in the right column 
show the expression ofpI6 (30 cycle, 211 bp), p18 (30 cycle, 384 bp), pI9 (30 
cycle, 336 bp), p21 (30 cycle, 328 bp), p27 (30 cycle, 351 bp), p53 (25 cycle, 
426) and c-myc (25 cycle, 484 bp) respectively. Three lanes on the right side of 
each panel are the negative controls without templates including absence of total 
RNA (no RNA), reverse transcriptase (no RT) and cDNA templates (no cDNA). 
No signal is shown in the controls. Panel 8 in the right column shows the 
expression of ~-actin mRNA (24 cycle, 249 bp) in the same samples as an 
internal standard. 
(B) Relative abundance of p21 mRNA transcripts in the ERRy stable-transfected 
PNT2 cells as detennined by semi-quantitative RT-PCR. The mean values ± 
S.D. obtained from three independent measurements are plotted. The level of 
p21 mRNA in ERRy stable-transfected cells (clone 1 and clone 2) is 
significantly higher than the empty vector stable-transfected cells (clone 1 and 
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Chapter 4. Results 
Figure 4.37 Protein expression of CDK inhibitor p21 in the ERRy stable-transfected 
PNT2 cells. 
CA) Western blot analysis of p21 in ERRy-stable transfected PNT2 cells. The upper 
panel shows the expression of p21 (21 kDa). The lower panel shows the 
expression of ~-actin (42 kDa) as the control of protein amount. 
CB) Relative expression level of p21 protein in ERRy stable-transfected PNT2 cells as 
determined by Western blot analysis. Signal intensity of the p21 is normalized to 
those of ~-actin in order to produce arbitrary units of relative expression level. 
The mean values ± S.D. obtained from three independent measurements are 
plotted. p21 level in the ERRy stable-transfected PNT2 cells (clone 1 and clone 2) 
is significantly higher than the both empty vector stable-transfected (clone 1 and 
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Chapter 4. Results 
Figure 4.38 Detection of cell cycle-related genes mRNA transcripts by RT -PCR and 
semi-quantitative RT-PCR analysis of p19 In the ERR)' 
stable-transfected DU 145 cells. 
(A) Detection of cyclins, CDK inhibitors, p53 and c-myc mRNA transcripts in the 
ERR)' stable-transfected, empty vector stable-transfected and parental DU 145 
cells by RT -PCR. Panels 1-7 in the left column show the expression of cyclin 
D 1 (25 cycle, 406 bp), cyclin D2 (25 cycle, 3 57 bp), cyclin D3 (25 cycle, 398 
bp), El (25 cycle, 4 73 bp), E2 (25 cycle, 318 bp), cyclin A (25 cycle, 476 bp) 
and cyclin B 1 (25 cycle, 440 bp) respectively. Panels 1-7 in the right column 
show the expression of p 16 (30 cycle, 211 bp), p 18 (30 cycle, 3 84 bp), p 19 (30 
cycle, 336 bp), p21 (30 cycle, 3 28 bp), p27 (30 cycle, 3 51 bp), p53 (25 cycle, 
426) and c-myc (25 cycle, 484 bp) respectively. Three lanes on the right side of 
each panel are the negative controls without templates including absence of total 
RNA (no RNA), reverse transcriptase (no RT) and cDNA templates (no cDNA). 
No signal is shown in the controls. Panel 8 in the right column shows the 
expression of ~-actin mRNA (24 cycle, 249 bp) in the same samples as an 
internal standard. 
(B) Relative abundance of p 19 mRNA transcripts in the ERRy stable-transfected DU 
145 cells as detennined by semi-quantitative RT-PCR. The mean values ± S.D. 
obtained from three independent measurements are plotted. The level of p 19 
mRNA in ERRy stable-transfected cells (clone 1 and clone 2) is significantly 
lower than the empty vector stable-transfected cells (clone 1 and clone 2) and 
the parental DU 145 cells. (*, p<O.05) 
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Chapter 5. Discussion 
Chapter 5. Discussion 
Nuclear hormone receptor superfamily is a large group of transcription 
factors involving in many aspects of animal development, tissue differentiation and 
homeostasis in the higher eurkaryotes. A subfamily of receptors, estrogen 
receptor-related receptors (ERRu, ~ and y), which are closely related to the classic 
ERs, are the first group of orphan nuclear receptor being cloned and identified. These 
receptors can bind and activate the transcription of genes through the classic estrogen 
response element (ERE) as well as the ERR response element (ERRE, SF -1) derived 
from ERE, but they are unaffected by estrogens. It is also demonstrate that ERRs are 
able to compete with ERs for the same coactivators and binding sites in gene 
transcription and thus a functional cross-talk could exist in cells which co-express 
both groups of nuclear receptors. Studies in the last two decades demonstrate that 
this group of orphan receptor plays important functions in the human including bone 
development and metabolism, metabolic regulation, breast cancer development as 
well as the normal placenta formation in the mouse. Nevertheless, so far study of 
ERRs in the human prostate gland is absent and their functional significances in this 
male assessory gland as well as its neoplastic growth remain to be elucidated. Thus, 
the present study was aimed to investigate the expression and functional roles of 
ERRs in the human prostatic cells and tissues, in order to gain a better understanding 
on the roles of ERRs in the prostate gland. 
5.1 Expression study of ERR isoforms in human prostatic cells, 
tumor xenografts and prostatic tissues 
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5.1.1 Differential expression patterns of ERRs in prostatic cell lines, cancer 
xenografts and tissues 
The expression patterns of ERR mRNA levels were examined in sixteen 
immortalized and neoplastic human prostatic epithelial cell lines, three CWR22 
tumor xenografts and human prostatic tissues obtained from hyperplasic (BPH) and 
neoplastic (Pca) clinical samples. The study of expression profiles of ERRs in 
different cell lines and xenografts could partially represent the expression of these 
orphan receptors in different stages of human prostate cancer progression. RWPE-1 , 
RWPE-2, PWR-1E, PZ-HPV-7, HPr-1, HPr-1-AR, PNT1A, PNT2 are immortalized 
epithelial cell lines derived from the normal prostates by viral gene immortalization 
while BPH -1 cells are the immortalized epithelial cell line derived from the benign 
prostatic hyperplasia (BPH) tissue. On the other hand, LNCaP, C4-2B, DU145, PC-3 
and MDA Pca 2b represent the metastasized prostate cancer, which were established 
from metastasized prostatic carcinomas to secondary sites. Besides, CWR22 and 
CWR22R prostatic tumor xenografts as well as CA-HPV-10 and CWR22Rv1 cell 
lines represent the early stage of prostate cancer as the two xenografts were 
established from the primary prostate cancer tissues (Pretlow et aI, 1993; 
Nagabhushan et aI, 1996) while CA-HPV-10 and CWR22Rv1 cells were derived 
from immortalized primary prostatic carcinoma cells and CWR22R xenograft 
respectively. CWR22-AIF, an androgen independent prostate tumor xenograft that 
was developed in our laboratory by growing the CWR22 xenograft in the female 
nude mice with high E2 to T ratio, represents the androgen-independent prostate 
cancer which is estrogen-responsive. 
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By semi-quantitative RT -peR analysis, ERRa transcripts were broadly 
detected in all prostatic cell lines and xenografts. Although the expression level of 
ERRa mRN A was variable among different prostatic cell lines, no correlation was 
apparent between the ERRa level and the phenotypes of prostatic cell lines or the 
stage of prostate cancer progression. A similar expression pattern was also observed 
in hyperplastic and neoplastic prostatic tissues as all tested samples expressed ERRa. 
Although ERRa transcripts were expressed at higher level in hyperplastic than 
neoplastic tissues, the down-regulation of ERRa in the progression of prostate cancer 
should be further verified with larger sample size. The present results agree with the 
previously published reports that the mRNA of ERRa is moderately expressed in the 
human prostate as detected by Northern blot analysis (Giguere et aI, 1988; Shi et aI, 
1997). By Western blot analysis, protein bands of approximate size 53 kDa were 
detected in five selected cell lines including RWPE-1 , LNCaP, DU145, PC-3 and 
CWR22Rvl using the ERRa antiserum and the size of the immuno-detected proteins 
are comparable to the size of His tagged-ERRa recombinant protein as detected by 
anti -HisG antibody. Several studies also detect the presence of ERRa protein of 
approximate 53 kDa in the human endometrial carcinoma RL95-2 cells, cervical 
carcinoma HeLa cells, fetal rat calvaria cells and mouse brown adipocytes using 
different sources of anti -ERRa antibodies although different groups report the 
detection the ERRa protein at different molecular sizes ranging from 43 kDa to 51 
kDa. (Yang et aI, 1996; sladek et aI, 1997, Vega and Keller, 1997; Bonnelye et aI, 
2002). This protein expression pattern agrees with the results of RT -PCR as the 
ERRa gene appeared to be expressed ubiquitously in all examined prostatic cell lines. 
Together with the results by Lu et al (2001) that they detect the mRNA of ERRa in 
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fourteen different breast cancer cell lines, with our present observation of the wide 
expression of ERRa orphan receptor in all prostatic cell lines, xenografts and human 
tissues, suggesting that this gene could be important to the prostate and breast, which 
both of them are hormone-dependent for their normal and neoplastic growth. On the 
other hand, human prostate cancer has the propensity to metastasize to the bone 
where reciprocal cellular interactions between prostate cancer and bone cells are 
known to occur and involved in the growth of cancer cells and bone cells. 
Osteopontin (OPN), a noncollagenous bone extracellular matrix, is known to be 
associated with malignant transformation as well as bone metastasis of prostate 
cancer cells (Thalmann et aI, 1999; Angelucci et aI, 2004). Since OPN is a known 
transcriptional target gene of ERRa and also expressed in normal and neoplastic 
prostates, the positive expression of ERRa in the prostatic cells suggests that ERRa 
might play some roles in the bone metastasis of the prostate cancer. Study of the 
ERRa deficiency mouse model (knock out model) demonstrates that functional 
disruption of ERRa gene does not affect the fertility of the animal (Luo et aI, 2003). 
However, the detail histological and functional changes in the prostate gland of the 
ERRa-knockout mouse should be further investigated. 
Comparing to the ERRa, ERR~ showed a much weaker expression pattern 
among the prostatic cell lines, xenografts and human tissues. Only four immortalized 
cell lines, RWPE-1, RWPE-2, PWR-1E, Pz-HPV-7 expressed relative high levels of 
ERR~ whereas its mRNA transcripts were barely detected or negatively expressed in 
other cell lines and xenografts. In the human prostatic tissues, 6 out of 9 hyperplastic 
but only lout of 5 neoplastic prostates expressed the detectable amount of ERR~ 
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mRNA. The combined observations from the cell lines and tissues suggest that its 
expression might be down-regulated in the progression of prostate cancer. Our 
detection of ERR~ mRNA expression in the adult human prostatic tissues does not 
agree with the results of previously studies by Giguere et al (1988) and Chen et al 
(1999) that expression of ERR~ is highly restricted in the adult human tissues and 
only detected at low levels in liver, stomach, skeletal muscle, heart and kidney but 
not the prostate. One possible explanation of this discrepancy is the sensitivity of the 
detection method used since RT -PCR is more sensitive than Northern blot analysis. 
By the Western blot analysis using the ERR~ antiserum, a protein band of 
approximately 48 kDa was detected in RWPE-1 cells but not in LNCaP, DU145, 
PC-3 and CWR22R vI cell lines. Our present observation is the first report showing 
the detection of native ERR~ protein in the human tissues or cell lines since ERR~ is 
the least studied one among the three ERR isoforms. Interestingly, the size of ERR~ 
protein is smaller than ERRa protein as demonstrated by native and His tagged-ERR 
recombinant proteins blotting although the calculated molecular size of ERR~ (49 
kDa) is larger than the ERRa (46 kDa) based on the full length sequences in 
pRSETA vectors. 
On the other hand, ERRy, the third isoform of ERRs showed a broad and 
similar expression pattern to ERRa than ERR~ in the prostatic cell lines and 
xenografts. Most of the cell lines and xenografts expressed ERRy mRNA at 
relatively high levels except HPr-1-AR, PNT-IA, PNT2, DU145 and MDA Pca 2b 
cells, which expressed lower level of ERRy or even negative. Its variable expression 
in different prostatic cancer cell lines might reflect the clonal and genetic 
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heterogeneity of the tumors. The distinct expreSSIon patterns of the three ERR 
isoforms in the prostate cells suggest that they might perform their own independent 
roles in the prostate and prostate cancer. Similar to the ERRa expression, no 
correlation was found between the ERR y expression level and the phenotypic 
behaviors of the prostatic cell lines or the stage of prostate cancer progression. 
However, its expression pattern shown in the human tissues was more similar to 
ERR~ than ERRa that both ERR~ and ERRy transcripts were variably detected in the 
hyperplastic and neoplastic prostates. The results might also suggest that ERR~ and 
ERRy genes might not be essential to the prostate gland, at least to the survival of the 
epithelial cells. The positive expression of ERRy mRNA transcript in the prostatic 
cells and tissues agree with the previous finding by Eudy et al (1998) that ERRy is 
moderately expressed in the human prostate as detected by northern blottings and 
RT-PCR. By Western blot analysis using the ERRy antiserum, protein bands of 
approximately 51 kDa were detected in all cell lines except DU 145. The absence or 
loss of expression of ERR~ and ERRy in some prostatic cell lines and · tissues might 
be due to the methylation of genes. The methylations of CpG islands, the 
cytosine-rich regions in the promoter, are known to be responsible for silencing of 
some genes that show tissue-specific expression pattern. De novo- methylated DNA 
could interact with specific methyl-CpG-binding proteins, which would prevent the 
accession of promoter regulator to the DNA, for instance, Sp-1 protein (Pugh and 
Tjian, 1990). Studies by Sasaki et al (2002) and Li et al (2000) demonstrate that 
down-regulation of estrogen receptors (ERs), progesterone receptor as well as 
androgen receptor in some prostate cancer cells are mediated by this mechanism. In 
the case of ERRs, Shi et al (1997) document that the presence of CpG islands in the 
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promoter region of human ERRa gene. Although the presence of CpG islands in the 
5' regulatory region of human ERR~ and ERRy genes are still unknown as their 
promoters have not been well-characterized, it is speculated that low or loss of 
expression of ERRs in the prostatic cells may be therefore related to the alteration of 
DNA methylation pattern in CpG islands of the their promoters or by other 
mechanism. 
Multiple promoter usage and alternative splicing of mRNA are known to 
be common features among the members of steroid hormone receptor superfamily, 
including estrogen receptors, progesterone receptor and retinoic acid receptor (Bollig 
and Miksicek, 2000; Lewandowski et al 2002; Kastner et aI, 1990; Leroy et aI, 1991). 
The mRNA isoforms usually have different potential functional significances and 
exhibit different tissue distribution patterns. Moreover, the transcription of these 
isoforms is often related to tissue or developmental-specific regulation of the genes. 
According to the previously findings, it is reported that both human ERRa and ERR~ 
consist of two major isoforms. In the first report on the molecular cloning of ERRa 
and ERR~, Giguere et al (1988) cloned the ERRa (named as hERR1 with 521 amino 
acids) and ERR~ (named as hERR2 with 433 amino acids) from kidney and heart 
cDNA libraries. In addition, a shorter spliced ERRa variant (named as hERRa 1, 423 
amino acids) using the translational start site that is 291 bp downstream to the start 
codon of hERR1 was identified later in the human RL95-2 and He La cells and 
predominantly expressed in the breast tumor tissues (Yang et aI, 1996; Yang et aI, 
1998). It is generally believed that the hERRa1 is the major ERRa isoform expressed 
in the human tissues. Additionally, Chen et al (1999) identified a longer form of 
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ERR~ (named as hERR~2, 500 amino acids) with an additional 67 extra amino acids 
residues present at the C-terminus that is present in hERR2, by bioinformatics and 
inverse PCR approaches. For the human ERRy, Heard et al (2000) show that the 
pre-mRNA of ERRy is extensively alternatively spliced at the 5' -end giving rise to at 
least six different transcripts coding for two major ERRy protein isoforms (named as 
hERRyl with 435 amino acids and hERRy2 with 458 amino acids). The authors also 
demonstrate that ERR y isoforms are expressed in a tissue-specific manner in the 
human adult tissues. In the present study, the results of RT -PCR cannot demonstrate 
and distinguish whether the shorter or longer alternatively spliced isoforms of ERRs 
were expressed in the prostatic cell lines and tissues since the primers are located 
nearly at the middle region of ERRs genes. However, the spliced variants could be 
demonstrated by Northern blottings. Comparing the molecular sizes of native ERRs 
proteins to the recombinant ERR proteins, one can predict that hERRal (423 a.a) and 
hERR2 (433 a.a) are the major isoforms expressed in the prostatic cell lines. 
However, it could also be possible that prostatic cells express the prostate specific 
isoforms of ERRs that have not been characterized by other researchers. The 
Oligonucleotide primers specific for the 5' end or 3 'end of the ERRs genes can be 
designed and used to further explore and confirm which isoforms of ERRs are 
expressed in the human prostate gland and cell lines. 
5.1.2 Co-localization of ERRs and ERIl in the human prostate 
The results of RT -PCR showed that all examined prostatic cell lines, origin 
from the luminal epithelial layer of normal or carcinomatous prostates, expressed one 
to three ERR isoforms. In order to demonstrate what cell types specifically expressed 
166 
Chapter 5. Discussion 
ERRs in the human prostate gland, immunohistochemistry was done in the normal, 
dysplastic as well as neoplastic prostates with low-grade and high-grade lesions 
using our own developed antisera against ERR cognate peptides. The specificities of 
the antiera were evaluated by Western blot analysis of His tagged-ERR recombinant 
proteins and the results showed that no cross-reaction was shown between these 
antibodies. By immunohistochemistry, immunosignals of both ERRa and ERR~ were 
predominately localized to the nuclei of luminal and basal epithelial cells and to a 
lesser extent in stromal cells whereas ERR y was expressed in both cytoplasm and 
nuclei of luminal epithelial cells in normal human prostate. In the human prostate, 
luminal secretory cells and basal cells are two morphologically distinct cell types 
present in the epithelial layer. Luminal epithelial cells tend to be differentiated and 
androgen dependent, and possess a relatively low proliferative capacity and a high 
apoptotic index induced by androgen stimulation or withdrawal. In contrast, it is 
generall y believed that basal cells are undifferentiated and andro gen independent, 
and they have a high proliferative capacity and a low apoptotic index. Therefore, it is 
hyprothesized that basal cells represent the stem cells of the prostatic epithelial 
population (Schalken and van Leenders, 2003). By immunohistochemical and cell 
kinetics studies, it is speculated that the basal cells could play crucial role in the 
carinogenesis of the prostate gland (Bonkhoff and Remberger, 1998; K wong et aI, 
2003). The expression of ERR a and ERR~ proteins in the basal epithelial cells of the 
human prostate suggests that the two nuclear receptors might play some but yet 
undefined roles in the differentiation of prostate gland. On the other hand, the 
localization patterns of ERRa and ERR~ in the prostate appear to be similar to the 
expressIon of ER~. During the past decade, conflicting results by 
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immunohistochemistry have been reported regarding the exact localization of ER~ in 
the human prostate tissue, in either the epithelial or stromal cells at variable levels. 
Such discrepancies are poorly understood but are considered due to the different 
antibodies being used. Nevertheless, it is generally accepted and believed that ER~ is 
predominantly expressed in the basal epithelial layer since several researchers 
demonstrated the presence of ER~ protein in this cell population by 
immunohistochemistry using different sources of antibodies (Royuela et at, 2001; 
Leav et aI, 2001; Tsurusaki et aI, 2003). In contrast, the expression of ERa is 
demonstrated to be restricted to the stromal cells in adult human prostate (Shulze and 
Claus, 1990; Brolin et at, 1992; Hiramatsu et at, 1996). The distinct expression 
pattern of the two ER isoforms in the prostate has lead to a view that the proliferative 
signals mediated by AR in the basal cells or by ERa and AR in stromal cells may be 
opposed by the purported growth-inhibitory action of ER~ expressed in the basal 
cells (Poelzl et aI, 2000; Chang and Prins, 1999; Lau et at, 2000). As basal cells are 
the purported precursor of secretory luminal cells, the co-expression and 
co-localization of ERRa, ERR~ and ER~ in the basal cells suggests that these two 
ERR isoforms might cross-talk to the classic estrogen signaling pathway mediated by 
the ligand-dependent ERs as well as involved in the growth regulation of the prostate 
gland. 
5.1.3 Differential expression patterns of steroid hormone receptors and 
prostatic specific markers in prostatic cells and xenografts 
In order to demonstrate any expression correlation between ERRs and 
other steroid hormone receptors, expression patterns of estrogen receptors (ERa and 
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ER~), androgen receptor (AR), glucocorticoid receptor (GR), two ER-regulated 
down-stream target genes including progesterone receptor (PR) and pS2 as well as 
two AR down-stream target genes including PSA (hK3) and KLK2 (hK2) in the 
prostatic cell lines and xenografts were evaluated by RT-PCR. In addition, the 
expression of aromatase, a cytochrome P450 enzyme that catalyzes the formation of 
aromatic C 18 estrogens from C 19 androgens, was also studied. Estrogen receptors, 
consisting of two isoforms a and ~, are the close relatives of ERRs based on their 
structural and functional similarity. By RT -PCR, differential expression of ERa was 
observed in the immortalized, cancer cell lines and xenografts. All immortalized 
epithelial cell lines but only 3 out of 10 cancer cell lines and xenografts including 
CA-HPV-I0, PC-3, CWR22Rvl expressed ERa transcripts at detectable levels and 
our results appeared to suggest that ERa is down-regulated in the progression of 
prostate cancer. In contrast, ER~ was persistently expressed in all tested cell lines and 
xenografts. The expression of ER genes in three well-characterized cell lines, LNCaP, 
PC-3 and DU1 45 has been studied by several individual groups and our results of 
agree with their findings (Linja et aI, 2003, Lau et aI, 2000; Kim et aI, 2002). All of 
them expressed ~ form of ER while only PC-3 expressed the a isoforms. In addition, 
it is known that epigenetic effect by hypermethylation of promoter is the major 
mechanism that leads to the silencing of ERa gene in the prostate cancer cells since 
treatment with demethylation agents can effectively reactivate the expression of ERa 
mRNA in these cells (Kim et aI, 2002; Li et aI, 2000). The expression pattern of ERa 
appears to be similar to the ERR~ in prostatic cells since absent or loss of expression 
of ERR~ and ERa was observed in some immortalized and cancer cell lines. 
Therefore, it is speculated that hypermethylation of ERR~ gene promoter might 
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occur in the prostatic cells, leading to its silencing in the cancer cell lines. On the 
other hand, ER~ is originally cloned from the rat prostate cDNA library and 
abundantly expressed in the epithelial cells (Kuiper et aI, 1996). Subsequently, the 
human and mouse homologues for ER~ is also cloned. However, the expression of 
this gene appears to be less prominent in human than in rat prostate (Mosselman et aI, 
1996; Linja et aI, 2003). In the present study, the results of RT-PCR after 35 cycles 
amplification showed that the expression levels of ER~ were not prominently high in 
human prostatic cells. Most of the prostatic cell lines and xenografts expressed ER~ 
at the comparable level to the MCF -7 cells, a estrogen-responsive breast cancer cell 
line. The results suggest that although certain tissue-specific functions for ER~ have 
been proposed (Weihua et aI, 2001; Weihua et al 2000, Zhu et aI, 2000), it may also 
possess more general functions in a variety of different tissue types. As comparsion 
to the expression of ERRs and ERs, ER~ and ERRa were co-expressed in all 
immortalized, cancer cells and xenografts. Taken into consideration with the results 
of immunohistochemistry, it is proposed that ERRa and ER~, the two members of 
nuclear receptor superfamily, which are different in their ligand dependence are 
co-expressed in prostatic cells and might crosstalk between one another or share 
similar regulatory pathways through their competition for DNA binding sites and 
co-regulatory proteins. On the other hand, expression of two estrogen-responsive 
genes, PR and pS2 were also examined in order to gain some insight into the 
functionality of the ERs in the prostatic cells. pS2, which is highly expressed in 
ER-positive human breast cancer, is a breast cancer prognostic marker. Several 
studies demonstrated the expression of these two genes in the human prostate and 
prostatic cells (Lau et aI, 2000; Yang et aI, 1992; Latil et aI, 2001; Bonkhoff et aI, 
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1995; Colombel et aI, 1999). However, the results of the present study showed that 
loss of expression of these two genes in some ERs-positive prostatic cells and 
suggests that a possible deregulation of estrogen signaling mediated by ERs in these 
cells. The over-expression of pS2 in the cancer cell lines and xenografts agrees with 
the previously reports that pS2 is a candidate specific marker for dysplasia and 
prostate cancer. Besides, although Coward et al (2001) show that ERRs can activate 
the pS2 expression through the binding of ERE and ERRE promoter sites, the 
regulation of this gene in the prostate and prostate cancer by ERRs should be further 
verified and studied. On the other hand, all the cell lines and xenografts expressed 
the mRNA of aromatase indicating that an in situ estrogen production by the 
prostatic cells or in the prostate gland. ERRa might regulate the expression of 
aromatase in the prostatic cells and xenografts as both are co-expressed in all 
prostatic cell lines and xenografts as Yang et al (1998) and Chen et al (2002) show 
that ERRa can interact a specific silencer element (S 1) situated between promoters 
1.3 and 11 of the human aromatase gene in the breast tissue. 
It is well established that the principal regulator of prostatic growth, 
differentiation and maintenance is androgen and its correspondent receptor AR. AR 
is expressed and localized in stromal, luminal epithelial as well as certain extend in 
basal epithelial cells in the human prostate gland (Leav et aI, 1996; Leav et aI, 2001,). 
The results of the present study showed that androgen receptor is not universally 
expressed in all prostatic cell lines especially its variably expressed in the normal 
immortalized cells. It is not sure whether these cell lines are originated from 
androgen receptor-negative prostatic cells or the androgen receptor expression is lost 
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during the long time culture as androgen receptor usually disappeared in late-passage 
normal prostate primary cultures or in established normal cell lines (Grant et aI, 
1996). On the other hand, several cancer cell lines expressed at abundant levels of 
AR transcripts, as compared to the immortalized cells. The positive expressions of 
two AR target genes, KLK2 (human glandular kallikrein 2, hK2) and KLK3 
(prostate-specific antigen, PSA, hK3) which have important applications in prostate 
cancer diagnostics, are correlated to the expression of AR in prostatic cell lines and 
indicates that the prostatic cells expressed the functional AR (Diamandis et aI, 2000). 
Interestingly, it was observed that the size of PCR product of AR amplified in 
CWR22Rv1 cells is apparent 120 bp larger than in other prostatic cell lines. It is 
because CWR22Rv1 contains a mutant AR with an in-frame tandem duplication of 
exon 3 (117 bp) that encodes the second zinc finger of the AR DNA-binding domain 
and leads to this cell line exhibiting both androgen-responsive and 
androgen-insensitive features (Tepper et aI, 2000). Although there is no correlation 
observed between the ERRs and AR expression levels in the prostatic cells, however, 
the up-regulation of ERRa (--- 2 fold) in the CWR22Rv1 cells as compared to the 
orginal xenograft CWR22R, might be due to the mutation of AR and the alteration of 
androgen signaling pathways. Ho·wever, this speculation requires further 
experimental evidence. Moreover, the serum in the culture medium may contain 
some unknown factors that can induce the expression the ERRa in this prostatic in 
vitro model. Besides the ERs and AR, the expression pattern of another class III 
steroid hormone receptor, glucocorticoid receptor (GR) was also examined in the 
prostatic cell lines. Previously literatures show positive expression that the presence 
of GR in the human prostatic tissues and cell lines (Schultz et aI, 1993, Mohler et aI, 
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1996). It is reported that glucocorticoids are mainly involved in the regulation of 
glucose metabolism, inhibition of inflammation, and immune functions (Porterfield, 
1996). Moreover, OR can minic the action of AR and possibly has the negative 
growth effects in the prostatic cells (Cleutjens et aI, 1997, Nishimura et aI, 2001). 
The results of the present study demonstrated that GR was universally expressed in 
all test prostatic cell lines and tumor xenografts indicating that GR might play some 
important roles in the prostate gland. Trapp and Holsboer (1996) report that the 
transcriptional activity of GR could be repressed by ERR~ in a cell-specific manner. 
Overall, the present results revealed that co-expression of ERRs and several steroid 
hormone receptors in the prostatic cells and therefore, they might cross-signaling to 
each other to interfere the growth, differentiation as well as the carcinogenesis of 
prostate gland. 
5.2 ERRa acts as a expression repressor of ERRy and ERa in PC-3 
cells 
The results of previous section demonstrated the co-expression of several 
steroid hormone receptors, especially the two closely related subfamilies, ERRs and 
ERs in the prostatic cells. In order to reveal whether they could cross talk to each 
other at the transcriptional level, the genes of ERRa, ERRy and ERa were transient 
transfected into the PC-3 cells that show endogenous expression of ERRs (a, y) and 
ERs. PC-3 is the most easiest cell line to be transfected among the different prostatic 
cells. The results of this experiment showed that over-expression of ERRa could 
repress the transcript levels of both ERRy and ERa but ER~. This observation 
indicates that ERRs and ERs possibly could cross talk at the transcriptional level. 
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Ligand-dependent estrogen receptors consist of two structurally and functionally 
similar isoforms, a and ~. A possible cross-signaling and interaction between them 
has previously been reported in different in vitro systems. It is demonstrated that ER~ 
and ERa can form heterodimeric complexes with retained DNA-binding ability 
(Pettersson et aI, 1997). Transient transfection assays have demonstrated that ER~ 
has the capacity to repress the transcriptional activity of ERa (Petters son et aI, 2000). 
Studies in wild type and ER~-knock out mouse indicate that ER~ can sometimes act 
as a dominant negative regulator of ERa activity and exhibits a "Ying Yang" 
counter-balancing relationship to ERa (Lindberg et aI, 2003). Therefore, 
co-expression of ERa and ER~ in cells or tissues might contribute a complex 
estrogen mediated signaling since they have distinct, but partially overlapping 
patterns of expression (Kuiper et aI, 1997). Additionally, studies also demonstrate 
that this cross signaling does not restrict to the two isoforms of ERs, but also involve 
of ERRs, the close relatives of ERs. Several individual groups reported that ERRa 
and ERa might potentially regulate the same target genes independently as well as 
interfere with each other 's transactivation activity by competition for binding with 
coactivator and response element (Kraus et at, 2002; Zhang and Teng, 2001 ; 
Vanacker et aI, 1999). The results of this study discover and suggest that the new 
mechanism of cross talking between these two subfamilies as ERRa could function 
as an expression repressor of ERR y and ERa gene in PC-3 cells which co-express 
both ERRs and ERs. On the other hand, several lines of evidence showed that 
estrogens, possibly act through the ERs, could regulate the expression of ERRa gene 
in several mouse tissues and human endometrial carinoma cells (Shigeta et aI, 1997; 
Bonnelye et aI, 2002; Liu et aI, 2003). However, our results do not support this 
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observation because overexpression of ERa gene together with the exogeneous 
estrogens had no effect on ERRa gene level in the PC-3 cells. The results indicate 
that the regulation of ERRa by ERa might be cell type specific and dependent on the 
endogenous ERRa and ERs transcript levels. 
Modulation of the ERs levels by exogenous or endogenous molecules 
have been studied in many models. Estrogens are well known to down regulate its 
cognate receptors (ERs) especially the a isoforrn in some estrogen responsive tissues 
and cell lines (Kaneko et aI, 1993; Borras et aI, 1994; Zhou et aI, 1993). Other 
molecules including prolactin, vitamin D, epidermal growth factor as well as p53 
tumor suppressor gene have also reported to involve in ERa expression regulation in 
certain tissues or cells (Stoica et aI, 2000; Stoica et aI, 1999; Angeloni et aI, 2004; 
Frasor et aI, 2003). Moreover, dietary genistein, the predominant isoflavone found in 
the soy, have been showed to down regulate to both ERa and ER~ in the rat prostate 
(Dalu et aI, 2002). Clinically, some estrogen receptor down-regulators, for instance, 
Faslodex and Fulvestrant, are widely used in the treatment of estrogen receptors 
positive breast cancer (Robertson, 2001; Jones, 2003). The regulation of estrogen 
receptors (ERs) is clearly very complex and is tissue and cell specific. The possible 
mechanisms of down regulation of ERa and ERRy genes by ERRa overexpressed 
PC-3 cells are suggested as follow: (1) ERRa can bind to the response element in the 
promoter regions and repress the trancription of ERa and ERRy genes through 
rescuing some corepressors. (2) Overexpression of ERRa might up or down regulate 
some responsive genes that could modulate the expression levels of ERa or ERRy. 
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5.3 ERRs are nuclear localized and constitutively active in PC-3 
cells 
In the last two decades, many structurally and functionally studies were 
conducted on ERRs and generally conclude that ERRs are ligand-independent 
transcriptional factors or considered as orphan nuclear receptors as they can activate 
specific promoters and induce the transcription of specific genes without binding to 
any physiological ligand. However, direct evidence of its nuclear localization was 
absent although they were classified as "orphan nuclear receptors". Therefore, in the 
present study, combined technique of fluorescence microscopy in conjunction with 
green fluorescence protein (GFP) - ERR fusion proteins were used to examine the 
intracellular distribution and localization of ectopic expressed ERRs in the 
transfected PC-3 prostatic cells. The GFP technique offers two advantages over the 
traditional biochemical fractionation and immunohistochemistry. First, it eliminates 
the use of fixation, cell permeabilization, and antibody incubation in 
immunohistochemistry, which normally requires when using antibodies tagged with 
chemical fluorophores. Second, the use of GFP tag permits kinetic studies of protein 
localization and intracellular trafficking due to the resistance of the GFP 
chromophore to photobleaching (Hager et aI, 2000). These properties of GFP thus 
make this protein as a good reporter for studying intracellular protein trafficking in 
living cells. Based on this technique, nuclear receptors can be divided into three 
different board categories according their intracellular distributions under unliganded 
condition. Firstly, the receptors including estrogen receptor a (ERa) and thyroid 
hormone receptor ~ (TR~) are found primarily and constitutively in the nucleus in 
the absent of ligand (Htun et aI, 1999; Baumann et aI, 2001). The latter are also 
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known to interact with specific DNA regulatory elements and repress selective genes 
in the absence of ligand. (Zamir et ai, 1996). Secondly, the receptors including 
glucocorticoid receptor (GR) and androgen receptor (AR) are found primarily 
cytoplasmic (Htun et ai, 1996; Georget et aI, 1997). Thirdly, the receptors including 
mineralocorticoid receptor (MR) and progesterone receptor (PR) consist of mixed 
distribution in both cytoplasmic and nuclear compartments (Fejes-Toth et aI, 1998; 
Lim et aI, 1999). However, addition of respective ligands induces a nearly complete 
nuclear localization of the receptors. On the other hand, focal concentration of 
receptor protein in a ligand-dependent fasion is a common feature of many steroid 
hormone nuclear receptors and suggests that these structures may participate in the 
biological life cycle of the receptors. (Htun et ai, 1999; Maruvada et ai, 2003) 
The results of the present study demonstrated that GFP-ERRs fusion 
proteins are functional and localized in the nucleus of PC-3 transfected cells in the 
presence of fetal bovine serum, representing the cells in the normal physiological 
fluids. The ability GFP-ERRs to transactivate both classical ERE and ERRE (SF-I) 
response elements agrees with the previously published results as these two promoter 
sequences are the transctiptional targets of the three isoforms of ERRs (Lu et aI, 
2001; Vanacker et aI, 1999; Heard et aI, 2000). The nuclear localizations of 
GFP-ERRs confirm that ERRs are the nuclear proteins. On the other hand, several 
independent lines of evidences showed that serum used in the normal culture 
medium contain some unknown unidentified factors those are necessary for the 
transactivation of ERRa (Vanacker et aI, 1999; Sumi et aI, 2003). Therefore, same 
experiment was then repeated in the absence of fetal serum. Interestingly, the results 
177 
Chapter 5. Discussion 
showed that ERRs could still transactivate the ERE and ERRE-driven luciferase 
reporters and further confirm that transcriptional activities of ERRs are independent 
of serum, at least in the PC-3 prostatic cells. Based on the results of above 
experiments, it is believed that ERRs are constitutively active orphan receptors 
independent of the exogenous ligand and constitutively localized in nucleus. Further 
experiments of GFP-ERRs tracking can be done in the presence of specific ERR 
antagonists such as diethylstilbestrol (DES) and 4-hydroxytamoxifen (OHT) since 
treatment of full antagonist to the cells · can alter the nucleocytoplasmic 
compartmentalization of ERa in the breast cancer cells (Htun et aI, 1999). Besides, 
comparison of the transcriptional activities among the three ERR isoforms showed 
that ERRy is the most potent ERE and ERRE transactivator while ERRa is the least 
potent one. So far, there is no publication showing direct comparison of 
transcriptional activities among the three ERR isoforms. However, solid conclusion 
cannot be drawn from the present study because the transcriptional activities of 
ectopical ERRs are also greatly depend on the availability of coactivators and the 
endogenous expression of ERRs and ERs because ERRs and ERs could compete for 
coactivators that are usually the limited factors in the cells (Vanacker et aI, 1999; 
Zhang and Teng, 2001; Kraus et aI, 2002). Apart from this, results of the present 
study also demonstrated that transcriptional activities of GFP-ERR~ towards the 
ERE and ERRE driven reporter and GFP-ERRy towards the ERRE driven reporter 
are different under the serum-free condition. It is proposed that this phenomenon is 
due to the change of expression of isoform-specific coactivators or endogenous 
ligand, such as PGC-1 a when the cells were cultured in the absence of serum 
(Schreiber et aI, 2003). Overall, the experiments of intracellular localization and 
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transcriptional activity on GFP-ERRs support preVIOUS results that ERRs are 
self-activated and functional in the absence of exogenous ligand when they are 
expressed in human prostatic cells. 
5.4 ERRs acts as the negative growth regulators of prostatic cells 
Class III nuclear hormone receptors are well known to trigger the 
fundamental physiological processes, particularly in primary and accessory sex 
organs, through regulating the cell proliferation and death. For instance, estrogens 
and progesterone and their cognate receptors (ERs) and (PR) can stimulate the 
proliferation of the mammary epithelial cells and trigger the lobular-alveolar 
development during pregnancy (Silberstein et aI, 1994; Lydon et aI, 1996). Moreover, 
the proliferation of the glandular epithelium and stroma of the endometrium of uterus 
correlates with circulating levels of estrogens and progesterone (Tabibzadeh et aI, 
1996; Graham and Clarke, 1997). On the other hand, androgen and its receptor (AR) 
are essential for the maintenance of prostate epithelial cell proliferation and 
differentiation during growth and development. Androgen withdrawal by surgical or 
chemical castration results in massive apoptosis of the prostatic epithelium and 
prostate involution. Therefore, AR is the target of endocrine therapy for prostate 
cancer and blockade of the androgen-signaling pathway could kill the 
androgen-dependent cancer cells through induction of programmed cell death (Cunha 
et aI, 1987; Denmeade et aI, 1996). In addition, Glucocorticoid and its receptor (GR) 
have strong growth-regulatory capacities that can be stimulatory or inhibitory, 
depending on the cell type. Since ERRs are also classified as class III nuclear 
hormone receptors since they have similar structural domains, protein sequence and 
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cognate honnone response elements especially closely related to ERs. Therefore. \-ve 
hypothesize that ERRs possibly play some gro"Wih regulatory roles in the prostatic 
cells. In the present study, the results sho\ved that transient expression of ERRs in the 
PC-3 cells and stable expression of ERRy in the PNT2 and DU 145 stable 
transfectants resulted in retardation of growth. The ERRs-mediated £TO\-vth inhibition ~ ~ 
in the prostatic cells involved alteration of expressions of several cell-cycle 
molecules and the cell cycle distribution. Additionally, over-expression of ERR y also 
abolished the anchorage independent gro\vih of PNT2 as \-vell as DU 145 cells. 
Overall, the three ERR isofonns, especially the y isofonn, could play some important 
roles in the growth regulation In a negative manner in both immortalized and 
prostatic cancer cells. 
5.4.1 Cell cycle control of mammalian cells 
The cell cycle of mammalian cells IS controlled by many different 
mechanisms that ensure the correct cell division and proliferation. Generally! cell 
division consists of two main stages: mitosis CM phase) and interphase. The latter can 
be subdivided into three different phases including G I! S and G2. The cell in the G 1 
phase is preparing for DNA synthesis , \vhile replication of DNA is occurred during 
the S phase. G2 phase is the gap period when the cell is preparing for mitosis. 
Besides, cells in G 1 phase might enter a resting state (GO phase) before proceeding to 
the DNA replication (Norbury and Nurse, 1992) . The transition of a cell from one 
cell cycle phase to another is mainly regulated by three groups of cell cycle-related 
proteins including cyclin dependent kinases (CDK), cyclins and CDK inhibitors. 
CDK are serine/threonine protein kinases that can be activated b; binding to cyclin 
180 
Chapter 5. Discussion 
(CDKlcyclin complexes) at specific points of cell cycle. Once the CDK is active, it 
can phosphorylate the target proteins (CDK substrates) that are essential for cell 
cycle progression. The most extensively studied one is the retinoblastoma tumor 
suppressor gene (PRb). During the early G 1 phase, pRb is phosphorylated by the 
CDK4/6-cyclin D and CDK2-cyclin E complexes and then the transcription factors 
E2F -1 and DP-1, which positively regulate the transcription of genes related to S 
phase progression including cyclin A are released (Kato et aI, 1993; Brehrn et aI, 
1998) Moreover, CDK-2 - cyclin E and CDK1 - cyclin B complexes can 
phosphorylate histone HI that are important for chromosome condensation during 
DNA replication (Bradbury et aI, 1974). The CDK activity can be balanced by CDK 
inhibitors that bind and inactivate the CDK - cyclin complexes. Two distinct families 
of CDK inhibitors have been found including INK4 family and Cip/Kip family. The 
INK family consists .p15, p16, p1 8 and p19, which specifically inactivate CDK 
involving in G 1 phase. The Cip/Kip family includes p21 , p27, p57 and they inhibit 
the G 1 CDK-cyclin complexes and to a lesser extent, CDKl - cyclin B complex 
(Camero and Hannon, 1998; Hengst and Reed, 1998). Apart from the these cell cycle 
regulatory proteins, the cell cycle checkpoints are present in order to arrest the cell 
cycle in response to DNA damage. p53 is the key regulatory protein involved in both 
G liS and G2/M DNA damage checkpoints which induces the transcription of genes 
related to cell cycle arrest, for examples, p21 and Bax, in order to provide the time 
for DNA repair (Levine, 1997; Taylor and Stark, 2001). In cancer, there are 
fundamental alterations in the genetic control of cell division, resulting in abnormal 
and uncontrollable cell proliferation. Mutations have been observed in genes 
encoding CDK, cyclins, CDK inhbitiors, CDK substrates and checkpoint proteins, 
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for instance, the tumor suppressor genes pRb and p53 (McDonald and EI-Deiry, 2000; 
Sherr, 1996) 
5.4.2 The roles of AR and ERs in the cell cycle regulation 
In the human prostate, androgen and its receptor (AR) are the principal 
regulator of epithelial cell proliferation and differentiation. Studies on the LNCaP 
prostate cancer cell model reveal a role of androgen in the G 1- S phase cell cycle 
transition of the prostatic cells (Fribourg et aI, . 2000; Kundsen et aI, 1998). On one 
hand, androgen could stimulate the expression of cyclin D1 and enhance the 
formation of cyclin D1 - CDK4 complex. On the other hand, androgen also regulates 
CDK2-complex activity through the post-translational mechanisms including 
PTEN -mediated regulation of CKI p21 expreSSIon. The net result of 
androgen-mediated CDK4 and CDK2 induction is phosphorylation of pRb, an 
essential gene of G 1-S phase transition. The hyperphosphorylated pRb then activates 
the cyclin A expression and causes the transition of cells to S phase. In addition, 
androgen withdrawal by castration induces apoptotic cell death in prostate also 
involves the cell cycle related genes. Study by Chen et aI (1996) show that castration 
reduces the CDK2 and CDK4 expression in rat ventral prostate and androgen 
treatment results in the virtual disappearance of p21 and increase of both CDK2 and 
CDK4 protein levels. Apart from AR, the two isoforms of ERs are also known to 
play some roles in the proliferation of prostatic epithelial cells. However, the exact 
mechanisms behind are still unclear and under the extensive investigation. In the 
normal breast epithelia and cancer cells, it is well established that the growth 
stimulatory effect of estrogens, mediated through their cognate receptors, results 
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from the induction of cell cycle progression. So far, previous studies identify cyclin 
D1, c-myc, CDK inhibitor p21 and cyclin E-CDK2 complex as the central 
components of estrogen regulation of G l-S phase cell cycle transition of the breast 
cancer cells (Doisneau-Sixou et aI, 2003; Planas-Silva and Weinberg, 1997). Female 
mice lacking the cyclin D 1 are defective in pregnancy-associated mammary tissue 
proliferation whereas overexpression of cyclin D 1 results in development of breast 
cancer in MMTV-D1 transgenic mice (Fantl et aI, 1995; Wang et aI, 1994). This 
growth stimulatory effect of estrogens is probably mediated ERa since re-expression 
of ERa in the ERa negative MCF -7 cells can restore the estrogen-mediated growth 
and knockout experiments in mice, suggesting that ERa, but not ER~, supports breast 
development (Oesterreich et aI, 2001; Krege et aI, 1998; Korach, 1994). On the other 
hand, one recent study show that adenovirus-mediated expression of ER~ in the ER~ 
negative MCF -7 cells inhibits the proliferation by repressing c-myc, cyclin D 1, 
cyclin A and increasing the CDK inhibitors p21 and p27 levels, which leads to G2/M 
phase cell cycle arrest (Paruthiyil et aI, 2004). ER~, therefore, might have a 
protective effect against the mitogenic action of estrogens. Above findings suggest 
that the two ER isofonns play the "Ying Yang" counter-balance effect to each other 
on growth regulation of breast cancer cells. This phenomenon has been also observed 
in the prostate since estrogens have both stimulatory and inhibitory effects on the 
growth of prostate gland through the two isofonns of ERs. However, ER-knockout 
mouse experiments demonstrate that lack of functional ERs does not prevent the 
nonnal growth and development of the prostate gland (Dupont et aI, 2000; Couse et 
aI, 1997; Fisher et aI, 1998; Honda et aI, 1998), which leads to our hypothesis that 
ERRs, the close relatives of ERs, might modulate or replace the ERs mediated 
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growth regulation in the prostatic cells. 
5.4.3 Inhibition of cell proliferation in ERRs transient transfected PC-3 cells 
and ERRy stable-expressed PNT2 and DU 145 cells 
In the present study, the expressions of ERRs were enforced ectopically in 
several prostatic cell lines using the chemical-mediated gene delivery method, 
transfection, in order to study the role of ERRs in the prostatic cells growth. 
Experiments in previous section showed that the in vitro expressed ERRs 
(GFP-ERRs) are functional and self-actived in the presence or absence of serum. A 
few reports in literature reveal that ectopic expression of ERa as well as vitamin D 
receptor (VDR) results in growth inhibition in the prostatic cells (Ye et aI, 2001; 
Hedlund et aI, 1996). In the present experiment, reduction of cell proliferation and 
GO/G 1 cell cycle arrest were observed in the ERRs transfected PC-3 cells. Since 
CDK inhibitors are the chief cell cycle regulators, the expressions of members of 
CDK inhibitors including p16, p18, p19, p21 and p27 were also examined by 
RT -PCR. The results showed that the expression p21 was up regulated in the three 
ERR isoforms transfected PC-3 cells. Additionally, it was observed that ERR')' 
appeared to be the most potent negative growth regulator in the transfected PC-3 
cells among the three ERR isoforms. To further confirm this observation, one 
immortalized cell line PNT2 and one androgen-independent cancer cell line DU 145, 
both of them express relative low levels of ERR,)" were selected for stable 
transfection of ERRy since PC-3 cells have relatively high endogenous level of 
ERRy. Similarly, ERRy stable-transfected PNT2 cells showed reduction of 
proliferation (increase of doubling time), cell cycle withdrawal in GO/G 1 phase as 
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well as an increase of expression level of CDK inhibitor p21. p21 is the most well 
studied one among different CDK inhibitors. It effectively inhibits cyclinD-CDK4/6 
and cyclin E-CDK2 complexes, which have a direct role in the G l-S phase cell cycle 
transition, but it is a poor inhibitor of other known CDKs (Harper et aI, 1995; Hengst 
and Reed, 1998). Moreover, p21 can bind and inhibit the activity of proliferating cell 
nuclear antigen (PCNA), an important marker of cell proliferation that plays 
important roles in nucleic acid metabolism, DNA replication and DNA excision 
repair (Waga et aI, 1994). The increase of p21 expression level in ERRy stable 
transfectants could partially explain the GO/G 1 cell cycle arrest in the PC-3 cells 
transient transfected with ERRs and ERRy stable-transfected PNT2 cells. Although 
the expression of p21 is under the transcriptional control of p53 tumor suppressor 
gene since p21 gene promoter contains a p53-binding site (el Deiry et aI, 1993). 
However, the induction of p21 in ERRy transfected cells seems to be 
p53-independent because the expression level of p53 in these cells remained 
unchanged. Several lines of evidences demonstrate that p21 has other physiological 
functions in addition to the normal cell cycle regulation. In the rat prostate, p21 play 
the important role in the differentiation during development and terminal 
differentiation through the interaction with transforming growth factor ~ 1 (TGF~ 1) 
and androgen receptor (AR) (Lu et aI, 2000; Reynisdottir et aI, 1995). One clinical 
study also concludes that p21 expression is associated with the progression of 
prostate cancer from androgen-dependent to androgen-independent (Fizazi et aI, 
2002). Apart from CDK inhibitors, the mRNA expressions of different cyclins (D 1, 
D2, D3, El, E2, A and E) were also investigated in the ERR y stable-transfected 
PNT2 cells. However, none of them showed significant change in their mRNA level. 
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Nevertheless, it should be concerned that the expression levels of cyclins depend on 
both transcriptional control as well as the degradation rate of proteins. Therefore, the 
present results cannot exclude the possibility that the presence of ERRy-mediated 
post-translational regulation of different cyclins involved in the GO/G 1 cell cycle 
arrest. On the other hand, expression of level of c-myc proto-oncogene, a cellular 
homologue of the avian myelocytic leukemia virus encoding for a nucleoprotein 
transcription factor that is strongly associated with cell proliferation, differentiation 
and tumor formation of prostate and breast cancer (Steiner et aI, 1998; Balaji et aI, 
1997), was also examined in the ERRy stable-transfected PNT2 cells. The unaltered 
level of c-myc in the transfected cells suggests that the mechanism of growth 
inhibition of ERRy in prostatic cells is different to the ERs mediated growth 
regulation as shown in the breast cancer cells since c-myc IS a well-known 
down-stream effector of estrogen-induced breast cancer proliferation. 
On the other hand, ectopic expression of ERRy in the DU 145 prostate 
cancer cell line resulted in a G2/M phase cell cycle arrest although they showed 
similar growth inhibition as in the ERRy transfected PC-3 and PNT2 cell lines. 
Moreover, transcript level of p21 is remained unchanged in the DU 145 ERRy 
transfectants but a reduction of p 19 expression was observed. p 19 is another negative 
growth regulator of cell cycle and belongs to the INK family of CDK inhibitor that 
specifically binds to cyclin D1-CDK4/6 complexes (Hirai et aI, 1995). 
Down-regulation of p19 in the ERRy transfected DU 145 cells might facilitate the 
entry of S phase of the cells. As over-expression of ERRy in DU 145 cells increased 
the cell fraction in the G21M, other cell cycle related molecules also might be 
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involved. For instance, in late 02 and early M phases, cyclin A complexes with 
CDK1 (cdc2) to promote entry into M phase. Mitosis (M) is further regulated by 
cyclin B in complex with CDK1 (King et at, 1994; ArelIano and Moreno, 1997). 
Although p53 tumor-suppressor is also well known in the control of the 02/M phase 
transition (Agarwal et at, 1995), its transcript level remained unchanged level in 
ERRy overexpressed DU 145 cells indicating that factors other than p53 might be 
involved in the ERRy-mediated cell growth retardation. It was also observed that 
transient expression of ERRy in PC-3 results in significantly increase fraction cells in 
both 00/01 and 02/M phases. Combining with the results of stable transfection, 
ERRy might acts as a negative growth regulator of prostatic cells by at least two 
different mechanisms depending on the genetic background of prostatic cells. Since 
PC-3 and DU 145 cell lines are established from metastatic prostate cancers while 
PNT2 is a SV 40-immortalized epithelial cells, mutations of cell cycle regulatory 
molecules might occur especially the two tumor suppressor genes, p53 and pRb. 
Evidences show that binding of certain tumor virus proteins, for instance, human 
papillomavirus (HPV) E7 and simian virus 40 (SV 40) large T antigen, to pRb could 
inhibit its activity (Hu et aI, 1990; Oage et aI, 1990). On the other hand, it is well 
documented that PC-3 are defective in both p53 alleles but normal in both pRb 
alleles whereas DU 145 cells consists of mutated p53 and pRb (Rubin et aI, 1991 ; 
Israel et aI, 1995). Therefore, it is speculated that the difference in cell cycle 
distribution between the ERRy over-expressed PC-3 , PNT2 and DU 145 cells are 
probably due to the degree of mutation of these cell cycle-related genes. 
The data of flow cytometry supported that the growth retardation in ERRs 
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over-expressed prostatic cells are due to (or partially due to) the direct alteration of 
cell cycle distribution but not induction of apoptosis. However, ERRs might also 
cross talk to other non-steroidal mitogenic pathways that exist in the prostate cells 
and in turn affect the cells proliferation. In mammary gland, ERa-epidermal growth 
factor (EFG) cross-talk might contribute to estradiol-dependent end-bud proliferation 
of mouse mammary gland (Ankrapp et aI, 1998). On the other hand, the principal 
growth regulator of prostate, AR, also shows cross-signaling to other growth 
pathways. For example, cytokine IL-6 and HER2lNeu receptor tyrosine kinase 
activates the AR in a MAPK dependent manner and initiates both androgen 
dependent or independent growth regulation (Hobisch et aI, 1998; Yeh et aI, 1999). 
Moreover, Migliaccio et aI, (2000) find that a ligand-induced ternary AR-ER-SRC 
complex activates the Src-Raf-1-Erk-2 pathway and stimulates the prostatic cancer 
cell proliferation. Therefore, it is believed that functional cross talk is common 
between the steroid hormone receptors and other growth signaling pathways. 
However, further experiments are required in order to demonstrate a clear 
involvement of other mitogenic signaling pathways in ERRy-mediated growth 
inhibition of prostatic cell. 
5.4.4 Inhibition of anchorage independent growth in ERRy stable-transfected 
PNT2 and DU 145 cells 
Besides the growth characteristics of prostatic cells, the effect of 
over-expression of ERRy on the transformation of PNT2 and DU 145 cells were also 
examined. The anchorage-independent growth of the ERRy stable-transfected cells 
were compared to the empty vector transfected and parental cells in the absence of 
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substratum attachment, soft agar assay. Transformed or cancer cells differ from 
normal cells in many aspects, one being their anchorage independent growth and thus 
usually can grow in this semi-solid substratum and form colonies with a higher 
efficiency than the untransformed cells. Their anchorage independent growth ability 
is also highly correlated to their tumorigenicity in immuno-deficient mice (Freedman 
and Shin, 1974; Colbum et aI, 1978). The results of present study showed that 
ectopic expression of ERRy in PNT2 and DU 145 greatly reduced their anchorage 
independent growth ability in the soft agar. Therefore, it indicates that ERR y might 
regulate the genes involved in the cellular transformation as well as tumorigenesis 
processes. Based on this observation, it is interesting to propose that ERRy possesses 
some tumor suppressor potential in the prostatic cells. Previous study shows that 
over-expression of a universal CDK inhibitor p21, in a tumor cell line can suppress 
its colony formation and a similar result is observed by p53 over-expression (Zakut 
and Givol, 1995). Although p21 level is up-regulated in the PNT2 ERRy transfected 
cells, its level remained unchanged in DU 145 ERRy transfectants suggesting that 
factors other than p21 might be involved in ERRy-mediated inhibition of anchorage 
independent growth. Besides the known oncogenes and tumor suppressor genes, 
other factors are also involved in the colony formation in the prostate cancer cells, 
for instance, epidermal growth factor (EGF), interleukin-6 (IL-6), transcription 
factor early growth response-1 (Egr-1) and transforming growth factor a (TGFa) 
(Okamoto et aI, 1998; Bae et aI, 1994; Baron et aI, 2003). However, further 
experiments are required to explore the possible interaction between ERRy and these 
molecules. 
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The present part of study showed that the three ERR isoforms, particularly 
the ERRy, play a role in inhibition of cell growth as well as the anchorage 
independent growth In the transformed immortalized PNT2 cell and 
androgen-independent DU 145 prostate cancer cells. This observation suggests that 
ERRy might be a potential target of prostate cancer treatment. Although ERRy is a 
self-activated nuclear hormone receptors, the discovery of new dietary or synthetic 
agonists that can enhance the transcriptional activity of ERRy, may be an alternative 
or supplement to androgen ablation therapy as well as estrogens/antiestrogens for 
treatment of both androgen dependent and androgen independent prostate cancer. 
190 
Chapter 6. Conclusion 
Chapter 6. Conclusion 
1. The differential expression patterns of the three ERR isoforms in a board panel of 
human prostatic cell lines, primary carcinoma xenografts and tissues suggest that 
the three isoforms of this orphan nuclear receptor might have their own 
individual role in the prostate. 
2. Co-expression of ERRa and ER~ in all tested cell lines and xenografts suggests 
that these two nuclear receptors might crosstalk between one another or share 
similar regulatory pathway. 
3. Repression of ERa and ERR)' expreSSIon in ERRa-overexpressed PC-3 cells 
further indicates that the presence of cross talking between the ERRs and ERs at 
the transcriptional level in the prostatic cells. 
4. The results of GFP-ERRs subcellular tracking experiment demonstrate that ERRs 
are the constitutive nuclear proteins. 
5. The capability of GFP-tagged ERRs in transfected PC-3 cells to transactivate the 
ERE and ERRE (SF -1) driven luciferase reportors in the absence of exogenous 
ligand indicates that ERRs are constitutively active in the prostatic cells. 
6. The combined evidences from transient and stable transfections of ERRs 
demonstrate that the three ERR isoforms, particularly ERR)" have a negative role 
in growth regulation and tumor suppressor function in the prostatic cells. 
7. Cell cycle analysis by flow cytometry showed that ERR)' induce a GO/G 1 phase 
arrest in PNT2 cells but G2/M phase arrest in DU 145 cells. This observation 
reveals that ERR)' might negatively regulate the growth of prostatic cells via two 
different mechanisms depending on the genetic background of the cells. 
191 
Chapter 7. References 
Chapter 7. References 
Agarwal ML, Agarwal A, Taylor WR, Stark GR. 1995 p53 controls both the 
G2/M and the G 1 cell cycle checkpoints and medicates reversible growth arrest in 
human fibroblasts. Proc Natl Acad Sci USA 92:8493-8497. 
Angeloni SV, Martin MB, Garcia-Morales P, Castro-Galache MD, Ferragut JA, 
Saceda M. 2004 Regulation of estrogen receptor - a expression by the tumor 
suppressor gene p53 in MCF-7 cells. J Endocrinol 180:497-504. 
Angelucci A, Festuccia C, Gravina GL, Muzi P, Bonghi L, Vicentini C, Bologna 
M. 2004 Osteopontin enhances the cell proliferation induced by the epidermal 
growth factor in human prostate cancer cells. Prostate 59157-166. 
Ankrapp DP, Bennett JM, Haslam SZ. 1998 Role of epidermal growth factor in 
the acquisition of ovarian steroid hormone responsiveness in the normal mouse 
mammary gland. J Cell Physiol 174:251-260. 
Aranda A, Pascual A 2001 Nuclear Hormone Receptors and Gene Expression. 
Physiol Rev 81(3):1296-304 
Arellano M, IVloreno S. 1997 Regulation of CDKJcyclin complexes during the cell 
cycle. lnt. J. Biochem. Cell BioI. 29:559-573 . 
Ariazi EA, Clark GM, Mertz JE. 2002 Estrogen-related receptor a. and 
estrogen-related receptor y associate with unfavorable and favorable biomarkers, 
respectively, in human breast caner. Cancer Res 62:6510-6518. 
192 
Chapter 7. References 
Arnold SF, Obourn ID, Jaffe H, Notides AC. 1995 Phosphorylation of human 
estrogen receptor by mitogen-activated protein kinase and casein kinase I1: 
consequence on DNA binding. J Steroid Biochem Mol BioI. 55:163-172. 
Bae VL, Jackson-Cook CK, Brothman AR, Maygarden SJ, Ware JL. 1994 
Tumorigenicity of SV 40 T antigen immortalized human prostate epithelial cells : 
association with decreased epidermal growth factor receptor (EGFR) expression. Int 
J Cancer 58:721-729. 
Balaji KC, Koul H, Mitra S, Maramag C, Reddy P, Menon M, Malhotra RK, 
Laxmanan S. 1997 Antiproliferative effects of c-myc antisense oligonucleotide in 
prostate cancer cells: a novel therapy in prostate cancer. Urology 50: 1007-1015. 
Baron V, De Gregorio G, Krones-Herzig A, Virolle T, Calogero A, Urcis R, 
Mercola D. 2003 Inhibition of Egr-1 expression reverses transformation of prostate 
cancer cells in vitro and in vivo. Oncogene 22:4 194-4204. 
Baumann CT, Maruvada P, Hager GL, Yen PM. 2001 Nuclear cytoplasmic 
shuttling by thyroid hormone receptors, multiple protein interactions are required for 
nuclear retention. J BioI Chem 276: 11237-11245. 
Beato M, Herrlich P, Schutz G. 1995 Steroid hormone receptors: many actors in 
search ofa plot. Cell 83:851-857. 
Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. 1997 Androgen 
responsive adult human prostatic epithelial cell lines immortalized by human 
papillomavirus 18 . Carcinogenesis 18: 1215 -1223 . 
193 
Chapter 7. References 
Berry SJ, Coffey DS, Walsh PC, Ewing LL. 1984 The development of human 
benign prostatic hyperplasia with age. ] Urol 132:477-479. 
Bianco J, Handelsman DJ, Pedersen J. 2002 Direct response of the murine prostate 
gland and seminal vesicles to estradiol. Endocrinology 143 :4922-4933. 
Bollig A, Miksicek RJ. 2000 An estrogen receptor-alpha splicing variant mediates 
both positive and negative effects on gene transcription. Mol Endocrinol 
14(5):634-49. 
Bonkhoff H, Fixemer T, Hunsicker I, Remberger K. 1999 Estrogen receptor 
expreSSIon In prostate cancer and premalignant prostatic lesions. Am ] Pathol 
155 :641 -647. 
Bonkhoff H, Remberger K. 1998 Morphogenetic concepts of nonnal and abnonnal 
growth in the human prostate. Virchows. Arch. 433: 195-202 
Bonkhoff H, Stein U, Welter C, Remberger K. 1995 Differential expression of the 
pS2 protein in the human prostate and prostate cancer: association with premalignant 
changes and neuroendocrine differentation. Hum Patho126:824-828. 
Bonnelye E, P ... ubin JE. 2002. Differential expression of estrogen receptor-related 
receptor a and ~ and estrogen s receptors a and ~ in osteoblasts in vivo and in vitro. J 
Bone Miner Res 17: 1392-1400. 
Bonnelye E, Kung V, Laplace C, Galson DL, Aubin JE. 2002 Estrogen 
receptor-related receptor a impinges on the estrogen axis in bone: potential function 
in osteoporosis. Endocrinology 143:3658-3670. 
194 
Chapter 7. References 
Bonnelye E, Vanacker JM, Dittmar T, Begue A, Desbiens X, Denhardt DT, 
Aubin JE, Laudet V, Fournier B. 1997 The ERR-1 orphan recetpor is a 
transcriptional activator expressed during bone development. Mol Endocrinol. 
11:905-916 
Bonnelye E, Vanacker JM, Spruyt N, Alric S, Fournier B, Desbiens X, Laudet V 
1997 Expression of the estrogen-related receptor 1 (ERR-I) orphan receptor during 
mouse development. Mech Dev 65:71-85 
Borras M, Hardy L, Lempeureur F, Elkhissun AH, Logros N, Gol-Winkler R, 
Leclercq G. 1994 Estradiol induced down-regulation of estrogen receptor. Effect of 
various modulation of protein synthesis and expression. J Steroid Biochem Mol BioI 
46:325-336. 
Bradbury EM, Inglis RJ, Matthews HR. 1974 Control of cell division by very 
lysine rich histone (PI) phosphorylation. Nature 247:257-261. 
Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T. 1998 
Retinoblastoma protein recruits histone deacetyIase to repress transcription. Nature 
391 : 5 97 -601 . 
Brolin J, Skoog L, Ekman P. 1992 Immunohistochemistry and biochemistry in 
detection of androgen, progesterone, and estrogen receptors in benign and malignant 
human prostatic tissue. Prostate. 20:281-295. 
Brooks SC, Locke ER, SouIe HD. 1973 Estrogen receptor in a human cell line 
(MCP -7) from breast carcinoma. J BioI Chem. 248 :6251-6253. 
195 
Chapter 7. References 
Calaf G, Russo J. 1993 Transformation of human breast epithelial cells by chemical 
carcinogens. Carcinogenesis 14:483-492. 
Carnero A, Hannon GJ. 1998 The INK4 family of CDK inhibitors. CUff Top 
McirobiollmmunoI227:43-55. 
Carreau S, Levallet J. 1997 Cytochrome P450 aromatase in male germ cells. Folia 
Histochem CytobioI35:195-202. 
Carruba G, Pfeffer U, Fecarotta E, Coviello DA, D' Amato E, Lo Castro M, 
Vidali G, Castagnetta L. 1994 Estradiol inhibits growth of hormone-nonresponsive 
PC-3 human prostate cancer cells. Cancer Res 54: 1190-1193. 
Castagnetta LA, Miceli MD, Sorci CM, Pfeffer U, Farruggio R, Oliveri G, 
Calabro M, Carruba G. 1995 Growth of LNCaP human prostate cancer cells is 
stimulated by estradiol via its own receptor. Endocrinology 136:2309-2319. 
Chambraud B, Berry M, Redeuilh G, Chambon P, Baulieu EE. 1990 Several 
regions of human estrogen receptor are involved in the formation of receptor-hear 
shock protein 90 complexes. J BioI Chem 265 :20686-20691. 
Cbang WY, Prins GS. 1999 Estrogen receptor-~: implications for the prostate gland. 
Prostate 40: 115-124. 
Cben F, Zhang Q, McDonald T, Davidoff MJ, Bailey W, Bai C, Liu Q and Casky 
CT. 1999 Identification of two hERR2-related novel nuclear receptors utilizing 
bioinformatics and inverse PCR. Gene 228: 101-109. 
196 
Chapter 7. References 
Chen S, Itoh T, Wu K, Zhou D, Yang C. 2002 Transcriptional regulation of 
aromatase expression in human breast tissue. J Steroid Biochem Mol BioI 83:93-99. 
Chen S, Zhou D, Yang C, Sherman M. 2001 Molecular basis for the constitutive 
activity of estrogen-related receptor a-I. J BioI Chem. 276:28465-28470. 
Chen Y, Robles AI, Martinez LA, Liu F, Gimenez-Conti IB, Conti CJ. 1996 
Expression of G 1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase 
inhibitors in androgen-induced prostate proliferation in castrated rats. Cell Growth 
Differ. 7: 1571-1578. 
Chiang JY. 2002 Bile acid regulation of gene expression: roles of nuclear hormones 
receptors. Endocr Rev 23 :443-463. 
Chlenski A, Nakashiro K, Ketels KV, Korovaitseva GI, Oyasu R. 2001 Androgen 
receptor expression in androgen-independent prostate cancer cell lines. Prostate 
47 :66-75 . 
Choo CK, Ling MT, Chan KW, Tsao SW, Zbeng Z, Zbang D, Ch an LC, Wong 
YC. 1999 immortalization of human prostate epithelial cells by HPV 16 E6/E7 open 
reading frames. Prostate 40: 150-158. 
Cleutjens CB, Steketee K, van Eekelen CC, van der Korput JA, Brinkmann AO, 
Trapman J. 1997 Both androgen receptor and glucocorticoid receptor are able to 
induce prostate-specific antigen expression, but differ in their growth-stimulating 
properties ofLNCaP cells. Endocrinology 138:5293-5300. 
Colburn NH, Bruegge WHY, Bates JR, Gray RH, Rossen ID, Kelsey WH and 
197 
Chapter 7. References 
Shimada T. 1978 Correlation of anchorage-independent growth with tumorigenicity 
of chemically transformed mouse epidermal cells. Cancer Res. 38:624-634. 
Colombel M, Dante R, Bouvier R, Ribieras S, Pangaud C, Marechal JM, Lasne 
Y. 1999 Differential RNA expression of the pS2 gene in the human benign and 
malignant prostatic tissue. ] Urol. 162:927-930. 
Corey E, Quinn JE, Emond MJ, Buhler KR, Brown LG, Vessella RL. 2002 
Inhibition of androgen-independent growth of prostate cancer xenografts by 
17beta-estradiol. Clin Cancer Res 8: 1003-1007. 
Couse JF, Curtis HS, Korach KS. 2000 Receptor null mice reveal contrasting roles 
for estrogen receptor alpha and beta in reproductive tissues.] Steroid Biochem Mol 
BioI. 74:287-296. 
Couse JF, Hewitt SC, Bunch DO, Sar M, Walker VR, Davis BJ, Korach KS. 
1999 Postnatal sex reversal of the ovaries in mice lacking estrogen receptors a and ~. 
Science. 286:2328-2331. 
Couse JF, Korach K. 1999 Estrogen receptor-null mice: what have we learned and 
where will they lead us? Endocr Rev 20:358-417. 
Coward P, Lee D, Hull MV, Lehmann JM. 2001 4-hydroxytamoxifen binds to and 
deactivates the estrogen-related receptor y. Proc Natl Acad Sci 98:8880-8884. 
Culig Z, Hobisch A, Cronauer MV, Radmayr C, Hittmair A, Zhang J, Thurnher 
M, Bartsch G, Klocker H. 1996 Regulation of prostatic growth and function by 
peptide growth factors. Prostate 26:392-405. 
198 
Chapter 7. References 
Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, 
Bartsch G and Klocker H. 1994 Androgen receptor activation in prostatic tumor 
cell lines by insulin-like growth factor-I , Keratinocyte growth factor, and epidennal 
growth factor. Cancer Res 54:5474-5478. 
Cunha GR, Alarid ET, Turner T, Donjacour AA, Boutin EL and Foster BA 1992 
N onnal and abnonnal development of the male urogenital tract. Role of androgens, 
mesenchymal-epithelial interactions, and growth factors. J Androl13:465-475 . 
Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, Sugimura 
Y. 1987 The endocrinology and developmental biology of the prostate. Endocr Rev 
8:338-362. 
Dalu A, Blaydes BS, Bryant CW, Latendresse JR, Weis CC, Barry Delclos K. 
2002 Estrogen receptor expression in the prostate of rats treated with dietary 
genistein. J Chromatogr B Analyt Technol Biomed Life Sci 777:249-260. 
Degeorges A, Hoffschir F, Cussenot 0, Gauville C, Le Duc A, Dutrillaux B, 
Calvo F. 1995 Recurrent cytogenetic alterations of prostate carcinoma and 
amplification of c-myc or epidennal growth factor receptor in subclones of 
immortalized PNTl human prostate epithelial cell line. IntJ Cancer 15 :724-731. 
Denmeade SR, Lin XS, Isaacs JT. 1996 Role of programmed (apoptotic) cell death 
during the progression and therapy for prostate cancer. Prostate 28:251-265. 
Diamandis EP, Yousef GM, Luo LY, Magklara A, Obiezu CV. 2000 The new 
human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol 
199 
Chapter 7. References 
Metab 11 :54-60. 
Doisneau-Sixou SF, Sergio CM, CarroIl JS, Hui R, Musgrove EA, Sutherland 
RL. 2003 Estrogen and antiestrogen regulation of cell cycle progression in breast 
cancer cells. Endocr Relat Cancer 10: 179-186. 
Dupont S, Krust A, GansmuIIer A, Dierich A, Chambon P, Mark M. 2000 Effect 
of single and compound knockouts of estrogen receptors a (ERa) and ~ (ER~) on 
mouse reproductive phenotypes. Development. 127 :4277 -4291. 
el Deiry WS, To kin 0 T, Velculescu YE, Levy DB, Parsons R, Trent JM, Lin D, 
Mercer WE, Kinzler KW, Vogelstein B. 1993 WAF1, a potential mediator ofp53 
tumor suppression. Cell 75: 817 - 825. 
El Etreby MF, Liang Y, Lewis RW. 2000 Induction of apoptosis by mifepristone 
and tamoxifen in human LNCaP prostate cancer cells in culture. Prostate. 2000 
43 :31-42. 
Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried 
G, Nordenskjold M, Gustafsson l A 1997 Human estrogen receptor ~ gene structure, 
chromosomal localization, and expression pattern. 1 Clin Endocrinol Metab 
82: 4258 -4265. 
Eudy ID, Yao S, Weston MD, Ma-Edmonds M, Talmadge CB, Cheng JJ, 
Kimberling W J, Sumegi J. 1998 Isolation of a gene encoding a novel member of 
the nuclear receptor superfamily from the critical region of Usher syndrome type Ha 
at 1q41. Genomics. 50:382-384. 
200 
Chapter 7. References 
Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C. 1995 Mice lacking cyclin 
D 1 are small and show defects in eye and mammary gland development. Genes Dev. 
9:2364-2372. 
Fejes-Toth G, Pearce D, Naray-Fejes-Toth A. 1998 Subcellular localization of 
mineralocorticoid receptors in living cells: effects of receptor agonists and 
antagonists. Proc Natl Acad Sci USA 95:2973-2978. 
Fisher CR, Graves KH, Parlow AF, Simpson ER. 1998 Characterization of mice 
deficient in aromatase (ArKO) because of targeted disruption of the cyp 19 gene. Proc 
Natl Acad Sci 95:6965-6970. 
Fixemer T, Remberger K, Bonkhoff H. Differerntial expression of the estrogen 
receptor ~ (ER~) in human prostate tissue, premalignant changes, and in primary, 
metastatic, and recurrent prostatic adenocarcinoma. 2003 Prostate 54:79-87. 
Fizazi K, Martinez LA, Sikes CR, Johnston DA, Stephens LC, McDonneII T J, 
Logothetis CJ, Trapman J, Pisters LL, Ordonez NG, Troncoso P, Navone NM. 
2002 The association of p21 (WAF -1 /CIP 1) with progressIon to 
androgen-independent prostate cancer. Clin Cancer Res. 8:775-781. 
Freedman VH, Shin SI. 1974 Cellular tumorigenicity in nude mice: correlation with 
cell growth in semi-solid medium. Cell 3:355-359. 
Gage JR, Meyers C, Wettstein FO. 1990 The E7 proteins of the nononcogenic 
human papillomavirus type 6b (HPV -6b) and of the oncogenic HPV -16 differ in 
retinoblastoma protein binding and other properties. J Virol 64:723-730. 
201 
Chapter 7. References 
Georget V, Lobaccaro JM, Terouanne B, Mangeat P, Nicolas JC, Sultan C. 1997 
Trafficking of the androgen receptor in living cells with fused green fluorescent 
protein - androgen receptor. Mol Cell Endocrinol 129:17-26. 
Giguere V. 1999 Orphan nuclear receptors: from gene to function. Endocr Rev 
20:689-725. 
Giguere V. 2002 To ERR In the estrogen pathway. Trends Endocrinol Metab. 
13:220-225. 
Giguere V, Yang N, Segui P, Evans RM. 1988 Identification of a new class of 
steroid hormone receptors . Nature 331 :91-94 
Graham ID, Clarke CL. 1997 Physiological action of progesterone in target tissues. 
Endocr Rev. 18:502-519. 
Grant ES, Batchelor KW, Habib FK. 1996 Androgen independence of primary 
epithelial cultures of the prostate is associated with a down-regulation of androgen 
receptor gene expression. Prostate 29:3 39-349. 
Greschik H , Wurtz JM, Sanglier S, Bourguet W, Dorsselaer AV, Moras D, 
Renaud JP. 2002 Structural and functional evidence for ligand-indepentent 
transcriptional activation by the estrogen-related receptor 3. Mol Cell 9:303-313 . 
Hager GL, Lim CS, Elbi C, Baumann CT. 2000 Trafficking of nuclear receptors in 
living cells. J Steroid Biochem Mol BioI. 74:249-254. 
Harper JW, Elledge SJ, Keyomarsi K, Dynlackt B, Tsai L, Zhang P, 
Dobtowolski S, Bai C, Connell-Crowley L, Swindell E, Fox lVIP, Wei N. 1995 
Inhibition of cyclin-dependent kinases by p21. Mol BioI Cell 6:387-400. 
202 
Chapter 7. References 
Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, Narayan P. 1995 
Establishment and characterization of an immortalized but non-transformed human 
prostate epithelial cell line: BPH-1. In Vitro Cell Dev BioI Anim 31: 14-24. 
Heard DJ, Norby PL, Holloway J, Vissing H. 2000 Human ERRy, a third member 
of the estrogen receptor-related receptor (ERR) subfamily of orphan nuclear 
receptors: tissue-specific isoforms are expressed during development and in the adult. 
Mol Endocrinol 14:382-392. 
Hedlund TE, Moffatt KA, Miller GJ. 1996 Stable expreSSIon of the nuclear 
vitamin D receptor in the human prostatic carcinoma cell line lCA-I: evidence that 
the antiproliferative effects of 1 u, 25-dihydroxyvitamin D3 are mediated exclusively 
through the genomic signaling pathway. Endocrinology. 137:1554-1561. 
H engst L, Reed SI. 1998 inhibitors of the Cip/kip family. Curr. Top. Microbiol. 
Immunol. 277:25-41. 
Hentschke M, Schulze C, Susens U, Borgmeyer U. 2003 Characterization of 
calmodulin binding of the orphan nuclear receptor ERRy. BioI Chem 384:473-482. 
Hentschke M, Susens U, Borgmeyer U. 2002 Domains of ERRy that mediate 
homodimerization and interaction with factors stimulating DNA binding. Eur J 
Biochem 269:4086-4097. 
Hobisch A, Eder lE, Putz T, Horninger W, Bartsch G, Klocker H, CuIig Z. 1998 
Interleukin-6 regulates prostate-specific protein expression in prostate carCInoma 
cells by activation of the androgen receptor. Cancer Res 58:4640-4645. 
203 
Chapter 7. References 
Hirai H, Roussel MF, Kato JY, Ashmun RA, Sherr CJ. 1995 Novel INK4 
proteins, p 19 and p 18, are specific inhibitors of cyclin D-dependent kinases CDK4 
and CDK6. Molec. Cell. BioI. 15 :2672-2681. 
Hoerer S, Schmid A, Heckel A, Budzinski RM, Nar H. 2003 Crystal structure of 
the human liver X receptor ~ ligand-binding domain in complex with a synthetic 
agonist. J Mol BioI 334:853-861. 
Honda S, Harada N, Ito S, Takagi Y, Maeda S. 1998. Disruption of sexual 
behavior in male aromatase-deficient mice lacking exons 1 and 2 of the cyp 19 gene. 
Biochem Biophys Res Commun 252:445-449. 
Hong H, Yang L, Stallcup MR. 1999 Hormone-independent transcriptional 
activation and coactivator binding by novel orphan nuclear receptor ERR3. J Bioi 
Chem.27:22618-22626. 
Horoszewicz JS, Leong SS, Kawinshi E, Karr JP, Rosenthal H, Chu TM, 
Mirand EA, Murphy GP. 1983 LNCaP model of human prostatic carcinoma Cancer 
Res 43:1809-1818. 
Htun H, Barsony J, Renyi I, Gould DL, Hager GL. 1996 Visualization of 
glucocorticoid receptor translocation and intranuclear organization in living cells 
with a green fluorescent protein chimera. Proc Natl Acad Sci USA 93:4845-4850. 
Htun H, Holth LT, Walker D, Davie JR, Hager GL. 1999 Direct visualization of 
the human estrogen receptor a reveals a role for ligand in the nuclear distribution of 
the receptor. Mol Bioi Cell 10:471-486. 
204 
Chapter 7. References 
Hu QJ, Dyson N, Harlow E. 1990 The regions of the retinoblastoma protein needed 
for binding to adenovirus El A or SV 40 large T antigen are common sites for 
mutations. EMBO J. 9:1147-1155. 
Huss JM, Kopp RP, Kelly DP. 2002 Peroxisome proliferator-activated receptor 
coactivator-1 a (PGC-1 a) coactivates the cardiac-enriched nuclear receptors 
estrogen-related receptor-a and -y. Identification of a novel leucine-rich interaction 
motif with PGC-1 a. J BioI Chem. 277:40265-40274. 
Ichida M, N emoto S, Finkel T. 2002 Identification of a specific molecular repressor 
of the peroxisome proliferator-activated receptor y coactivator-1 a (PGC-1a). J BioI 
Chem 277:50991-50995. 
Ingle IN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, NichoIs 
WC, Creagan ET, Hahn RG, Rubin J, Frytak S. 1981 Randomized clinical trial of 
diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast 
cancer. N Engl J Med. 304: 16-21. 
Israel K, Sanders BG, Kline K. 1995 RRR-alpha-tocopheryl succinate inhibits the 
proliferation of human prostatic tumor cells with defective cell cycle/differentiation 
pathways. Nutr Cancer 24:161-169. 
Jarred RA, Cancilla B, Prins GS, Thayer KA, Cunha GR, Risbridger GP .. 2000 
Evidence that estrogens directly alter androgen-regulated prostate development. 
Endocrinology 141 :3471-3477. 
Johnston SD, Liu X, Zuo F, Eisenbraun TL, Wiley SR, Kraus RJ, Mertz JE. 
205 
Chapter 7. References 
1997 Estrogen-related receptor alpha 1 functionally binds as a monomer to extended 
half-site sequences including ones contained within estrogen-response elements. Mol 
Endoerinol. 11 :342-352. 
Jones SE. 2003 Fulvestrant: an estrogen receptor antagonist that dowmegulates the 
estrogen receptor. Semin Oncol 30: 14-20. 
Jordan VC. 2001 Selective estrogen receptor modulation: a personal perspective. 
Cancer Res. 61 :5683-5687. 
Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. 1979 Establishment 
and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol 
17:16-23. 
Kaneko KJ, Fur low ID, Gorshi J . 1993 Involvement of the coding sequence for the 
estrogen gene in autologous ligand-dependent down-regulation. Mol Endocrinol 
7:879-888. 
Karin M 1998 New twists in gene regulation by glucocorticoid receptor: is DNA 
binding dispensable? Cell 93 :487 -490. 
Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer J, Chambon P. 
1990 Two distinct estrogen-regulated promoters generate transcripts encoding the 
two functionally different human progesterone receptor forms A and B. EMBO 
9:1603-1614. 
Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ. 1993 Direct binding of 
cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the 
206 
Chapter 7. References 
cyclin D - dependent kinase CDK4. Genes Dev 7:331-342. 
Kim IY, Kim BC, Seong DH, Lee DK, Seo JM, Hong YJ, Kim HT, Morton RA, 
Kim SJ. 2002 Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in 
androgen-independent human prostate cancer cell lines. Cancer Res 62:5365-5369. 
King RW, Jackson PK, Kirschner MW. 1994 Mitosis In transition. Cell 
79:563-571. 
King W J, Greene GL 1984 Monoclonal antibodies localize oestrogen receptor in 
the nuclei of target cells. Nature 307:745-747. 
Korach KS. 1994 Insights from the study of animals lacking functional estrogen 
receptor. Scicence 266: 1524-1527. 
Kraus RJ, Arizazi EA, Farrell ML, Mertz JE. 2002 Estrogen-related receptor 
alpha 1 actively antagonizes estrogen receptor-regulated transcription in MCP-7 
mammary cells. J BioI Chem 277:24826-24834. 
Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, 
Korach KS, Gustafsson JA, Smithies O. 1998 Generation and reproductive 
phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci 
95:15677-15682. 
Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, 
Gustafsson JA. 1997 Comparsion of the ligand binding specificiey and transcripti 
tissue distribution of estrogen receptors alpha and beta. Endocrinology 138:863-870. 
207 
Chapter 7. References 
Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. 1996 
Cloning of a noval estrogen receptor expressed in rat prostate and ovary. Proc N atl 
Acad Sci USA 93:5925-30. 
Kuiper GG, Lemrnen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, 
van der Burg B, Gustafsson JA. 1998 Interaction of estrogenic chemicals and 
phytoestrogens with estrogen receptor beta. Endocrinology 139:4252-4263. 
Kundsen KE, Arden KC, Cavenee WK. 1998 Multiple G 1 regulatory elements 
control the androgen-dependent proliferation of prostatic carcinoma cells. J BioI 
Chem 273 :20213-20222. 
Kwong J , Lui K, Chan PS, Ho SM, Wong YC, Xuan JW, Chan FL. 2003 
Expression study of three secretory proteins (prostatic secretory protein of 94 amino 
acids, pro basin, and seminal vescicle secretion 11) in dysplastic and neoplastic rat 
prostates. Prostate 56:81-97. 
Latil A, Bieche I, Vidaud D, Lidereau R, Berthon P, Cussenot 0, Vidaud M. 
2001 Evaluation of androgen, estrogen (ERa and ER~) , and progesterone receptor 
expressIon In human prostate cancer by real-time quantitative reverse 
transcription-polymerase chain reaction assays. Cancer Res 61: 1919-1926. 
Lau KM, LaSpina M, Long J, Ho Srn. 2000 Expression of estrogen receptor ERa 
and ER~ in normal and malignant prostatic epithelial cells: regulation by methylation 
and involvement in growth regulation. Cancer Res 60:3175-3182. 
Leav I, Lau KM, Adarns JY, McNeal JE, Taplin ME, Wang J, Singh H, Ho SM. 
208 
Chapter 7. References 
2001 Comparative studies of the estrogen receptors ~ and a and the androgen 
receptor in normal human prostate glands, dysplasia, and in primary and metastatic 
carcinoma. Am J Pathol159:79-92. 
Leav I, McNeal JE, Kwan PW, Komminoth P, Merk FB. 1996 Androgen receptor 
expression in prostatic dysplasia (prostatic intraepithelial neoplasia) in the human 
prostate: an immunohistochemicla and in situ hybridization study. 29:137-145. 
Leav I, Merk FB, Ofner P, Goodrich G, Kwan PW, Stein BM, Sar M, Stumpf 
WE. 1978 Bipotentiality of response to sex hormones by the prostate of castrated or 
hypophysectomized dogs. Direct effects of estrogen. Am J Pathol 93 :69-92. 
Leroy P, Kurst A, Zelent A, Mendelsohn C, Garnier JM, Kastner P, Dierich A, 
Chambon P. 1991 Multiple isofonns of the mouse retinoic acid receptor a are 
generated by alternative splicing and differential induction by retinoic acid. EMBO 
10:59-69. 
Levine AJ. 1997 p53, the cellular gatekeeper for growth and division. Cell 
88:323-313. 
Lewandowski S, Kalita K, Kaczmarek L. 2002 Estrogen receptor beta. Potential 
functional significance ofa variety ofmRNA isofonns. FEBS Lett. 524(1-3):1-5. 
Li SC, Chen CF, Chan PSF, Choi HL, Ho SM, Chan FL. 2001 Altered expression 
of extracellular matrx and prosteinases in Noble rat prostate gland after long-term 
treatment with sex steroids. Prostate 49:58-71. 
Li LC, Chui R, Nakajima K, Oh BR, Au HC, Dahiya R. 2000 Frequent 
209 
Chapter 7. References 
methylation of estrogen receptor in prostate cancer: correlation with tumor 
progression. Cancer Res 60:702-706. 
LiIja H, Laurell CB 1985 The predominant protein in a human seminal coagulate. 
Scand J Clin Lab Invest 45:635. 
Lim CS, Baumann CT, Htun H, Xian W, Irie M, Smith CL, Hager GL. 1999 
Differential localization and activity of the A- and B-forms of the human 
progesterone receptor using green fluorescent protein chimeras. Mol Endocrinol 
13 :366-375. 
Lindberg MK, Moverare S, Skrtic S, Gao J, Dahlman-Wright K, Gustafsson JA, 
Ohlosson C. 2003 Estrogen receptor (ER)-beta reduces ERa-regulated gene 
transcription, supporting a flying yang" relationship between ERa and ER~ in mice. 
Mol Endocrinol 17:203-208. 
Ling MT, Chan KW, Choo CK. 2001 Androgen induces differentiation of a human 
papillomavirus 16 E6/E7 immortalized prostate epithelial cell line. J Endocrinol 
1 70:287 -296. 
Linja MJ , Savinainen KJ, Tammela TL, Isola JJ, Visakorpi T. 2003 Expression 
of ERa and ER~ in prostate cancer. Prostate 15: 180-186. 
Liu D, Zbang Z, Gladwell W, Teng CT. 2003 Estrogen stimulates estrogen-related 
receptor a gene expression through conserved hormone response elements. 
Endocrinology. 144:4894-4904. 
Lombes M, Farman N, Oblin ME, Baulieu EE, Bonvalet JP, Erlanger BF, and 
210 
Chapter 7. References 
Gasc JM 1990 Immunohistochemical localization of rat renal mineralocorticoid 
receptor by using an anti-idiotypic antibody that is an internal image of aldosterone. 
Proc. Natl. Acad. Sci. 87:1086-1088. 
Lorke DE, Sus ens U, Borgmeyer U, Hermans-Borgmeyer I 2000 Differential 
expression of the estrogen recetpor-related receptor y in the mouse brain. Mol Brain 
Res 77:277-280. 
Lu D, Kiriyama Y, Lee KY, Giguere V. 2001 Transcriptional regulation of the 
estrogen-inducible pS2 breast cancer marker gene by the ERR family of orphan 
nuclear receptors. Cancer Res. 61 :6755-6761. 
Luo JM, Sladek R, Bader JA, Matthyssen A, Rossant J and Giguere V. 1997 
Placental abnormalities in mouse embryos lacking the orphan nuclear receptor 
ERR-~. Nature 388:778-782. 
Luo JM, Sladek R, Carrier J, Bader JA, Richard D, Giguere V. 2003 Reduced fat 
mass in mice lacking orphan nuclear receptor estrogen-related receptor a. Mol Cell 
BioI. 23:7947-7956. 
Lydon JP, DeMayo FJ, Conneely OM, O'Malley BW. 1996 Reproductive 
phenotypes of the progesterone receptor null mutant mouse. J steroid Biochem Mol 
BioI. 56:67-77. 
Macpherson L, Montagnier L. 1964 Agar suspension culture for the selective assay 
of cells transformed by polyoma virus. Virology 23 :291-294. 
Malkowicz SB. 2001 The role of diethylstilbestrol in the treatment of prostate cacner. 
211 
Chapter 7. References 
Urology 58:108-113. 
Mangelsdorf DJ, Evans RM. 1995 The RXR heterodimers and orphan receptors. 
Cell 83:841-850. 
Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, 
Diconcini D, Puxeddu E, Esen A, Eastham J, Weigel NL and Lamb DJ. 2000 
Androgen receptor mutations in prostate cancer. Cancer Res 60:944-949. 
Maruvada P, Baumann CT, Hager GL, Yen PM. 2003 Dynamic shuttling and 
intranuclear mobility of nuclear hormone receptors. J BioI Chem 278:12425-12432. 
McDonald ER Ill, EI-Deiry WS. 2000 Cell cycle control as a basis for cancer drug 
development. lnt. J Oncol16:871 :876. 
Mckenna NJ, Lanz RB, O'Malley BW. 1999 Nuclear receptor coregulators: 
cellular and molecular biology. Endocr Rev. 20:321-344. 
McNeal JE. 1981. The zone anatomy of the prostate. The prostate. 2:35-49. 
McNeal JE 1983 The prostate gland. Morphol Pathol Monogr Urol 4:3 
McNeal JE. 1988. Normal histology of the prostate. The American journal surgical 
pathology. 12:619-633. 
Mickey DD, Stone KR, Wunderli H, Mickey GH, Vollmer RT, Paulson DF. 1977. 
Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. 
Cancer Res 37:4049-4058. 
Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, 
212 
Chapter 7. References 
Barone MV, Ametrano D, Zannini MS, Abbondanza C, Auricchio F. 2000 
Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers 
prostate cancer cell proliferation. EMBO 19:5406-5017. 
Mitsunaga K, Araki K, Mizusaki H, Morohashi K, Haruna K, Nakagata N, 
Giguere V, Yamamura K, Abe K. 2004 Loss of POC-specific expressioin of the 
orphan nuclear receptor ERR -~ results in reduction of germ cell number in mouse 
embryos. Mech Dev. 121 :237-246. 
Mohan R, Heyman RA. 2003 Orphan nuclear receptor modulators. CUff Top Med 
Chem 14:1637-1647. 
Mohler JL, Chen Y, Hamil K, H all SH, Cidlowski JA, Wilson EM, French FS, 
Sar M. 1996 Androgen and glucocorticoid receptors in the stroma and epithelium of 
prsotatic hyperplasia and carcinoma. Clin Cancer Res 2:889-95. 
Mosselman S, Polman J, Dijkema R. 1996 ER~:identification of a novel human 
estrogen receptor. FEBS Lett 392:49-53 . 
Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, 
Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini 
SB, Pretlow TG. 1996 CWR22: the first human prostate cancer xenograft with 
strongly androgen-dependent and relapsed strains both in vivo and in soft agar. 
Cancer Res. 56:3042-3046. 
Nativ 0, Umehara T, Colvard DS, Therneau TM, Farrow GM, Spelsberg TC, 
Lieber MM. 1997 Relationship between DNA ploidy and functional estrogen 
213 
Chapter 7. References 
receptors in operable prostate cancer. Eur Urol 32:96-99. 
Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, 
Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. 1997. Establishment of 
two human prostate cancer cell lines derived from a single bone metastasis. Clin 
Cancer Res 3 :2493-2500. 
Norbury C, Nurse P, 1992 Animal cell cycles and their control. Annu Rev Biochem 
61 :441-470. 
Oesterreich S, Zhang P, Guler RL, Sun X, Curran EM, Welshons WV, Osbome 
CK, Lee AV. 2001 Re-expression of estrogen receptor a in estrogen receptor 
a-negative MCF -7 cells restores both estrogen and insulin-like growth 
factor-mediated signaling and growth. Cancer Res. 61 :5771-5777. 
Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, Ouchi Y, 
Muramatsu M. 1998 The complete primary structure of human estrogen receptor ~ 
(hER~) and its heterodimerization with ER a in vivo and in vitro. Biochem Biophys 
Res Commun 243:122-126. 
Okamoto M, Webber MM, Quader S, Oyasu R. 1998 Interleukin-6 and epidermal 
growth factor promote anchorage-independent growth of immortalized human 
prostatic epithelial cells treated with N-methyl-N-nitrosourea. Prostate 35:255-262. 
Ostberg T, Jacobsson M, Attersand A, Mata de Urquiza A, Jendeberg. 2003 A 
triple mutant of the Drosophila ERR confers ligand-induced suppression of activity. 
Biochemistry 42:6427-6435. 
214 
Chapter 7. References 
Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson JA, Kushner PJ, 
Scanlan T. 1997 Differential ligand activation of estrogen receptors ERa and ER~ at 
AP1 sites. Science 277.1508-1510. 
Parker SL, Tong T, Bolden S, Winger PA. 1997 Cancer statistics CA Cancer J Clin 
47:5-27. 
Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC. 1991 Influence of 
age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol 
145:405-409. 
Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. 
2004 Estrogen receptor ~ inhibits human breast cancer cell proliferation and tumor 
formation by causing a G2 cell cycle arrest. Cancer Res. 64:423-428. 
Pasquali D, Rossi V, Esposito D, Abbondanza C, Puca GA, Bellastella A, Sinisi 
AA. 2001 Loss of estrogen receptor beta expression in malignant human prostate 
cells in primary cultures and in prostate cancer tissues.1 Clin Endocrinol Metab. 86: 
2051 -2055. 
Pasquali D, Staibano S, Prezioso D, Franco R, Esposito D, N otaro A, Rosa GD, 
Bellastella A, Sinisi AA 2001 Estrogen receptor ~ expression in human prostate 
tissue. Mol Cell Endocrinol 178:47-50. 
Pettersson K, Delaunary F, Gustafsson JA. 2000 Estrogen receptor ~ acts as a 
dominant regulator of estrogen signaling. Oncogene 19:4970-4978. 
Pettersson K, Grandien K, Kuiper GG, Gustafsson JA. 1997 Mouse estrogen 
215 
Chapter 7. References 
receptor ~ forms estrogen response element-binding heterodimers with estrogen 
receptor u. Mol Endocrinol 11: 1486-1496. 
Pettersson K, Svensson K, Mattsson R, Carlsson B, Ohlsson R, Berkenstam A. 
1996 Expression of a novel member of estrogen response element-binding nuclear 
receptors is restricted to the early stages of chorion formation during mouse 
embryogenesis. Mech Dev 54:211-223. 
Picard D, and Yamamoto KR 1987 Two signals mediate hormone-dependent 
nuclear localization of the glucocorticoid receptor. EMBO J 6:3333-3340. 
Poelzl G, Kasai Y, Mochizuki N, Shaul PW, Brown M, Nendelsohn ME. 2000 
Specific association of estrogen receptor ~ with the cell cycle spindle assembly 
checkpoint protein, MAD2. Proc Natl Acad Sci USA 97:2836-2839. 
Porterfield SP. 1996 Adrenal gland. In: Endocrine physiology. Chap 7. St. Louis: 
Mosby-Year Book, Inc.; 139-146. 
Pretlow TG, Wolman SR, Micale MA, Pelley RJ, Kursh ED, Resnick MI, 
Bodner DR, Jacobberger JW, Delmoro CM, Giaconia JM. 1993 Xenografts of 
primary human prostatic carcinoma. J Natl Cancer Inst. 85:394-398. 
Prins GS, Birch L, Couse JF, Choi I, Katzenellenbogen B, Korach KS. 2001 
Estrogen imprinting of the developing prostate gland is mediated through stromal 
estrogen receptor u: studies with aERKO and ~ERKO mice. Cancer Res 
61 :6089-6097. 
Pugh BF, Tjian R. 1990 Mechanism of transcriptional activation by Sp 1: Evidence 
216 
Chapter 7. References 
for coactivators. Cell 61 : 1187 -1197. 
Reynisdottir I, Polyak K, Lavarone A and Massague J. 1995 Kip/Cip and Ink4 
cdk inhibitors cooperate to induce cell cycle arrest in response to TGF -~. Genes 
Devel 9: 1831-1845. 
Risbridger G, Wang H, Young P, Kurita T, Wang YZ, Lubahn D, Gustafsson JA, 
Cunha G, Wong YZ. 2001 Evidence that epithelial and mesenchymal estrogen 
receptor-alpha mediates effects of estrogen on prostatic epithelium. Dev BioI. 
229:432-442. 
Risbridger GP, Bianco JJ, Ellem SJ, McPherson SJ. 2003 Oestrogen and prostate 
cancer. Endocr Relat Cancer 10(2): 187 -191. 
Robertson JF. 2001 Faslodex (rCr 182, 780), a novel estrogen receptor 
dowmegulator - future possibilities in breast cancer. J Steroid Biochem Mol BioI 
79:209-212. 
Royuela M, de Miguel MP, Bethencourt FR, Sanchez-Chapado M, Fraile B, 
Arenas MI, Paniagua R 2001 Estrogen receptor a and ~ in the normal, hyperplastic 
and carcinomatous human prostate. J Endocrinol 168:447-454. 
Rubin SJ, Hallahan DE, Ashman CR, Brachman DG, Becket MA, 
Virudachalam S, Yandell DW, Weichselbaum RR. 1991 Two prostate carcinoma 
cell lines demonstrate abnormalities in tumor suppressor genes. J Surg Oncol 
46:31-36. 
Russo J, Hu YF, Tahin Q, Mihaila D, Slater C, Lareef MH and Russo IH. 2001 . 
217 
Chapter 7. References 
Carcinogenicity of estrogens in human breast epithelial cells. APMIS 109:39-52. 
Santti R, Newbold RR, Makela S, Pylkkanen L, McLachlan JA. 1994 
Developmental estrogenization and prostatic neoplasia. Prostate 24:67-78. 
Sanyal S, Kim JY, Kim HJ, Takeda J, Lee YK, Moore DD, Choi HS. 2002 
Differential regulation of the orphan nuclear receptor small heterodimer partner 
(SHP) gene promoter by orphan nuclear receptor ERR isoforms. J BioI Chem 
277: 1739-1748. 
Sasaki M, Tanaka Y, Perinchery G, Dharia A, kotcherguina I, Fujimoto S, 
Dahiya R. 2002 Methylation and inactivation of estrogen, progesterone, and 
androgen receptors in prostate cancer, J Natl Cancer Inst 94:384-390. 
Schreiber SN, Knutti D, Brogli K, Uhlmann T, Kralli A. 2003 The transcriptional 
coactivator PGC-1 regulates the expression and activity of the orphan nuclear 
receptor estrogen-related receptor a (ERRa). J BioI Chem. 278:9013-9018. 
Schultz R, Isola J, Parvinen M, Honkaniemi J, Wikstrom AC, Gustafsson JA, 
Pelto-Huikko M. 1993 Localization of the glucocorticoid receptor in testis and 
accessory sexual organs of male rat. Mol Cell Endocrinol 95 : 115-120. 
Schwartz JA, Brooks SC. 1997 Neutral mutations to three acidic AF2 residues in 
the mouse estrogen receptor confer agonist activity to A -ring isomers of estradiol. J 
Steroid Biochem Mol BioI 62: 173-184. 
Sherr CJ. 1996 Cancer cell cycles Science 274:1672-1677. 
218 
Chapter 7. References 
Shi H, Shigeta H, Yang N, Fu K, O'Brian G, Teng CT. 1997 Human estrogen 
receptor-like 1 (ESRL1) gene: genomic organization, chromosomal localization, and 
promoter characterization. Genomics 44:52-60. 
Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. 
1998 The structural basis of estrogen receptor/coactivator recognition and the 
antagonism of this interaction by tamoxifen. Cell. 95:927-937 
Shigeta H, Zuo W, Yang N, DiAugustine R, Teng CT. 1997 The mouse estrogen 
receptor-related orphan receptor al: molecular cloning and estrogen responsiveness J 
Mol Endocrinol 19:299-309. 
Shulze H, Claus S. 1990 Histological localization of estrogen receptors in normal 
and diseased human prostates by immunocytochemistry. Prostate 16:331-343. 
Silberstein GB, Van Horn K, Shyamala G, Daniel CW. 1994 Essential role of 
endogenous estrogen in directly stimulating mammary growth demonstrated by 
implants containing pure antiestrogens. Endocrinology 134:84-90. 
Sladek R, Bader JA, Giguere V. 1997 The orphan nuclear receptor estrogen related 
receptor a is a transcriptional regulator of the human medium-chain acyl coenzyme 
A dehydrogenase gene. Mol and Cell BioI. 17:5400-5409. 
Sladek R, Beatty B, Squire J, Copeland NG, Gilbert DJ, Jenkins NA, Giguere V. 
1997 Chromosomal mapping of the human and murine orphan receptors ERRa 
(ESRRA) and ERR~ (ESRRB) and identification of a Novel Human ERRa-related 
pseudogene. Genomics 45:320-326. 
219 
Chapter 7. References 
Smith OWe 1999 Diethylstilbestrol in the prevention and treatment of complications 
of pregnancy. 1948. Am J Ob stet Gyneco156:821-827. 
Sramkoski RM, PretIow TG, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, 
Marengo SR, Rhim JS, Zhang D, Jacobberger JW. 1999. A new human prostate 
carcinoma cell line, 22Rvl. In Vitro Cell Dev BioI Anim 35:403-409. 
Steiner MS, Anthony CT, Lu Y, Holt JT. 1998 Antisense c-myc retroviral vector 
suppresses established human prostate cancer. Hum Gene Ther 9:747-755. 
Stoica A, Saceda M, Doraiswamy VL, Coleman C, Martin MB. 2000 Regulation 
of estrogen receptor-a gene expression by epidermal growth factor. J Endocrinol 
165:372-378. 
Stocia A, Saceda M, Fakhro A, Solomon HB, Fenster BD, Martin MB. 1999 
Regulation of estrogen receptor-a gene expression by 1, 25 - dihydroxyvitamin D in 
MCF -7 cells. J Cell Biochem 75:640-651. 
Stone NN, Fair WR, Fishman J. 1986 Estrogen formation in human prostatic tissue 
from patients with and without benign prostatic hyperplasia. Prostate 9:311-318. 
Sumi D, Ignarro LJ. 2003 Estrogen-related receptor a 1 up-regulates endothelial 
nitric oxide synthase expression. Proc Natl Acad Sci 100: 14451-14456. 
Susens U, Hermans-Borgmeyer I, Borgmeyer U. 2000 Alternative splicing and 
expression of the mouse estrogen receptor-related receptor y. Biochem Biophys Res 
Commun 267:532-535. 
220 
Chapter 7. References 
Tabibzadeh S. 1996 The signals and molecular pathways involved in human 
menstruation, a unique process of tissue destruction and remodelling. Mol Hum 
Reprod 2:77-92. 
Taylor WR, Stark GR. 2001 Regulation of the G2/M transition by p53 Oncogene 
20:1803-1815. 
Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG, Kung 
HJ. 2002 Characterization of a novel androgen receptor mutation in a relapsed 
CWR22 prostate cancer xenograft and cell line. Cancer Res 62:6606-6614. 
Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, 
Farach-Carson CM, Studer DE, Chung LW. 1999 Osteopontin: possible role in 
prostate cancer progression. Clin Cancer Res 5:2271-2277. 
Thompson SA, Rowley DR, Heidger PM. 1979 Effects of estrogen upon the fine 
structure of epithelium and stroma in the rat ventral prostate gland. Invest Urol. 
17:83-89. 
Timms BG, Chandler JA. 1985 The effects of estradiol-17 beta on the ultrastructure 
and subcellular distribution of zinc in the prostatic epithelium of castrated rats. 
Prostate 6:61-79. 
Trapp T, Holsboer F. 1996 Nuclear orphan receptor as a repressor of glucocorticoid 
receptor transcriptional activity. J BioI Chem 271 :9879-9882. 
Tremblay GB, Bergeron D, Giguere V. 2001 4-hydroxytamoxifen is an 
isoform-specific inhibitor of orphan estrogen-receptor-related (ERR) nuclear 
221 
Chapter 7. References 
receptors ~ and y. Endocrinology 142:4572-4575. 
Tremblay GB, Kunath T, Bergeron D, Lapointe L, Champigny C, Bader JA, 
Rossant J, Giguere V. 2001 Diethylstilbestrol regulates trophoblast stem cell 
differentiation as a ligand of orphan nuclear receptor ERR~. Genes Dev 15:833-838. 
Tsurusaki T, Aoki D, Kanetake H, Inoue S, Muramatsu M, Hishikawa Y, Koji T 
2003 Zone-dependent expression of estrogen receptors alpha and beta in human 
benign prostatic hyperplasia. J Clin Endocrinol Metab. 88: 1333-1340. 
Vanacker JM, Bonnelye E, Chopin-Delannoy S, Delmarre C, Cavailles V, 
Laudet V. 1999 Transcriptional activities of the orphan nuclear receptor ERRa 
(estrogen receptor-related receptor-a). Mol Endocrinol 13 :764-773. 
Vanacker JM, Bonnelye E, Delmarre C, Laudet V. 1998 Activation of the thyroid 
hormone recetpor a gene promoter by the orphan nuclear receptor ERRa Oncogene 
17:2429-2435. 
Vanacker JM, Delmarre C, Guo X, Laudet V. 1998 Activation of the osteopontin 
promoter by the orphan nuclear receptor estrogen receptor related a. Cell Growth 
Differ 9: 1007 -1014. 
Vanacker JM, Pettersson K, Gustafsson JA, Laudat V. 1999 Transcriptional 
targets shared by estrogen receptor- related receptors (ERRs) and estrogen receptor 
(ER) a, but not by ER~. EMBO J 18:4270-4279. 
Vega RB, Kelly DP. 1997 A role for estrogen-related receptor a in the control of 
mitochondrial fatty acid ~-oxidation during brown adipocyte differentiation. J BioI 
222 
Chapter 7. References 
Chem 272:31693-31699. 
Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, 
Palotie A, Tammela T, Isola J and Kallioniemi OP. 1995 In vivo amplification of 
the androgen receptor gene and progression of human prostate cancer. Nat Genet 
9:401-406. 
Waga S, Hannon G, Beach D, Stillman B. 1994 The p21 inhibitor of 
cyclin-dependent kinases controls DNA replication by interaction with PCNA. 
Nature 369:574-578. 
WaIter P, Green S, Greene G, Krust A, Bornert JM, Jeltsch JM, Staub A, 
Jensen E, Scrace G, Waterfield M, Chambon P. 1985 Cloning of the human 
estrogen receptor cDNA. Proc Natl Acad Sci USA 82:7889-7893. 
Wang TC, Cardiff RD, Zukerberg L, Lees E, Amold A, Schmidt EY. 1994 
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 
369:669-671. 
Webber MM, Bello D, Kleinman HK, Wartinger DD, Williams DE, Rhim JS. 
1996 Prostate specific antigen and androgen receptor induction and characterization 
of an immortalized adult human prostatic epithelial cell line. Carcinogenesis 
1 7: 1641-1646. 
Weihua Z, Lathe R, Warner M, Gustafsson JA. 2002 An endocrine pathway in the 
prostate, ER~, AR, 5a-androstane-3~, 1 7~-diol , and CYP7B 1, regulates prostate 
growth. Proc Natl Acad Sci 99(21):13589-94. 
223 
Chapter 7. References 
Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, Webster JI, Jensen EV, 
Nilsson S, Warner M, Gustafsson JA. 2001 A role for estrogen receptor beta in the 
regulation of growth of the ventral prostate. Proc Natl Acad Sci 98:6330-6335. 
Weihua Z, Saji S, Makinen S, Cheng G, Jensen EV, Warner M, Gustafsson JA. 
2000 Estrogen receptor (ER) ~ , a modulator of Era in the uterus. Proc Natl Acad Sci 
97:5936-5941. 
Weijerman PC, Konig JJ, Wong ST, Niesters HG, Peehl DM. 1994 
Lipofection-mediated immortalization of human prostatic epithelial cells of normal 
and malignant origin using human papillomavirus type 18 DNA. Cancer Res 
54:5579-5583. 
WHey SR, Kraus RJ, Zuo F, Murray EE, Loritz K, Mertz JE. 1993 SV 40 
early-to-late switch involves titration of cellular transcriptional repressors. Genes 
Dev 7:2206-2219. 
Witkowska HE, Carlquist M, Engstrom 0 , Carlsson B, Bonn T, Gustafsson JA, 
Shackleton CH. 1997 Characterization of bacterially expressed rat estrogen receptor 
beta ligand binding domain by mass spectrometry: structural comparison with 
estrogen receptor alpha. Steroids 62: 621-31. 
Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. 1994. 
Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: 
role of bone stromal cells. Int J Cancer 57 :406-412. 
Xie W, Hong J, Yang NN, Lin RJ, Simon CM, Stallcup MR, Evans RM. 1999 
224 
Chapter 7. References 
Constitutive activation of transcription and binding of coactivator by estrogen-related 
receptors 1 and 2. Mol Endocrino!. 13:2151-2162. 
Xie W, Wong YC, Tsao SW. 2000 Correlation of increased apoptosis and 
proliferation with development of prostatic intraepithelial neoplasia (PIN) in ventral 
prostate of the Noble rat. Prostate 44:31-39. 
Yang C, Chen S. 1999 Two organochlorine pesticides, toxaphene and chlordane, are 
antagonists for estrogen-related receptor a 1 orphan receptor. Cancer Res 
59:4519-4524. 
Yang C, Zbou D, Chen S. 1998 Modulation of aromatase expression in the breast 
tissue by ERRal orphan receptor. Cancer Res 58:5695-5700. 
Yang N, Shigeta H, Shi H, Teng CT. 1996 Estrogen-related receptor, hERR1 , 
modulates estrogen receptor-mediated response of human lactoferrin gene promoter. 
J BioI Chem 27 1 :5795-5804. 
Yang Y, Chisholm GD, Habib FK. 1992 The distribution of PSA, cathepsin-D, and 
pS2 in BPH and cancer of the prostate. Prostate 21 :201-208. 
Ye Q, Cinar B, Edlund M, Chung LW, Zhau HE. 2001 Inhibition of growth and 
cell cycle arrest of ARCaP human prostate cancer cells by ectopic expression of 
ER-a. Mol Cell Biochem 228: 105-110. 
Yeh S, Lin HK, Kang HY, Thin TH, Lin MF and Chang C. 1999 From 
HER2lNeu signal cascade to androgen receptor and its coactivators: a novel pathway 
by induction of androgen target genes through MAP kinase in prostate cancer cells. 
225 
Chapter 7. References 
Proc Natl Acad Sci USA 96:5458-5463. 
Zakut R, Givol D. 1995 The tumor suppression function of p21 Waf is contained in 
its N-terminal half (,half-WAF'). Oncogene 11 :393-395. 
Zamir I, Harding HP, Atkins GB, Horlein A, Glass CK, Rosenfeld MG, Lazar 
MA. 1996 A nuclear hormone receptor corepressor mediate transcriptional silencing 
by receptors with distinct repression domains. Mol Cell BioI 16:5458-5465. 
Zhang Z, Teng CT. 2001. Estrogen receptor a and estrogen receptor-related receptor 
al compete for binding and coactivator. Mol Cell Endocrinol 172:223-233. 
Zhou D, Quach KM, Yang C, Lee SY, Pohajdak B, Chen S. 2000 PNRC: a 
proline-rich nuclear receptor coregulatory protein that modulates transcriptional 
activation of multiple nuclear receptors including orphan receptors SF 1 
(sterodiogenic factor 1) and ERRa 1 (estrogen related receptor a-I) Mol Endocrino!. 
14:986-998 . 
Zhou Y, Chorich LP, Mahesh VB, Ogle TF. 1993 Regulation of estrogen receptor 
protein and messenger ribonucleic acid by estradiol and progesterone in rat uterus. J 
Steroid Biochem Mol BioI 46:687-698 . 
226 
Chapter 8. Publication 
Chapter 8. Publication 
1. Conference abstract 
Cheung CP, Lui K, Chan PSF, Chan LW, Chen S, Chan FL: Expression of estrogert 
receptor-related receptors and steroid hormone receptors in human prostatic cells. 
Abstract # 4897, p4897. Cancer Research's 94th Annual Meeting, on 5-9, 2003, in 
Toronto, Ontario, Canada. (this abstract was also presented at the 15th Annual 
Scientific Meeting of the Hong Kong Society of Endocrinology, Metabolism and 
Reproduction, on 19th October, 2003, Hong Kong) 
2. Book Chapter 
CP Cheung, Lung-Wai Chan, Ki Lui, Uwe Borgmeyer, Shiuan Chen and Franky L 
Chan: Expression study of estrogen receptor-related receptors and steroid hormone 
receptors in human prostatic cells. In: lonathan 1. Li (ed). "Hormonal 
Carcinogenesis " Volume 4. New York: Springer-Verlag (in press). 
3. Journal Paper 
Ki Lui, Yu Huang, H.L. Choi, C.P. Cheung, Uwe Borgmeyer, Shiuan Chen, and 
Franky L, Chan: Molecular cloning and expression of estrogen receptor-related 
receptor y in rat prostate gland. Submitted to Endocrinology. 
227 

CUHK Libraries 
1111111111111111111111111111111111111111111111111111111 
004144454 I 
